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ABSTRACT
Trillions of bacteria live within the gastrointestinal tract and are critical for
maintaining intestinal homeostasis; however, the mechanisms utilized by specific
bacterial molecules to contribute to homeostasis are not well understood. We
utilize a mouse model in which a single oral dose of the probiotic, Bacillus
subtilis, protects mice from acute colitis induced by the enteric pathogen
Citrobacter rodentium. Our goal is to elucidate the mechanism by which B.
subtilis prevents inflammation.
We identified exopolysaccharides (EPS) to be the active molecule of B.
subtilis, and a single dose of EPS protects mice from disease. EPS binds
F4/80+CD11b+ peritoneal macrophages, and adoptive transfer of macrophagerich peritoneal cells from EPS-treated mice confers protection from disease to
recipient mice. Following EPS treatment, macrophages increase expression of
CD206, arginase-1, YM-1, FIZZ-1, and IL-4Rα, markers indicative of antiinflammatory M2 macrophages. EPS does not protect TLR4-deficient mice from
C. rodentium-induced disease, and as expected, M2 macrophages do not develop
in TLR4-/- mice following EPS treatment.
CD4+ T cells drive much of the inflammation associated with C. rodentium
infection, and we hypothesized that EPS-induced M2 macrophages inhibit CD4+
T cell responses in vivo. Accordingly, we measured levels of IFN-γ (Th1), IL-17
(Th17), and IL-13 (Th2) in splenic T cells following EPS treatment and found
xx

decreased levels of these cytokines. In vitro, EPS-induced M2 macrophages
inhibit activation and proliferation of both CD4+ and CD8+ T cells. The inhibition
of CD4+ T cells is dependent on TGF-β, whereas inhibition of CD8+ T cells
is dependent on both TGF-β and PD-L1. We suggest that administration of B.
subtilis EPS can be utilized to broadly inhibit T cell activation and thus control T
cell-mediated immune responses in numerous inflammatory diseases.

xxi

CHAPTER ONE
LITURATURE REVIEW
Introduction.
Humans are home to trillions of bacteria that inhabit virtually all surfaces
and mucosal tissues of the body. The gastrointestinal tract (GIT) shares the
majority of the bacterial load, providing a home to 100 trillion individual
organisms at a density of 1011 to 1014 cells per gram of luminal contents (Ley et al.
2008). Millions of years of co-evolution have interwoven many aspects of the
microbiota and host; humans provide a nutrient rich environment and safehaven and in exchange, bacteria provide paramount benefits to the host.
Beneficial bacteria aid in food digestion, synthesize vitamins, provide essential
nutrients, promote angiogenesis and enteric nerve function, defend against
opportunistic pathogens, and contribute to the development and maintenance of
the immune system (Hooper, Wong, A. Thelin, et al. 2001).
Disruption of the normal microbiota which can occur through diet,
antibiotic use and other environmental factors, contributes to a wide range of
diseases (Hooper et al. 2012). Western civilization has brought an era of
increased sanitation, widespread overuse of antibiotics, and alterations in diet.
These changes have been accompanied by dramatic increases in allergy and
asthma, IBD, obesity, and diabetes, all of which are associated with dysbiosis of
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the microbiota, often in individuals with increased genetic susceptibility to these
diseases.
Currently, we have limited knowledge of the mechanisms by which
bacteria exert beneficial effects or how they can be used to treat disease. The coevolution of the microbiota and the immune system has given rise to very
complex and intricate mutualistic-symbiotic relationships, while many bacterial
species may be true commensals. Of the thousands of different species that
reside in the GIT, only a handful of organisms have been identified to have
immunomodulatory functions. Additionally, several organisms not typically
thought to be a part of the microbiota, such as those present in fermented foods
such as yogurt, possess beneficial effects as probiotics.
Given the complexity of the established interactions, many other species
undoubtedly exert a wide array of effects not only on the immune system, but
other physiological processes, as well. Additionally, some species may promote
similar pathways to those already identified to maintain homeostasis.
Outstanding questions: how does the host respond to bacterial colonization? Do
bacteria promote normal development of the host? How do different bacteria
promote immunity? Can beneficial bacteria be used as therapeutics? All of these
are important questions in understanding how the microbiota contributes to the
health of the individual, and importantly, how the microbiota can be used to treat
disease.

3
Section 1: Role of the Microbiota in the Development of the Immune
System
Early-life Microbial Exposure.
Our current understanding states that the fetal gastrointestinal tract is
sterile. At birth, upon passage through the birth canal, the baby is exposed to
microbes and seeding of the skin and gastrointestinal microbiota begins. This
marks the first interaction between the immune system and bacteria, viruses and
fungi, commencing the training of the immune system to tolerate these microbes.
In infants born vaginally, Lactobacillus species, similar to the vaginal
microbiome, comprise the majority of the gut microbiota. In infants born via
cesarean section, the gut microbiota resembles the skin microbiome of the
mother, including Staphylococcus, Streptococcus or Propionibacteria
(Dominguez-Bello et al. 2010). Additionally, Pre-term birth is often associated
with intrauterine infection and a breakdown of maternal-fetal tolerance, leading
to an altered microbiome (Romero et al. 2014). By two years of age, the
microbiota compositions between these groups are fairly similar; however, a
delay in exposure to certain bacteria during this crucial developmental period for
the immune system highly correlates with immune disorders later in life
(Bäckhed et al. 2015; Weng & Walker 2013).
The tolerogenic environment of the neonate allows colonization of the
microbes to occur, without eliciting a strong inflammatory response. Neonates
have blunted inflammatory cytokine responses and a high percentage of
regulatory T cells, which help maintain tolerance to the influx of microbes. This
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immunosuppressed state, however, leaves the infant highly susceptible to
infection and unable to mount protective responses following vaccination.
Recently, impaired neonatal host defense to bacterial infections has been
attributed to highly-suppressive erythroid cells (Elahi et al. 2013). These cells
actively protect against excessive inflammation triggered by commensal
microbes, allowing colonization to occur, which seemingly outweighs the risk of
infection.
Following birth, nutrition, environmental factors, host genetic factors, and
antibiotic use impact the developing microbiota. During this immunosuppressed
state, breast milk provides nutrients, bacteria and immune protection to the
infant (Koenig et al. 2011). Oligosaccharides present in breast milk influence the
final composition of the infant microbiota to an adult-like state by promoting the
expansion of Bifidobacteria and Bacterioides species (Marcobal et al. 2010).
Additionally, maternal IgA in the breast milk shapes the neonatal microbiota by
binding to nutrients or bacteria, allowing selection of certain bacteria, including
Bifidobacteria and Bacterioides species, in the GIT (Peterson et al. 2007).
Bacteria that colonize the infant GIT play a vital role in fine-tuning of the
developing immune system. The mode of delivery and host genetics contribute to
the colonization of the microbiota in infants and development of immune
responses. Recent evidence suggests that infants may also be exposed to
microbial products that cross the placenta (Aagaard et al. 2014), suggesting that
microbes may begin to shape the immune system prior to birth. At birth, T
helper (Th)-2-dominant immune responses prevail, but colonization with
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Bacterioides spp. contributes to Th1 skewing (Weng & Walker 2013). In formulafed infants compared to breast-fed infants, and more dramatically in infants born
via cesarean section compared to vaginal delivery, the microbiome is less diverse
and Th1-skewing does not occur (Dominguez-Bello et al. 2010). Indeed, many of
the diseases associated with early-life alterations in the microbiota are Th2driven immune disorders.
Environmental factors also contribute to the maturation of the microbiota.
In Western civilizations, relatively sterile living environments and good hygiene
limit early childhood exposure to microbes. Additionally, the high-prevalence of
antibiotic use in infants and in early childhood dramatically alters colonization.
This dysbiosis is associated with increased risk of asthma, atopic dermatitis,
allergy and autoimmune disorders (Sellitto et al. 2012). Children with early-life
exposure to cats and dogs, presumably a less clean environment, have a
decreased risk of developing asthma and allergy (Ownby et al. 2002). Further,
children with siblings or living on or near a farm have lower rates of hay fever and
atopic disorders compared to children raised in cities (Genuneit et al. 2013).
These observations and studies in humans demonstrate the importance of
the microbiota early in life, but have not elucidated the mechanisms by which the
microbiota shapes the immune system, and in turn, the immune system shapes
the microbiota.
Influence of Microbiota on Development of Lymphoid Tissues.
Animal models have provided mechanistic insights for these correlations
seen in humans. Germ-free animals have extensive immune system defects
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compared to conventionally raised animals. In rabbits, development of gut
associated lymphoid tissue (GALT) requires the microbiota (Perey & Good 1968;
Stramignoni et al. 1969). Further, interactions between GALT and the intestinal
microbiota stimulate development and expansion of the preimmune antibody
repertoire (Lanning et al. 2000; Rhee et al. 2005). Similarly in mouse GALT,
Peyer’s patches, mesenteric lymph nodes (MLN), the cecal patch and isolated
lymphoid follicles (ILF) all show developmental defects in size and function in
germ-free mice compared to mice housed under normal conditions (specificpathogen free (SPF) mice) (Falk et al. 1998; Bouskra et al. 2008). Although
lymphoid tissue inducer (LTi) cells (reclassified as RORγt+ Innate Lymphoid
Cells (ILC)-3, discussed later) induce development of lymph nodes and Peyer’s
patches prior to birth, selective colonization of germ-free mice restores these
underdeveloped tissues. In some cases, such as ILFs, bacterial molecules appear
to be sufficient. In contrast to GALT that begins development in a sterile
environment, ILFs develop from LTi-like cryopatches and recruited B cells in the
lamina propria (Pabst et al. 2006; Eberl & Littman 2004), and induction of this
entire process requires the gut microbiota (Hamada et al. 2002; Pabst et al.
2006; Pabst et al. 2005). Specifically, peptidoglycan from Gram (-) bacteria
induces intestinal ILF formation in germ-free mice in a NOD1-dependent manner
(Bouskra et al. 2008).
Interactions between the Immune System and Microbiota During
Development.
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Humoral immune responses. Developing lymphoid tissues support
important cellular responses to the microbiota. The generation of IgA-producing
B cells that recognize the microbiota occurs in GALT. Normally, dendritic cells
within the Peyer’s patch phagocytose bacteria and promote IgA production by B
cells. Secretion of IgA then limits bacterial penetration through the epithelium
(Macpherson & Uhr 2004; Macpherson et al. 2001). Germ-free mice have
decreased antibody responses; in particular, secretory IgA in the colon (Moreau
et al. 1978). Colonization with several different bacterial species restores IgA
production, as well as expression of the polymeric IgA receptor (Moreau et al.
1978; Hooper, Wong, Thelin, et al. 2001; Macpherson & Uhr 2004). In the
absence of class switch recombination, somatic hypermutation and IgA
production, a 100-fold expansion of anaerobic flora occurs in the small intestine,
demonstrating a vital role for IgA in promoting homeostasis (Fagarasan et al.
2002).
T Helper cell responses: Th1 and Th2 balance. Bacteriodes fragilis
is the best-characterized commensal in terms of immune regulatory and
developmental effects. Bacteriodes species colonize early in development. As
discussed above, these species rapidly proliferate in response to oligosaccharides
present in breast milk thereby constituting a major portion of the bacteria
present in the GIT. B. fragilis is a Gram (-) anaerobic bacteria that produces
several capsular polysaccharides. One particular polysaccharide, polysaccharide
A (PSA), is zwitteronic, possessing both positive and negative charges
(Mazmanian et al. 2005). In vitro, antigen-presenting cells (APCs) internalize,
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process and present PSA, which leads to proliferation of

CD4+

T cells (Brubaker

et al. 1999; Tzianabos & Kasper 2002; Cobb et al. 2004). Due to these
immunomodulatory effects, the Kasper lab examined the effects of PSA and B.
fragilis in germ-free mice. SPF mice have a greater proportion of CD4+ T cells
compared to germ-free mice. Upon mono-colonization of germ-free mice with B.
fragilis, CD4+ T cells expand and normal development of splenic lymphoid
follicles occurs. These effects require PSA production by B. fragilis, and purified
PSA is sufficient to recapitulate these effects. In vitro, PSA upregulates the
production of the cytokine, IFN-γ, in T cells (Mazmanian et al. 2005).
Naïve CD4+ T cells differentiate into several T helper cell effector subsets
based on their environment. Thus far, six subsets have been identified: Th1, Th2,
Th17, Th9, Th22 and Treg cells, but new subsets of T helper cells are continuously
being described (Nakayamada et al. 2012). Th1 cells differentiate in the presence
IL-12 and IL-18 and produce IFN-γ and TNF-α to protect against intracellular
pathogens. Th2 cells are induced by IL-4 and produce IL-4, 5, 6 and 13. They
mediate responses to extracellular pathogens such as helminthes, and have been
implicated in allergy and asthma. TGF-β and IL-6 promote Th17 cells. These
cells are involved in immunity to mucosal pathogens and contribute to
autoimmune disorders. Th9 and Th22 cells have recently been identified to
contribute to tumor and skin/barrier immunity, respectively. Th9 cells
differentiate in response to IL-4 and TGF-β, and produce IL-9, whereas Th22
cells differentiate in the presence of IL-6 and TNF-α and produce IL-22
(Nakayamada et al. 2012).
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At the time when Kasper and colleagues determined the involvement of
PSA in CD4+ T cell development, Th1 and Th2 cytokines were the only wellestablished subsets. Th1 cytokine production suppresses Th2 responses;
conversely, Th2 cytokine expression inhibits Th1 responses. Proper balance of T
helper cell effector responses plays a critical role in human health. As mentioned
above, at birth, prior to colonization, humans have a Th2-skewed environment,
which is also seen in germ-free mice. Colonization of germ-free mice with B.
fragilis restores the Th1/Th2 balance to that of SPF mice in a PSA-dependent
manner (Mazmanian et al. 2005). These studies demonstrate an essential role
for PSA in shaping mammalian immune development by stimulating normal
splenic CD4+ T cell numbers, establishing and maintaining Th1/Th2 balance, and
thereby directing splenic organogenesis. Since other T helper subsets have been
identified, new studies are underway to determine the role of the microbiota in
the development and maintenance of each subset.
Invariant natural-killer T cells. Microbial exposure early in life also
diminishes excessive responses of inflammatory cells. Invariant natural-killer
(iNKT) cells accumulate in the lamina propria and the lung in germ-free mice.
iNKT cells are implicated in the pathogenesis of ulcerative colitis (UC). In mouse
models, iNKT cells mediate oxazolone-induced colitis and germ-free mice have
exacerbated disease compared to SPF mice (Olszak et al. 2012; An et al. 2014).
Similar results are seen in asthma models, suggesting that microbiota are
required to control iNKT cell responses. Interestingly, colonization of neonatal,
but not adult mice, with a conventional microbiota alleviates disease. iNKT cells

10
express CD1d, an MHC class I-like molecule that presents lipid antigens. The
protective effects have been attributed to a single sphingolipid produced by the B.
fragilis. The sphingolipid GSL-Bf717, purified from B. fragilis, reduces iNKT cell
proliferation, and neonatal mice treated with this sphingolipid are protected from
oxazolone-induced colitis later in life (An et al. 2014). These studies demonstrate
that early-life exposure to microbes establishes tolerance and without these
exposures, stimulation of iNKT cells, and perhaps other inflammatory cells, later
in life can be detrimental to the host.
Section 2: Maintaining Homeostasis Between the Immune System and
Microbiota
Epithelial cells. Intestinal epithelial cells provide a physical barrier to
the luminal contents of the GIT. Although thick layers of mucus separate a vast
majority of microbial species from direct contact with the epithelium, specialized
epithelial cells including paneth cells and M cells can directly sense or take up
bacteria. Further, dendritic cell protrusions through the epithelial layer sample
the microbiota and produce cytokines to alter epithelial cell responses. Germfree mice exhibit decreased epithelial cell turnover, altered microvilli formation,
and decreased expression of cytokines and PRRs, suggesting bacteria contribute
to epithelial cell responses (Artis 2008).
Interactions between intestinal epithelial cells and immune cells are
critical in maintaining homeostasis with the microbiota. T cell cytokines
contribute to epithelial barrier integrity by regulating epithelial permeability,
proliferation, repair, and expression of tight junctions, mucins and anti-microbial
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peptides (Artis 2008). Distribution of TLRs and other PRRs on epithelial cells
remains controversial. Epithelial cells minimally express TLRs on the luminal
surface, or, in some studies, the expression is below the limits of detection. In
contrast, these cells seem to express TLRs on the basolateral side of the cells,
allowing the innate immune system to rapidly detect bacteria that may breach the
barrier (Abreu 2010). Specialized epithelial cells, however, directly sense
bacteria via innate immune mechanisms. Paneth cells detect Bacteroides
thetaiotaomicron, and potentially other bacteria, leading to a MyD88-dependent
upregulation of the anti-microbial peptide RegIIIγ (Vaishnava et al. 2008;
Sonnenburg et al. 2006). In the absence of this pathway, mice are highly
susceptible to infection with Listeria monocytogenes (Brandl et al. 2007).
Epithelial cells also contribute to IgA production. Direct sensing of
commensal bacteria by TLR upregulates A Proliferation-Inducing Ligand
(APRIL) expression in epithelial cells, which activates dendritic cells (DCs) to
promote class switch to IgA2 (He et al. 2007). It is unclear if these bacteria were
sensed by TLR in the lumen or if bacteria translocate through M cells and are
then detected by epithelial cells.
Immunoglobulin A. IgA contributes to homeostasis at mucosal
surfaces and is highly produced in the gut. As discussed above, the microbiota
contribute to IgA production during development. IgA not only functions to
eliminate pathogens and limit their ability to infiltrate the mucosa, but also
directs the composition of the microbiota. IgA contributes to the selection of
Firmicutes in a complex process: Firmicutes induce expansion of Treg cells, that
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induce germinal centers and Firmicute-specific IgA, leading to their retention in
the GIT, demonstrating a feedback loop between the microbiota and adaptive
immune cells (Kawamoto et al. 2014). Other studies suggest that location within
the GIT, rather than specific bacterial species, induced commensal-specific IgA.
B1b cells that traffic from the peritoneal cavity to the small intestine and B2 cells
give rise to T-independent IgA-producing plasma cells specific to commensal
bacteria. Certain bacteria, including Segmented Filamentous Bacteria (SFB),
evade T-independent responses and instead induce T-dependent B2 cell
production of IgA (Bunker et al. 2015).
Innate lymphoid cells (ILCs). More recently, ILCs have been
identified to play a critical role in maintaining intestinal homeostasis through
direct and indirect interactions with the microbiota. ILCs are most likely the
main source of ‘T cell cytokines’ previously established, and discussed above, to
contribute to intestinal homeostasis. Development of the three ILC subsets
appears to occur independently of commensal bacteria, although there are many
conflicting reports (Monticelli et al. 2011; Vonarbourg et al. 2010; Bouskra et al.
2008; Tsuji et al. 2008). More consistently, it seems each subset of ILCs has
impaired function in the absence of bacteria. Recently, genome-wide screens of
intestinal ILCs in SPF mice compared to antibiotic-treated or germ-free mice
revealed that the microbiota contribute to epigenetic regulation and gene
expression in intestinal ILCs (Gury-BenAri et al. 2016).
ILCs and microbiota interactions occur through both direct and indirect
mechanisms. Some ILCs have limited expression of TLRs that can respond to

13
viruses and bacteria to enhance anti-viral and bacterial responses. Additionally,
metabolic by-products generated by commensals also stimulate ILC responses
(Stockinger et al. 2011). ILCs can also shape the microbiota through indirect
interactions by producing cytokines that influence epithelial cell permeability and
production of antimicrobial peptides (Clark et al. 2005; Mullin & Snock 1990;
Monticelli et al. 2011). Conversely, microbes stimulate cytokine production by
epithelial cells and myeloid cells that can activate ILCs (Vonarbourg et al. 2010;
Hughes et al. 2010).
T helper cell responses: Th17 induction. Several years after the
discovery of the immunomodulatory functions of PSA, Th17 cells were identified
as a new T helper cell subset (Mangan et al. 2006). These cells produce IL-17A,
IL-17F and IL-22 and have been implicated in both inflammatory and antiinflammatory processes. During bacterial and fungal infections, these cells
provide vital mucosal immunity, but excessive activation of these cells
contributes heavily to autoimmune disorders (Mangan et al. 2006). Th17 cells
accumulate in high numbers in the GIT and are notably absent in germ-free mice,
suggesting their development is induced by the microbiota (Ivanov et al. 2008;
Ivanov et al. 2009). Indeed, re-colonization of germ-free mice restores numbers
of Th17 cells within the lamina propria and colon. Interestingly, identical mouse
strains purchased from different commercial vendors had strikingly different
levels of Th17 cells within the small intestine. Upon analysis of the microbiota of
mice from each vendor, mice with no Th17 cells also had undetectable levels of
SFB compared to mice with Th17 cells from a different vendor (Ivanov et al.
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2008). In germ-free mice or in conventional mice lacking Th17 cells, colonization
with SFB potently induces Th17 cells and associated cytokine production in the
lamina propria (Ivanov et al. 2009). SFB are Gram (+) spore-forming anaerobic
bacteria highly prevalent in the gut microbiota. SFB colonize the terminal ileum
of mice, humans, and a variety of other vertebrates including non-human
primates, birds, frogs and fish (Klaasen et al. 1993), suggesting SFB and the
immune system have evolved this symbiotic relationship for a vast period of time.
In fact, SFB colonization appears to be species specific. Whereas most bacteria
lie in the upper of two mucus layers, SFB penetrate through the thin upper and
thick lower mucus layers and intimately attach to epithelial cells, leading to actin
reorganization. In response to SFB binding, epithelial cells upregulate serum
amyloid A and reactive oxygen species, which act on myeloid cells to upregulate
Th17-inducing cytokines, thereby inducing Th17 cells (Atarashi et al. 2015). This
tight adhesion with epithelial cells is species specific in that mouse SFB bind
specifically to mouse epithelial cells and cannot be transferred to rats, and vice
versa (Atarashi et al. 2015; Prakash et al. 2011). These studies suggest that SFB
have undergone host-specific adaptation. In exchange for potent immune
modulation, the host provides the auxotrophic SFB with amino acids and
nutrients essential for its survival (Sczesnak et al. 2011).
Prior to the discovery that SFB induce Th17 cells, SFB were identified to
stimulate secretory IgA production and recruitment of intraepithelial
lymphocytes (Umesaki et al. 1999; Talham et al. 1999). Recently, Hirota et al.
established a link between SFB induction of Th17 cells and IgA production. In

15
Peyer’s patches, SFB-induced Th17 cells acquire a T follicular helper cell
phenotype and induce IgA production by germinal center B cells (Hirota et al.
2013). These studies highlight nearly thirty years of research on independent
diverse subjects coalescing into a remarkable mechanism by which a commensal
bacterium has evolved a highly complex interaction with the host immune
response.
The development of tolerance between the colonizing bacteria and the host
response is pertinent for the health of the host. The picture of how the immune
system and commensal bacteria work together to maintain this environment is
constantly evolving as our understanding of new immune cells and bacteria
change with newly developed technologies. What is clear is that defects in any of
these arms of immunity and host defense leave the host susceptible to an array of
immune disorders.
Section 3: Induction of Regulatory Responses by Commensal Bacteria
Aberrant immune responses to commensal bacteria are prevented through
multiple different mechanisms. The mucus layers and IgA prevent direct
association of the bacteria with epithelial and immune cells; T helper cells and
ILCs produce cytokines to reinforce the barrier through antimicrobial peptide
and mucin production; but what maintains these inflammatory cells from
excessive responses? A failure to regulate these responses can lead to diseases
including IBD, allergies, and metabolic syndromes.
T Helper Cell Responses: Regulatory T cells.
Regulatory T cells (Treg) maintain peripheral and mucosal tolerance.
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These cells develop in the thymus (nTreg) under control of the master regulator,
Foxp3, but can also be induced (iTreg) from naïve CD4+ T cells in the periphery.
In the absence of Treg cells, the immune system runs rampant, leading to
exacerbated autoimmune disorders; these mice develop a fatal
lymphoproliferative disease, leading to multi-organ failure, and die within 3-5
weeks of age (Brunkow et al. 2001).
In humans, mutations in Foxp3 lead to IPEX autoimmune syndrome
(Immunedysregulation, Polyendocrinopathy, Enteropathy, X-linked syndrome),
and most children die within the first two years of life (Wildin et al. 2001). Treg
cells suppress immune responses through the effector molecules CTLA-4,
Transforming Growth Factor-β (TGF-β) and IL-10. The latter anti-inflammatory
cytokines act on a wide array of cells and potently inhibit cell activation and
proliferation. In the GIT, Treg cells also promote class switch to IgA via TGF-β
production, demonstrating another mechanism by which this essential molecule
is induced (Cong et al. 2009).
Inducible regulatory T cells (iTreg). In the gut, iTreg cells play an
essential role in the induction of tolerance to food and other oral antigens
(Coombes et al. 2007; Mucida et al. 2005). The microbiota help generate the
regulatory environment necessary to induce iTreg cells; Treg cell numbers and
production of effector cytokines are reduced in germ-free mice. Gut-resident DCs
promote iTreg development through TGF-β and vitamin A (Coombes et al. 2007)
and many of the signals driving the regulatory DCs come from the microbiota.
Clostridia, which comprise a large portion of the gut microbiota, play an
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instrumental part in iTreg induction. The Clostridia clusters IV, XIVa and XVIII
provide bacterial antigens and induce a TGF-β-rich environment, resulting in
substantial increases in iTreg cells (Atarashi et al. 2011; Atarashi et al. 2013).
Induction of regulatory T cells by Bacteroides fragilis. In
addition to expanding CD4+ T cell populations within the spleen of germ-free
mice, B. fragilis also generates iTreg cells in a process requiring PSA. B. fragilis
secretes PSA-filled outer membrane vesicles that are taken up by dendritic cells
in a TLR2-dependent manner. DCs process and present PSA to T cells via MHC
class II, thereby inducing IL-10–producing Treg cells (Shen et al. 2012). PSA can
also directly induce and expand nTreg cells when administered to germ-free
mice, or in germ-free mice monocolonized with B. fragilis (Round & Mazmanian
2010; Mazmanian et al. 2008; Round et al. 2011). B. fragilis PSA is a single
bacterial molecule capable of both inducing development of immune responses
and regulating immune responses. Although this molecule is the best
characterized, it is likely not alone; more bacteria and specific bacterial molecules
are likely to be identified to critically regulate immune responses.
Induction of regulatory T cells by microbial metabolites. A long
understood benefit afforded by the microbiota is aiding in food digestion. As they
break down food, the microbiota produces many metabolites, including shortchain fatty acids (SCFA). SCFA, and in particular butyrate, not only induce
differentiation of iTreg cells, but also expand colonic nTreg cells (Smith et al.
2013; Furusawa et al. 2013), demonstrating that bacterial metabolites as well as
physiological factors such as polysaccharides contribute to shaping immune
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responses. In Westernized countries, plant-based diets have decreased in
popularity, which may contribute to disregulation of the microbiota and Treg cell
development, providing a possible link to disease correlations mentioned
previously. Although much of the focus on the capacity for the microbiota to
regulate immunity has been focused on Treg cells, other regulatory cells
undoubtedly play a part in sustaining this environment.
Section 4: Probiotics and Disease
Clearly, commensal microbes provide integral benefits to the development
and regulation of the immune system and other bacteria undoubtedly share these
beneficial properties. Can we harness the power of these bacteria to treat human
disease? Probiotics are live microorganisms considered to benefit the health of
the host. The mechanisms by which probiotics benefit the host, and which
specific bacterial species among the hundreds found in different probiotics
currently on the market are not well appreciated. As we grow in our
understanding of how commensal bacteria influence the immune system, these
bacteria can be rationally be used as probiotics to treat and prevent different
ailments.
History of the Microbiota as a Therapeutic.
The use of the gastrointestinal microbiota as a therapeutic was first
documented in ancient Egypt in 1700 BC in papyrus texts, although it most likely
dates back further (Parkins, 2001). Excrement of different animals was used for
a variety of internal and external ailments and thought to magically repel demons
(Parkins, 2001). In the 4th century, Chinese physicians treated diarrhea with
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yellow soup, a broth consisting of dried stool from a healthy individual. These
anecdotes continue throughout history, from Antiquity to the Italians during the
Renaissance. From these early examples of ‘fecal transplants,’ modern
physicians and scientists developed invaluable treatments for many more
diseases.
Early in the 1900s, Ilya Mechnikov developed the first probiotics in today’s
understanding of the term. Fearing toxic biproducts of the GIT poisoned tissues
and contributed to senility, he believed fermented dairy products possessed
health benefits. He hypothesized that the microbiota was the main cause of the
poisoning and that if consumed regularly, the bacteria in fermented milk would
replace the damaged microflora by altering the intestinal phagocyte population
(Metchnikoff & Metchnikoff 1908).
Decades later, the idea would take hold again, with the return of fecal
transplants to treat enteric disease. The first documentation in a modern medical
journal comes from Dr. Ben Eiseman who used fecal transplants to cure four
patients suffering from pseudomembraneous colitis induced by Clostridium
difficile infection in 1958 (Eiseman et al. 1958).
Clearly the microbiota possessed a powerful therapeutic benefit that took
modern scientific advances to begin to tease apart. For years, people speculated
that the benefits exerted by these transplants were due to antibiotic production or
metabolites produced by the bacteria. Today, hundreds of fecal transplants have
been performed to treat C. difficile infection, and probiotics constitute a multibillion dollar industry world-wide. The numbers of implications are growing, but
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how the microbiota and specific probiotics contribute to health benefits is not
understood. Finally, after significant technological advances, we now understand
that the mechanisms of the benefits exerted by the microbiota are more complex
and far-reaching into the immune system than we had ever imagined.
Prevention of Colitis by Probiotics.
As we have already discussed, germ-free mice are wrought with problems
in the immune system. As expected, germ-free mice are highly susceptible to
bacterial, viral and fungal infections (Carthew & Sparrow 1980; Taguchi et al.
2002; Kamada et al. 2012). These studies suggest that when dysbiosis of the
microbiota occurs, a normal microbiota or probiotics can be added back to
restore the normal homeostatic balance between the immune system and the
microbiota.
Studies of probiotics in disease prevention, as with fecal transplants, have
mainly focused on models of inflammatory bowel diseases (IBD), or pathogeninduced colitis. IBD are chronic inflammatory disorders of the small intestines
and colon, in which patients suffer from rectal bleeding, severe diarrhea,
abdominal pain, fever, and weight loss (Strober et al. 2007). In many cases of
IBD, the mucosal barrier to the microbiota breaks down, and the immune system
mounts improper responses to the microbiota. Host genetics and dietary
influences can also contribute to IBD. All of these factors can lead to a loss of
tolerance to the microbiota, resulting in excessive inflammation and disease.
Mouse models of IBD attempt to take into account many of these different facets
of disease. Chemically-induced colitis models utilize a variety of chemicals and
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haptens to cause damage in the intestines and mimic the breakdown of the
mucosa and homeostasis, similar to what occurs in IBD. Exacerbated T helper
cell responses drive many of these models of chemically-induced colitis, including
2,4,6-trinitro benzene sulfonic acid (TNBS)-, dinitrobenzene sulfonic acid
(DNBS)-, and oxazolone-induced colitis. DSS is believed to be directly toxic to
colonic epithelial cells and induce gut leakiness, allowing the bacterial products
and bacteria to infiltrate the lamina propria (Wirtz et al. 2007). Other models
more directly exploit the T cell-mediated nature of colitis or host genetic
contributions. IL-10-/- mice spontaneously develop colitis at 8-10 weeks of age,
since IL-10 is a main contributor to mucosal tolerance. Additionally, adoptive
transfer of naïve T cells into Rag1-/- mice induces a similar pathology to Crohn’s
disease in humans (Ostanin et al. 2009), as do SAMP1/YitFc (SAMP) mice which
have chronic Crohn’s Disease-like ileitis (Pagnini et al. 2010).
In models of pathogen-induced colitis, pathogens including Helicobacter
hepaticus, Salmonella enterica, and Citrobacter rodentium induce damage,
inflammation and disease through complex immune responses, although
inflammatory T cell responses contribute to much of the inflammation. Many of
these are human enteric pathogens or mouse models of human pathogens, and
give clues as to how probiotics can be used to treat human infections.
Probiotics can limit disease in several different ways. First, in the case of
pathogen infection, they can block colonization of the invading pathogen or
compete for nutrients, not allowing the pathogen access to the specific niche
required for infection. Additionally, probiotics can increase barrier integrity.
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This can occur by promoting antimicrobial peptide (AMP) production (or
producing AMPs themselves), increasing mucus production, or upregulating tight
junctions between epithelial cells, decreasing permeability. Last but not least,
probiotics can alter the host immune response, leading to protection from
disease.
Colonization. Many pathogens need to occupy a certain niche within the
gastrointestinal tract to upregulate production of toxins or virulence factors and
induce disease. Many probiotics are thought to block adherence and colonization
of pathogens, ultimately preventing disease. Bifidobacterium breve produces
exopolysaccharide to promote its own colonization within the GIT, which in turn
prevents colonization with the enteric pathogen C. rodentium (Fanning et al.
2012). Although B. breve limits pathogen colonization, it must first modulate the
immune response to promote its own persistence. B. breve produces
exopolysaccharide (EPS) that suppresses B cell responses to B. breve. In a strain
of B. breve deficient in EPS production, high titers of antibody to B. breve are
present in the feces, and colony-forming units (CFUs) of B. breve are drastically
reduced, indicating that EPS production is crucial for B. breve persistence.
Further, EPS-deficient strains do not limit C. rodentium colonization,
demonstrating the importance of EPS production in disease prevention.
SFB also help to limit infection with C. rodentium by decreasing bacterial
colonization in the colon. Induction of Th17 cells by SFB leads to upregulation of
a signaling cascade that increases expression of IL-23, IL-22 and the AMP
RegIIIγ that are vital to controlling C. rodentium infection (Ivanov et al. 2009).
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Commensals and probiotics can also inhibit pathogen colonization by
competing for nutrients or producing inhibitory molecules including antimicrobial peptides and antibiotics. B. thetaiotaomicron competes with C.
rodentium for carbohydrates (Kamada et al. 2012), directly inhibits toxin
production by enterohaemorrhagic E. coli (De Sablet et al. 2009), and also
upregulates RegIIIγ, an anti-microbial peptide that binds Gram (-) bacteria
(Vaishnava et al. 2008). Bifidobacterium species produce peptides that serve as
antibiotics to pathogenic bacteria (Trejo et al. 2006; Gagnon et al. 2004),
demonstrating that certain species exert a plethora of beneficial effects.
Antibiotic treatment increases susceptibility to a wide-range of infections
and allows for proliferation of antibiotic-resistant pathogens such as vancomycinresistant Enterococcus species and C. difficile (Stecher et al. 2005; Barthel et al.
2003; Buffie & Pamer 2013). Cocktails of probiotics decrease pathogen
colonization and limit disease (Felley & Michetti 2003; Siggers et al. 2008). Even
though these bacteria decrease pathogen colonization, many of the identified
mechanisms involve innate immune modulation. More in depth analysis of the
molecular mechanisms by which probiotics limit pathogen colonization may
identify novel pathways of immune modulation.
Epithelial barrier integrity. Probiotics also promote epithelial barrier
integrity to prevent colitis; however, similar to prevention of colonization, these
effects are often due to alterations in innate immune responses. The probiotic
cocktail VSL#3 stimulates TNFα production in epithelial cells to promote barrier
integrity, which prevents ileitis in SAMP mice. Several studies have
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demonstrated that probiotics such as E. coli Nissle, Lactobacillus species, and
VSL#3 increase barrier function and anti-microbial peptide expression in cellculture models in vitro (Schlee et al. 2008; Wehkamp et al. 2004; Schlee et al.
2007). Lactobacillus species and VSL#3 require MAP kinase, and NF-κB and
AP-1 pathways, demonstrating that these effects require innate immune sensing
of bacteria or bacterial products (Schlee et al. 2008).
Modulation of immune responses. Probiotics clearly prevent enteric
diseases by modulating innate immune response, leading to decreased pathogen
colonization and increased barrier integrity. But how do probiotics limit IBD?
Many beneficial microbes appear to enhance anti-inflammatory responses
through modulation of adaptive immune responses (Table 1.1).

TLR2-dependent induction of iTreg by
IL-10+ DCs
Induction of Tr1 and Treg cells; reduction
of B. breve-specific antibody production
Negative regulation of iNKT cells in
neonatal mice
Inhibition of NF-κB in intestinal epithelial
cells
TLR2-dependent induction of IL-10+
F4/80+CD11b+CD11cint cells
Induction of IL-10+ Treg; upregulates
IL-22 by ILC
Reduction of pro-inflammatory mucosal
cytokines
Induction of Th17 cells; IgA production
Induction of TNF-α production by
epithelial cells; IL-10+ TGF-β+ T cells

Bacteriodes fragilis

Bifidobacterium
spp.

Bacteriodes fragilis

Faecalibacterium
prausnitzii

Clostridium
butyricum

Clostridia spp.

Lactobacillus spp.

Segmented
filamentous bacteria

VSL#3

n/a

n/a

n/a

n/a

n/a

Anti-inflammatory
protein MAM

Sphingolipid GSL-Bf717

Possibly
Exopolysaccharide

Polysaccharide A (PSA)

Exopolysaccharide (EPS)

Bacterial Molecule
Responsible for
Protection

Chronic CD-like ileitis
(SAMP mice), TNBSinduced colitis

C. rodentium-induced
colitis, T1D

H. hepaticus-induced
IBD

DSS-induced colitis,
food allergy

DSS-induced colitis

DNBS- induced colitis

Oxazolone-induced
colitis

C. rodentium-induced
colitis

H. hepaticus-induced
colitis, TNBS-induced
colitis, EAE

C. rodentium-induced
colitis

Inflammatory
Disease

Pagnini et al.; Di
Giacinto et al.

Ivanov et al.;
Kriegel et al.

Peña et al.

Stefka et al.;
Atarashi et al.; Cao
et al.

Hayashi et al.

Sokol et al.;
Quévrain et al.

An et al.

Jeon, et al;
Fanning, et al.

Mazmanian et al.;
Round et al.; Shen
et al.; OchoaRodrigez et al.

Jones et al.

Ref

Abbreviations: CD- Crohn’s Disease; DCs- Dendritic cells; DSS- Dextran sulfate sodium; DNBS- Dinitrobenzene sulfonic acid; EAEExperimental autoimmune encephalocyelitis; GIT- Gastrointestinal tract; iTreg- Inducible regulatory T cells; IBD- Inflammatory bowel
disease; ILC- Innate Lymphoid Cell; MAM- Microbial anti-inflammatory molecule; n.d.- not determined; TNBS- 2,4,5Trinitrobenzenesulfonic acid; T1D- Type 1 Diabetes

TLR4-dependent induction of M2
macrophages

Elicited Immune Response

Bacillus subtilis

Bacteria

Table 1.1. Commensal Bacteria with Beneficial Immunomodulatory Effects on
Inflammatory Diseases.
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As discussed above, B. fragilis and Clostridia strains help maintain
homeostasis between the immune system and microbiota through induction of
Treg cells. Upon disruption of this homeostatic environment with enteric
pathogens or in models of chemically induced colitis, administration of B.
fragilis, or the active component PSA, alleviates disease induced by H. hepaticus
and TNBS-induced colitis (Mazmanian et al. 2008; Shen et al. 2012). Further,
Clostridia strains induce and expand Treg cells through butyrate production, and
protect mice from DSS- and TNBS-induced colitis, as well as T cell transferinduced colitis (Atarashi et al. 2011; Furusawa et al. 2013; Atarashi et al. 2013;
Smith et al. 2013).
Other probiotics, including B. breve and other Bifidobacteria species,
VSL#3 and Lactobacillus rhamnosus GG, also induce IL-10 or TGF-β producing
Tr1 cells and iTreg cells that ameliorate disease in several inducible mouse
models, both pathogen and chemical, of colitis (Jeon et al. 2012; O’Mahony et al.
2008; Peña et al. 2005; Di Giacinto et al. 2005) . These studies demonstrate the
importance of regulatory T cells in maintaining intestinal homeostasis and their
versatility in limiting inflammation.
Few Treg cell-independent mechanisms have been established, but
probiotics potentially modulate other regulatory cells. The probiotic Clostridium
butyricum mediates protection from DSS-induced colitis in a Treg-independent
manner, through TLR2-dependent, IL-10–producing F4/80+CD11b+CD11cint
macrophages (Hayashi et al. 2013). Interestingly, inhibition of iNKT cells by B.
fragilis spingolipids at birth is essential for control of oxazalone-induced colitis

27
in adulthood. If mice are not exposed to B. fragilis, increased iNKT cells develop,
leading to exacerbated disease (An et al. 2014). Faecalibacterium prausnitzii is
one of the few bacteria for which an inhibitory bacterial molecule has been
identified and appears to alter innate immune signaling in epithelial cells. The
microbial anti-inflammatory molecule (MAM) is a peptide produced by F.
prausnitzii that prevents DNBS colitis. MAM is thought to inhibit NF-κB
signaling in epithelial cells, decreasing inflammation; but the precise molecules
mediating protection have not been identified (Quévrain et al. 2015; Sokol et al.
2008).
The overarching theme of the beneficial effects of probiotics seems to be
control of inflammation and induction of tolerance. Indeed, many other
probiotics, including Lactobacillus species, B. lactis, and E. coli Nissile, have
been shown to limit experimental colitis by altering the cytokine balance, even
though the precise mechanisms are undetermined (Peran et al. 2007; Grabig et
al. 2006; C et al. 2005; Peña et al. 2005).
Probiotics and Disease Outside the Intestine.
Pathogens and chemical models of colitis alike, promote pro-inflammatory
T helper cell responses. Probiotics promote Treg and Tr1 cells, or other
regulatory cells, and control exacerbated T cell responses, and restore
homeostasis to limit disease. Inflammatory T cells drive many different diseases
outside of the GIT, but can probiotics be used to treat systemic diseases?
Antibiotic-mediated disruption of the microbiota accelerates development of
Type-1 diabetes in mice, and is also linked to increased pathology of numerous
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systemic diseases including autoimmune diseases, e.g., lupus, arthritis, and
chronic obstructive pulmonary disease. These studies and the mechanistic
studies detailed above suggest that restoring a healthy microbiota with probiotics
may alleviate disease outside the GIT.
Many probiotics will likely be useful for treating or preventing other
inflammatory diseases, including diabetes, allergy and experimental autoimmune
encephalomyelitis (EAE) (Ochoa-Repáraz et al. 2010; Hu et al. 2015; Stefka et al.
2014; Cao et al. 2014). In fact, SFB-induces Th17 cells in the gut and lung that
regulate immunity to fungal infections (McAleer et al. 2016). Disruption of IL-17
receptor signaling, however, results in outgrowth of SFB and enhanced disease
severity during autoimmune diseases, namely, EAE (Kumar et al. 2016). This
study highlights the importance of a balance between the microbiota and the
immune system in regulating dysbiosis. SFB-induced Th17 cells can also prevent
the spontaneous development of type 1 diabetes in non-obese diabetic (NOD)
mice (Kriegel et al. 2011). In cases of type 2 diabetes, increased systemic
inflammation, often associated with obesity, drives insulin resistance and
metabolic syndrome, promoting the development of diabetes. Insulin resistance
in non-diabetic humans and patients with type 2 diabetes is associated with
increased levels of serum branched-chain amino acids. The presence of
Prevotella copri and Bacteroides vulgatus, species with enhanced biosynthetic
potential for branched-chain amino acids, correlates with insulin resistance in
humans. In mice, administration of P. copri increased insulin resistance and
glucose intolerance, suggesting that detrimental members of the microbiota can
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expand during dysbiosis (Pedersen et al. 2016). Restoring a healthy microbiota
with probiotics or targeting pathogenic bacteria may reduce insulin resistance.
Oral administration of B. fragilis PSA prevents development of paralysis
in EAE, a mouse model of multiple sclerosis (MS), by inducing IL-10-producing
Treg cells (Ochoa-Repáraz et al. 2010). Further, Clostridia species alter innate
lymphoid cells to secrete IL-22, which decreases epithelial permeability and
prevents development of food allergy (Stefka et al. 2014). Additionally,
Clostridia species-induced Treg cells prevent allergen-induced diarrhea (Atarashi
et al. 2011; Atarashi et al. 2013). These studies are of particular importance given
the rise of asthma and allergies in children raised in clean enviroments and not
exposed to a wide range of bacteria to train their immune responses. As our
understanding of the mechanisms by which specific commensal bacteria
modulate the immune system increases, we will likely identify more diseases for
which these probiotics will be beneficial.
Purified Bacterial Molecules as Therapeutics.
B. fragilis PSA and sphingolipids, and F. prausnitzii MAM protein
(Mazmanian et al. 2005; An et al. 2014; Sokol et al. 2008), are the only bacterial
molecules identified to have immunomodulatory effects. B. fragilis PSA and
sphingolipids have been purified, administered to mice and shown to exert the
given effects. MAM protein has been expressed in E. coli and shown to prevent
colitis; F. prausnitzii superantants containing MAM have anti-inflammatory
effects, but an active molecule has not been purified. B. breve modulates IgA
responses in an EPS-dependent manner, but this molecule has not been purified.
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Most likely, the majority of bacterial molecule(s) and metabolic products
responsible for protection have not yet been identified or purified, but perhaps
some share characteristics of the established molecules described above.
Undoubtedly, additional molecules from a large number of commensal bacteria
ware expected to regulate immune responses. Utilizing purified molecules as
therapeutics will be a useful alternative to the entire bacteria, especially for
immune-compromised individuals unable to tolerate or risk the entire organism.
Fecal transplants and now probiotics seem to be efficacious in treating severe C.
difficile infection, but many people suffering from recurrent C. difficile are elderly
or immune-compromised. These individuals could benefit immensely from an
anti-inflammatory molecule instead of an entire bacterium that could potentially
cause detrimental effects not seen in healthy individuals.
Section 5: Bacillus subtilis: From Soil to Bench to Probiotic
B. subtilis is a Gram (+), spore-forming bacterium ubiquitous in the
environment. B. subtilis has been extensively studied for many years as a model
organism for Gram (+) physiology, sporulation and biofilm formation. It is
highly amenable to genetic engineering, and also has the capacity to secrete large
amounts of proteins, making it very attractable in biotechnology and industrial
settings. Many purified enzymes on the market are produced in B. subtilis. It is
also widely used in agricultural and aquaculture to prevent pathogen
colonization, support bioremediation, and reduce abdominal fat in broiler
chickens (Samanya & Yamauchi 2002). New fields of study revolve around the
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capacity of B. subtilis to serve as a probiotic and a vaccine vector (Duc et al. 2003;
Jones & Knight 2012).
Due to its high prevalence in soil, air and drinking water, B. subtilis is
often found in insects, animals, and humans. Although vegetative cells would not
survive transit through the GIT, B. subtilis in spore form is virtually
indestructible, and would transit unimpeded. Once in the intestine, spores
germinate, proliferate, and then resporulate within the GIT (Spinosa et al. 2000;
Tam et al. 2006). Although not typically considered a true commensal or
resident bacteria in the GIT, many studies report Bacillus species present in the
majority of individuals surveyed, at levels from 103 to 108 CFU/gram of feces
(Macfarlane et al. 1986; Tam et al. 2006). Approximately 30% of the 84 Bacillus
isolates in humans were determined to be B. subtilis (Tam et al. 2006).
Additionally, B. subtilis is often found in the elderly and breast-fed infants
(Benno et al. 1986; Benno et al. 1984). Much importance has been placed on
Bifidobacteria, Bacteroides and Lactobacillus species since they persist in high
numbers and can reach 1011 colony-forming units (CFU)/gram of feces. Less
prevalent species may play an important role in modulating immune responses,
and clearly B. subtilis has adapted to living in the gut.
Bacillus subtilis as a Probiotic.
B. subtilis is present in high levels in the soil, and as expected, B. subtilis
and plants have evolved a symbiotic relationship. Upon infection with the plant
pathogen Pseudomonas syringae, the leaves of the Arabidopsis plant turn yellow.
If B. subtilis is added to the soil, the plants are perfectly healthy. The plant

32
secretes malic acid that acts as a distress signal to attract B. subtilis to the roots,
where it forms a biofilm. During biofilm formation, B. subtilis secretes a
surfactin with antibacterial activity against P. syringae as well as other bacteria
(Bais et al. 2004). Innate immune responses are remarkably conserved in
insects, mammals and plants. Bacterial infection triggers the plant flagellin PRR,
leading to activation of the highly conserved MAP kinase signaling pathway and
innate response genes. B. subtilis secretes a peptide that suppresses the innate
immune response of Arabidopsis and over 1000 other plants, allowing itself to
efficiently colonize the plant roots. Interestingly, suppression of plant PRRstimulated genes is dependent on TasA, the molecule that tethers
exopolysaccharide to the bacteria’s surface, however epsG and epsO mutants
deficient in EPS production still exerted suppressive activity (Lakshmanan et al.
2012). This immune suppression, however, could potentially leave the plant
susceptible for a short period of time to pathogens before B. subtilis, and the
plant itself, can mediate anti-bacterial effects.
B. subtilis limits pathogen infection in several other species including fish
and chickens (La Ragione et al. 2001; La Ragione & Woodward 2003; Tactacan et
al. 2013). Both of these are highly cultivated for commercial use, and as many
regulatory agencies begin limiting antibiotic use in animal and fish farming, B.
subtilis has been widely studied for probiotic potential as an alternative to
antibiotic treatments. Administration of B. subtilis to chicks 24 h prior to
infection with an avian E. coli infection suppresses disease and reduces pathogen
colonization. Interestingly, the window of protection is about 5 days (La Ragione
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et al. 2001). Pretreatment of chicks with B. subtilis also suppresses colonization
and persistence of Salmonella enteritidis and Clostridium perfringens,
demonstrating the versatility of this response (La Ragione & Woodward 2003;
Tactacan et al. 2013). In shrimp, B. subtilis controls pathogenic Vibrio species
through production of a secreted molecule that reduces shrimp mortality in
shrimp feeding ponds by 90% (Vaseeharan & Ramasamy 2003). Clearly, Bacillus
subtilis exerts a wide-range of effects that are beneficial to hosts across kingdoms
and species.
B. subtilis has been available as a probiotic in many European countries
for decades. The Japanese also regularly consume B. subtilis in the form of
Natto. Natto is made by fermenting soybeans with B. subtilis and is believed to
have probiotic properties, including vitamin synthesis. Several studies have
demonstrated that B. subtilis from Natto stimulates the immune system and
contributes to growth of other commensals (Hosoi et al. 2000; Tsukamoto et al.
2001; Hosoi et al. 1999).
Several clinical trials using multiple Bacillus species have shown some
beneficial effects in several disease states. B. coagulans has been used
successfully to prevent antibiotic-associated diarrhea in children (La Rosa et al.
2003). In other studies, B. subtilis reduced bacterial load in urine in the elderly
with urinary tract infections, though the probiotic used, Enterogermina, is
actually made of B. clausii and not B. subtilis (Coppi et al. 1985). In a clinical
trial to determine if B. subtilis improved immunity in the elderly, patients taking
B. subtilis had increased fecal and salivary IgA compared to placebo controls and
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decreased respiratory infections, although no changes were seen in
gastrointestinal disorders (Lefevre et al. 2015). B. subtlis did prevent antibioticassociated diarrhea in a clinical trial in Russia. Patients receiving B. subtilis and
antibiotics had a 7.8% occurrence of antibiotic-associated diarrhea compared to
32% in the placebo group. Patients receiving B. subtilis also reduced abdominal
pain, nausea, bloating and vomiting (Horosheva et al. n.d.). Several other
Bacillus species are effective in treating symptoms of IBD and diarrhea; however,
no mechanistic insights have been identified outside of the demonstrated
antibacterial properties of Bacillus products in other species.
Immune Modulation by B. subtilis.
B. subtilis produces a variety of molecules shown to directly target
pathogenic bacteria and reduce pathogen colonization of the symbiont, but does
B. subtilis alter immune responses?
Investigating if specific bacteria mediated the ability of the rabbit
microbiota to promote GALT development, the Knight Lab determined that B.
subtilis in combination with B. fragilis promoted B cell proliferation and
development of the preimmune antibody repertoire (Rhee et al. 2004). Spores
are also immunogenic in mice, but the dosing and administration schemes differ
vastly between studies resulting in a variety of immune responses. Mice dosed
three days in a row, every 3 weeks, develop systemic IgG and mucosal IgA
responses and rapid increases in TNF-α and IFN-γ in the MLN. Antibodies have
specificities for both spores and vegetative cells (Duc et al. 2004). In vitro, B.
subtilis upregulates APRIL production in intestinal epithelial cells, which
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promotes IgA class switch by germinal center B cells, providing mechanistic
insight for changes seen in vivo (He et al. 2007).
Other cell types have also been shown to respond to B. subtilis. Murine
macrophages phagocytose B. subtilis spores in vitro. Spores germinate within
the phagosome and may initiate protein synthesis. However, vegetative cells fail
to grow and divide and are destroyed within 5 h (Duc et al. 2004). This amount
of time however, seems to be enough to trigger innate immune responses. Cells
rapidly upregulate IL-6 mRNA upon treatment; minimal changes occur in TNF-α
and IL-1α.
Protection from C. rodentium-induced Disease by B. subtilis.
To further investigate the immune-stimulatory properties of Bacillus
subtilis, the Knight lab focused on a mouse model of the enteric human pathogen,
EPEC. C. rodentium is an attaching and effacing pathogen that induces acute
colitis. Disease is characterized by colonic hyperplasia, mucosal infiltration, an
increase in chemokines and pro-inflammatory cytokines, and diarrhea, similar to
the pathology of EPEC infection in humans. During infection, CD4+ T cells
infiltrate the intestinal mucosa and drive much of the pathology associated with
disease. CD4+ T cells increase the proliferation of intestinal epithelial cells and
deplete mucus-producing goblet cells in an IFNγ-dependent manner (Chan et al.
2013; Higgins et al. 1999). Additionally, infected mice display an increase in Th1
cytokines including IL-12, IFNγ and TNFα in the colon, as well as an increase in
the Th17 cytokine, IL-17A, in the Peyer’s patches (Li et al. 2014). These cytokines
lead to increased production of other chemokines that recruit innate immune
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cells to the site of infection, furthering the progression of disease. In most strains
of immunocompetent mice, C. rodentium is not lethal and is cleared by both
innate and adaptive immune responses 3 to 4 weeks post-inoculation; pathogen
clearance requires MyD88-dependent signaling, CD4+ T cells and IgG (Bhinder et
al. 2013; Kamada et al. 2015).
To test if B. subtilis protects mice from C. rodentium-induced disease,
mice were orally administered 109 B. subtilis spores 24 h prior to infection with
5x108 CFU of C. rodentium by oral gavage. Jones & Knight then assessed levels
of serum pro-inflammatory cytokines, colonic hyperplasia, and the development
of diarrhea 10 days post-infection. C. rodentium infected mice had increased
levels of the pro-inflammatory cytokine KC or CXCL1 in serum, mucosal
infiltration and loss of goblet cells in the colon, and develop soft stool. In mice
treated with a single oral dose of B. subtilis prior to infection, mice had no
evidence of disease. Serum KC and colonic histology of mice treated with B.
subtilis prior to C. rodentium infection are comparable to naïve mice. Further,
these mice have normal stool, suggesting that B. subtilis prevents C. rodentiuminduced inflammation (Jones & Knight 2012). In a separate study, D’Arienzo et
al. found that B. subtilis spores protected suckling mice from C. rodentiuminduced disease, but in adult mice, found no differences in disease progression
(D’Arienzo et al. 2006). The doses of B. subtilis and C. rodentium, as well as the
strains of mice, differed in these studies, which likely contributed to different
experimental outcomes.
Jones et al. (2014) first tested if B. subtilis reduces pathogen colonization,
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thereby limiting disease. In fact, D’Arienzo et al. did find reductions in C.
rodentium colonization in both suckling and adult mice following repeated doses
of B. subtilis. In our model using a single dose of B. subtilis, we see no alterations
in pathogen colonization in the lumen or mucosa, demonstrating that the
pathogen is still present at the same levels, but not causing disease. Jones et al.
also tested if B. subtilis alters the localization of C. rodentium in the GIT using a
luciferase-expressing strain of C. rodentium. Mice were monitored using an in
vivo imaging system throughout the course of disease. Administration of B.
subtilis did not change the localization or quantity of luminescence of C.
rodentium (Jones et al. 2014). These experiments demonstrate that B. subtilis
does not protect mice by altering the localization, adherence or density of the
pathogen.
Jones et al. (2014) also tested if B. subtilis increases epithelial barrier
integrity to limit disease. During C. rodentium infection, epithelial cell loss leads
to gut ‘leakiness’. We measure this by orally administering FITC-dextran and
assessing the serum for fluorescence. If B. subtilis functions by preventing
epithelial damage, then little to no FITC-dextran should be present in the serum.
During infection, we find about a two-fold increase in serum FITC-dextran
compared to PBS-treated mice, regardless of B. subtilis administration or not
(Jones et al. 2014). These data suggest that B. subtilis does not protect by
preventing epithelial barrier damage. We have not, however, explored the
possibility of increased IgA in the mucosa due to B. subtilis, as other groups have
seen, which may help to limit C. rodentium.
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Dr. Jones then asked which bacterial molecules produced by B. subtilis
mediate the protective effects, hypothesizing that B. subtilis formed a biofilm
within the GIT, blocking C. rodentium from attaching to epithelial cells and
causing damage. To test this hypothesis, Dr. Jones screened mutants deficient in
biofilm production, epsH and tasA, for protective effects in the C. rodentium
model. The epsH mutant did not protect mice from disease, however, the tasA
mutant, that also cannot form a biofilm, did protect mice from disease (Jones &
Knight 2012). These data suggest that the epsH gene product, a
glycosyltranferase, is required for protection, but formation of a biofilm is not.
As a negative control, mice were treated with hag mutant spores, which do
not produce flagella. Interestingly, the hag mutant also did not protect mice
from disease, suggesting flagella are required for B. subtilis-mediated protection.
There are two possibilities by which the flagella could provide protection: first,
TLR5 recognizes flagella and B. subtilis flagella could potentially stimulate TLR5
to activate the innate immune response. The second possibility is that B. subtilis
needs to localize to a particular niche within the GIT to mediate protection. To
test these possibilities, Dr. Jones utilized a motAB B. subtilis mutant, which
produces structurally intact flagella that cannot rotate. Therefore, if the bacteria
need to stimulate TLR5, this mutant will be protective, but if protection requires
localization of B. subtilis to a given niche, this mutant will not be protective. The
motAB mutant did not protect mice from C. rodentium-induced inflammation,
suggesting protection requires functional flagella (Jones & Knight 2012). To
further support this conclusion, mice were administered purified B. subtilis
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flagella, which did not protect mice from disease (Dr. Sara Jones, unpublished
observations). These studies demonstrated that B. subtilis spores germinate
within the GIT and vegetative cells express functional flagella to localize to a
certain niche, where cells also express epsH, which together induce a protective
response during C. rodentium infection.
Exopolysaccharide.
EPSs are secreted heterogeneous structures composed primarily of
carbohydrates that often coat bacteria and are major components of the biofilm
matrix. The role of EPS during pathogen infection is well appreciated. For
example, pathogenic Staphylococcus aureus are coated with an EPS-containing
capsule that prevents phagocytosis and allows adherence of the bacteria to host
tissues and subsequent immune evasion. Much less is known about EPS from
commensal bacteria. EPS might be important for probiotic or commensal
organisms to establish and maintain an intestinal niche that could prevent
pathogen colonization, as is the case with B. breve (Fanning et al. 2012).
Alternatively, gut metabolism of EPS could contribute to short chain fatty acid
synthesis, a process that regulates intestinal permeability and Treg cell induction
(Smith et al. 2013).
The epsH gene is encoded within the 15 gene eps operon required for
exopolysaccharide (EPS) production. B. subtilis produces EPS in the transition
from planktonic cells to cell aggregates known as biofilms. Biofilms contain nonmotile cells encapsulated within an extracellular matrix often composed of
polysaccharides, proteins and DNA. EPS and the amyloid protein TasA are the
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main components of the B. subtilis biofilm and serve to stabilize the biofilm
(Romero et al. 2010; Branda et al. 2006; Kearns et al. 2005). The epsH gene
encodes one of several glycosyltransferases within the operon, which are most
likely required for EPS biosynthesis (Guttenplan et al. 2010). In the absence of
epsH, B. subtilis does not produce EPS (Guttenplan et al. 2010).
We tested if B. subtilis EPS is required for protection by purifying EPS
from B. subtilis. We collaborated with the laboratory of Dr. Daniel Kearns at
Indiana University, where they produced a sinRtasA B. subtilis mutant. The sinR
gene encodes a DNA binding protein that binds to the promoter region of the eps
operon, and represses transcription of genes responsible for production of EPS
(Kearns et al. 2005). In the sinRtasA mutant, EPS is constantly being produced
and is no longer tethered to the surface of cells, allowing us to purify EPS from
culture supernatants. The Kearns Lab also produced a sinRtasAepsH mutant to
serve as a negative control, since it would produce all the background
polysaccharide, but would not produce EPS. Using these mutants we harvested
B. subtilis supernatants, digested nucleic acids and protein, and further purified
the remaining polysaccharide on a size exclusion column. Mice were injected
intraperitoneally (i.p.) with EPS or the same volume of material purified from the
sinRtasAepsH material then infected with C. rodentium 1 day later and disease
was assessed 10 days post-infection (dpi). Mice treated with EPS showed no
evidence of disease, whereas mice treated with the negative control material from
the EPS-deficient strain had increased levels of serum KC, colonic hyperplasia
and soft stool (Jones et al. 2014). These data indicate that EPS mediates
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protection from inflammation by B. subtilis.
How does EPS limit C. rodentium-induced inflammation? Bacterial
polysaccharides from both pathogens and commensal bacteria are ligands for
many types of PRRs, including TLRs, NOD-like receptors (NLRs), and C-type
lectins. Because many of these PRRs signal through MyD88, an adaptor protein
that often leads to NF-κB activation, we tested if EPS-mediated protection
requires MyD88. MyD88 is essential for controlling C. rodentium-induced
inflammation and MyD88-deficient mice are highly susceptible to disease
(Gibson et al. 2008). Jones et al. (2014) titrated the dose of C. rodentium to a
level where disease was comparable to that of wild-type (WT) mice, then tested if
EPS alleviated disease symptoms. MyD88-/- mice treated with EPS prior to
pathogen infection develop disease comparable to mice not treated with EPS,
suggesting EPS requires MyD88 to prevent disease (Dr. Sara Jones, unpublished
observations).
We further explored the dependency on MyD88 for protection using celltype-specific MyD88-/- mice. Mice lacking MyD88 in myeloid cells (LysM-cre)
and mice lacking MyD88 in epithelial cells (villan-cre) were treated with EPS one
day prior to infection with C. rodentium and disease was assessed 10 dpi.
Myeloid-specific MyD88-/- mice treated with EPS had elevated serum KC, crypt
hyperplasia and diarrhea; in comparison, EPS protected epithelial-specific
MyD88-/- mice from disease (Jones et al. 2014). These data suggest that EPS
utilizes MyD88 signaling in a myeloid lineage cell to mediate protection. Many
TLRs signal through MyD88. Other bacterial polysaccharides signal through
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TLR4, therefore we tested if EPS requires TLR4 signaling for protection.

TLR4-/-

mice treated with EPS develop C. rodentium-induced disease (Jones et al. 2014).
These studies suggest that B. subtilis prevents C. rodentium-induced
inflammation by producing EPS that signals through TLR4 on a myeloid cell to
elicit a protective response.
Section 6: Macrophages
Metchnikoff identified macrophages over 100 years ago as ‘phagocytes’
that phagocytose bacteria and apoptotic cells (Metchnikoff & Metchnikoff 1908;
Gordon 2008). He viewed these cells as essential components to maintaining
homeostasis. Today, we know that macrophages play a crucial part in
homeostasis by clearing apoptotic cells and promoting tissue development and
repair. Macrophages are also critical for host defense to intracellular and
extracellular pathogens; these cells produce antimicrobial factors that can
directly target pathogens within endosomes in the cell (Lawrence & Natoli 2011).
Additionally, macrophages produce cytokines and chemokines that initiate and
regulate adaptive immune responses.
Macrophage Development.
Tissue-resident macrophages. Macrophages are present in most
tissues throughout the body and have important functions in tissue development,
as well as sensing tissue damage and orchestrating tissue repair. Each tissue has
a specialized subset of macrophages, with distinct transcriptional master
regulators, that contribute to tissue-specific maintenance, even in immuneprivileged sites such as the eye, brain and testes (Okabe & Medzhitov 2016).
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Tissue-resident macrophages highly express PRRs including TLRs and NLRs, but
relative amounts of each PRR varies between tissues. Normal development and
function of some tissues and organs is dependent on macrophages that reside in
these organs, but macrophages in every tissue sense tissue damage and
orchestrate tissue-repair responses. Microglia, resident CNS macrophages,
function in synaptic formation and remodeling, which are vital to memory and
learning (Parkhurst et al. 2013; Blank et al. 2014). Bone macrophages, or
osteoclasts, perform bone resorption, which is imperative in bone remodeling
and tissue repair. In the liver, Kupffer cells clear pathogens and toxic
metabolites. Alveolar macrophages clear bi-products of neighboring cells such as
surfactins, as well as dust, allergens and microorganisms. In all tissues,
macrophages clear apoptotic debris, especially in the spleen where marginal zone
macrophages suppress immune responses to apoptotic cells and red-pulp
macrophages clear senescent red blood cells (McGaha et al. 2011). Intestinal
macrophages aid in tolerance to food antigens and the microbiota and help to
remove enteric pathogens (Schreiber et al. 2013).
Tissue-resident macrophages arise from the yolk sac, fetal liver, and
hematopoietic stems cells (HSCs) in the bone marrow. Until recently,
macrophage dogma dictated that the majority of tissue macrophages
differentiated from infiltrating blood monocytes. We now understand that the
majority of tissue-resident macrophages seed tissues before birth and are
maintained for the life-span of the organism by self-renewal (Jenkins et al. 2011;
Jenkins et al. 2013; Yona et al. 2013; Hashimoto et al. 2013). Judith Allen and
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colleagues first established the proliferative capacity of tissue-resident
macrophages during steady state and their increased proliferation in response to
parasite infection in the pleural cavity (Jenkins et al. 2011). Fate-mapping and
parabiosis studies have provided insight into the actual origins of tissue-resident
macrophages versus macrophages that differentiate from monocytes (Yona et al.
2013; Hashimoto et al. 2013). In both of these studies, there was no evidence
that monocytes contributed to liver, skin, splenic, or alveolar macrophages in
steady-state conditions. The majority of peritoneal macrophages appear to arise
prior to birth, but a small population of monocyte-derived macrophages resides
within the peritoneum and is discussed in detail below (Ghosn et al. 2010).
Whether macrophages within different tissues have different rates of
proliferation and survival has not been established. In cases of irradiation or
extreme inflammation, bone marrow-derived macrophages may repopulate
certain macrophage tissue populations.
Monocyte-derived macrophages. Monocytes differentiate from HSCs
in the bone marrow and circulate in the blood. Upon infection or acute
inflammation, monocytes infiltrate the site of damage and differentiate in situ
into macrophages or dendritic cells. Within the tissue, monocyte-derived
macrophages respond to environmental stimuli and contribute to inflammation
or help to resolve inflammation and promote repair (Schreiber et al. 2013).
Tumor-associated macrophages also differentiate from monocytes and are highly
anti-inflammatory. As discussed, very few macrophages arise from an influx of
monocytes to a given tissue under steady-state conditions. It is unclear, however,
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whether monocyte-derived macrophages dissipate with the resolution of
inflammation or if they persist and self-maintain in the tissue.
Certain tissues, including the intestine, rely on infiltrating monocytes as
the main source of macrophages (Little et al. 2014). The main population of
CX3CR1hi macrophages in the intestine differentiates from Ly6Chi monocytes that
expand within the gut lamina propria (Bogunovic et al. 2009; Jaensson et al.
2008). These cells have a half-life of roughly 3 weeks. Intestinal macrophages
help maintain homeostasis and prevent inflammatory responses to commensal
bacteria and food proteins (Murai et al. 2009). During colitis, macrophages
further infiltrate and accumulate in the gut and drive pathogenesis. The skin and
splenic marginal zone also contain resident macrophages that are monocytederived (Tamoutounour et al. 2013; A-Gonzalez et al. 2013). These tissues, along
with the gut, are regularly exposed to microbes and microbial products, which
may explain the need to be regularly replenished by monocytes.
Peritoneal Macrophages.
Macrophages comprise over half the cells within the peritoneal cavity of
mice. Due to their large numbers and the easy accessibility of the peritoneum,
these cells have been extensively studied in characterizing macrophage innate
immune responses, and for their ability to phagocytose pathogens. Peritoneal
macrophages are not a homogeneous population, but rather two distinct
populations. Small peritoneal macrophages (SPMs) are bone marrow-derived
F4/80low, CDllblow, and Ly6C+, and present in small numbers within the
peritoneal cavity. During infection, monocytes infiltrate the peritoneal cavity and
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differentiate into SPMs (Ghosn et al. 2010). As expected, SPMs highly express
CCR2, the chemokine receptor critical for monocyte recruitment. These cells are
highly phagocytic and produce large amounts of nitric oxide. Large peritoneal
macrophages (LPM) are the main population of macrophages within the
peritoneal cavity. As are most tissue-resident macrophages, these cells develop
during embryonic development in the yolk sac and are maintained through selfrenewal. During infection, these cells undergo rapid proliferation (Jenkins et al.
2013); however, they are less phagocytic and produce less nitric oxide compared
to SPMs. Following peritoneal injection of TLR agonists or even PBS, LPMs
rapidly disappear from the peritoneal cavity and the influx of monocytes leads to
an increased percentage of SPMs (Ghosn et al. 2010). Okabe and Medzhitov
determined that when macrophages disappear in the peritoneal cavity following
intraperitoneal injection of LPS, LPMs accumulate within milky spots of the
omentum, a fatty tissue within the peritoneum (Okabe & Medzhitov 2014). These
milky spots are clusters of mostly lymphoid cells and some other leukocytes.
Here, the omentum provides retinoic acid to macrophages, allowing them to
migrate back to the peritoneal cavity. Retinoic acid regulates expression of the
transcription factor GATA-6. GATA-6 controls expression of peritoneal
macrophage-specific genes in LPMs and localization of LPMs within the
peritoneal cavity under normal conditions and their return following peritoneal
inflammation (Okabe & Medzhitov 2014). Among these genes are Tgfb2 and
other genes related to deposition and activation of the latent form of TGF-β.
Since TGF-β and retinoic acid promote B cell homing to the gut and induce IgA
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class switching (Baumgarth 2011), Okabe and Medznikov investigated the
function of GATA-6 and LPM in gut IgA production. Interestingly, they
determined that GATA-6 in macrophages controls IgA production by B1 cells that
migrate to the lamina propria. Overall, these studies demonstrate that
macrophage subsets within the peritoneal cavity have diverse roles in
maintaining immunity inside and outside of the peritoneum.
Peritoneal cell trafficking. In contrast to other tissue-resident
macrophages, peritoneal macrophages float within the peritoneal fluid that
circulates toward lymphatics (Avraham-Chakim et al. 2013), allowing them to
constantly survey abdominal organs. Trafficking into the peritoneal cavity has
been much better characterized than cells leaving the peritoneal cavity to travel to
other parts of the body. Peritoneal cells are thought to traffic from the peritoneal
cavity to other organs through two routes. By one route, cells traffic through
milky spots in the omentum and into the lymphatics. Early studies demonstrated
that capillaries within these lymphoid aggregates are points of cellular traffic for
multiple cell types, including monocytes (Hodel 1970; Beelen et al. 1980; Doherty
et al. 1995). Another route seemingly exists, however, much less is understood.
Recently, Wang and Kubes identified a non-vascular route by which macrophages
from the peritoneal cavity directly enter the liver in a model of sterile
inflammation. In this model, macrophages rapidly accumulate in the liver by
upregulating CD44, an adhesion molecule that binds to exposed hyaluronan
present on liver mesothelium (Wang & Kubes 2016). Although other organs were
not examined in this study, it stands to reason that macrophages, and other
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peritoneal cells, can directly enter other organs covered by the peritoneum,
including the gut.
Macrophage Polarization.
Macrophages polarize into different activation states following microbial
stimulation or environmental and cytokine stimuli. Activation phenotypes are
thought to occur across a spectrum and be fairly plastic, allowing cells to rapidly
adjust to different environments. Traditionally, two activation states, classical
(M1) and alternative (M2) (Figure 1), encompassed most identified macrophages,
but these subtypes are fairly heterogeneous. Different transcription factors have
been identified to regulate classical versus alternative polarization.

Figure 1.1. Macrophage Polarization. Tissue-resident macrophages (MΦ)
adopt different activation states based on their environment. M1 macrophages
are induced following LPS and/or IFNγ stimulation and produce proinflammatory cytokines and are highly phagocytic. M2 macrophages develop in
the presence of IL-4, IL-13 and potentially other anti-inflammatory factors.
They induce an anti-inflammatory environment.
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M1 Macrophages.
M1, or classical, activation occurs following TLR ligation and/or IFN-γ
stimulation, and cells express high levels of inducible nitric oxide synthase
(iNOS). IFN-γ often comes from natural killer (NK) cells or other innate cells.
M1 macrophages are pro-inflammatory, highly phagocytic, and mediate host
defense to bacteria, viruses, and protozoa, and contribute to anti-tumor
immunity. Upon phagocytosis of pathogens, the phagosome containing the
pathogen fuses with the lysosome where nitric oxide, reactive oxygen species, and
enzymes aid in destruction of intracellular pathogens. Depending on the
pathogen, these cells produce large amounts of IL-12p40 and TNF-α that
promote Th1 effector cell differentiation, or IL-23 that can promote Th17
differentiation (Italiani & Boraschi 2014). These effector T cell subsets produce
cytokines that help to maintain the M1 phenotype. As the pathogen is eliminated,
the reduction in M1-stimuli and increase in M2 stimuli are thought to give rise to
M2 macrophages that promote wound healing and repair tissue damage that
occurred during inflammation.
M2 Macrophages.
M2, or alternatively-activated, macrophages are anti-inflammatory and
regulate wound healing and tissue repair. M2 activation primarily occurs in
response to IL-4 and IL-13 (Dyken & Locksley 2013). These cytokines are
produced by granulocytes such as basophils, eosinophils and mast cells, and
lymphoid cells including Th2 cells, ILC2 and NKT cells (Jenkins & Allen 2010).
Several other M2 macrophage-inducing stimuli have been described. Each
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resulting ‘subtype’ exhibits anti-inflammatory properties, but often differ in
marker expression and often produce varying effector molecules. Other M2inducing factors include IL-10, TGF-β, immune complexes, and glucocorticoids
(Cao et al. 2010). Additionally, TLR stimulation also can drive M2 polarization.
Another population of macrophages, regulatory macrophages, produce large
amounts of IL-10 in response to Fc receptor ligation. Within the tumor
microenvironment, tumor-associated macrophages (TAMs) and myeloid-derived
suppressor cells (MDSCs) have been identified and are quite functionally similar
to M2 macrophages (Mills 2012).
M2 macrophage markers include arginase-1, CD206, Fizz-1, YM-1, and
effector cytokines; these molecules are described in detail below. Table 1.2
contains a summary of M2 macrophage markers that are upregulated in response
to different stimuli, however, different studies utilize various combinations of
these markers or as little as one marker to define these cells.
Table 1.2. M2 Macrophage Markers and Functions
Molecule

Full Name

Function

CD206/
MRC1

Macrophage mannose receptor, Ctype mannose receptor-1

C-type lectin, phagocytosis of pathogens

IL-4Rα

---

Dimerizes with the common γ-chain or
IL-13Rα1 to form IL-4 and IL-13 receptor

Arginase-1

---

Competes with iNOS to catalyze L-arginine
hydrolysis to urea and ornithine, production of
prolines and polyamines to promote tissue
repair/fibrosis

Relmα/
FIZZ-1

Resistin-like molecule alpha or
found in inflammatory zone protein

Cysteine-rich small proteins, not well
characterized

Ym-1/
Chi3l3

chitinase-3-like protein 3

Lectin, chitinase-like molecule, not well
characterized

Abbreviations: Chi3l3: chitinase-like 3 ; FIZZ-1:found in inflammatory zone 1 ; IL-4Rα: interleukin-4
receptor α; IL-13Rα1: interleukin-13 receptor α 1; iNOS: inducible nitric oxide sythase; MRC1: ; Relmα:
resistin-like molecule α
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Arginase-1. Arginase-1 (Arg-1) catalyzes the conversion of L-arginine
into L-ornithine and urea. IL-4 and IL-13 upregulate Arg-1 expression in
macrophages via STAT6, STAT3 and PPAR-γ, supporting the fact that various
stimuli drive Arg-1+ M2 macrophages. Arg-1 competes for substrates with iNOS,
which is induced by M1 stimuli. These factors, therefore, have become defining
characteristics in the M2 versus M1 macrophages. Additionally, Arg-1
contributes to M2 macrophage-anti-inflammatory functions. Arg-1 production
by macrophages inhibits CD4+ T cell proliferation and IFN-γ production, since T
cells require arginine to proliferate (Pesce et al. 2009; Gobert et al. 2004).
Mannose receptor. The mannose receptor, or CD206, is a C-type lectin
expressed by macrophages in many tissues and upregulated by IL-4/IL-13.
CD206 binds serum glycoproteins and contributes to their clearance (Lee et al.
2002). CD206 also contributes to endocytosis and possibly antigen presentation
(Gazi & Martinez-Pomares 2009). Expression of this receptor contributes to
immunity to fungal and parasitic infections, most likely by serving as a PRR for
mannosylated ligands.
Ym-1. Ym-1, or Chi3l3, is a chi-lectin that is induced in an IL-4/IL-13 and
STAT6-dependent manner in macrophages. Chi-lectins, including Ym-1, are
homologous to chitinases that bind and degrade chitin; chi-lectins bind chitin,
but lack enzymatic activity. Chi-lectins bind β-1,4-N-acetylglucosamine that can
be found on parasites, fungi and dust mites that elicit Type 2 immune responses.
Although Ym-1 upregulation on M2 macrophages occurs during allergic
responses and helminth infections and could potentially recognize chitin motifs,

52
Ym-1 accumulates intracellularly. It is unclear if it can contribute to M2mediated anti-inflammatory effects.
FIZZ-1. FIZZ-1, found in inflammatory zone (FIZZ-1), or resistin-like
molecule α (Relmα), is upregulated during helminth infection or allergeninduced inflammation in epithelial cells, eosinophils and macrophages. As with
Ym-1, FIZZ-1 is consistently described as an M2 marker, but the function of this
molecule is not well understood. Some evidence suggests that FIZZ-1 is a
negative regulator of Type 2 inflammation and that recombinant FIZZ-1 can
directly inhibit Th2 cell cytokine production (Nair et al. 2009), while contrasting
studies suggest FIZZ-1 promotes allergy-induced lung inflammation (Doherty et
al. 2012). Both of these studies use recombinant FIZZ-1. The actual function of
FIZZ-1 production by macrophages has not been identified.
A recent publication discussed the difficulties across the macrophage field
due to various methods of generating and polarizing macrophages and their
transient nature (Murray et al. 2014). Instead of classifying macrophages into M1
versus M2 macrophages, this large group of macrophage biologists suggest that
future studies directly reference the stimulus in the name, i.e. M(IFN-γ) or M(IL4). This will undoubtedly be difficult to establish as a new basis of naming
macrophages. As our understanding grows of transcriptional programs
controlling macrophage polarization in different environments and disease
states, perhaps new nomenclature methods will be identified.
M2 Macrophages in Health and Disease.
M2 macrophages have primarily been characterized during helminth
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infections, and allergy, but recent studies have linked them to an array of normal
processes including systemic metabolism, cold adaptation and tissue
homeostasis. Dysregulation of these normal functions is linked to
atherosclerosis, osteoporosis, obesity and type 2 diabetes, fibrosis and cancer
(Martinez et al. 2008). Interestingly, many of these diseases are also linked to
disruptions of the microbiota.
Metabolism. Immune cells can regulate metabolic homeostasis. In a
lean state, Th2 cells, Treg cells, ILCs, and eosinophils promote M2 macrophages
that all help maintain an anti-inflammatory environment within brown adipose
tissue, and maintain insulin sensitivity (Carey et al. 2013; Molofsky et al. 2013).
These cells that maintain adipose tissue homeostasis are dysregulated in obesity
when fat tissue becomes highly inflamed. M1 macrophages are highly prevalent,
as well as Th1 cells, ILC1s and CD8+ T cells (O’Sullivan et al. 2016). These cells
secrete proinflammatory cytokines that contribute to insulin resistance and Type
2 diabetes.
There are three main types of adipose tissue; white adipocytes store energy
as lipids and contribute to metabolic disease in obesity, whereas brown
adipocytes, or ‘healthy fat,’ dissipate chemical energy for heat production in
response to cold and counteract obesity and metabolic disease. White fat can
undergo a ‘beiging’ process, increasing energy expenditure, and become beige
adipocytes. Brown and beige adipocytes function to prevent weight gain in mice
and humans (Feldmann et al. 2009; Carey et al. 2013). During cold exposure,
M2 macrophages produce norepinephrine and epinephrine that promote beiging
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of white adipocytes and decreases adiposity (Wu et al. 2011; Qiu et al. 2014).
Allergy and asthma. Allergic disease is caused by the immune system
inappropriately reacting to innocuous substances. Allergic reactions occur upon
exposure to an allergen in pre-sensitized individuals. Antigen-presenting cells
(APC), such as dendritic cells (DC), macrophages or B cells, initiate the process of
allergic sensitization by capturing and internalizing allergen. APC present
antigen, especially to T cells which secrete cytokines, interleukin-4 (IL-4), IL-5,
and IL-13 that help drive the inflammatory response. IL-4 is critical for class
switch to IgE, which mediates allergic symptoms (Galli & Tsai 2012).
Numerous studies have identified roles for M2 macrophages in allergic
responses driven by IL-4 and IL-13. However, their function in allergy and
asthma remains controversial, with some studies suggesting that M2
macrophages promote allergic inflammation and others indicating a suppressive
role for these cells. In several types of allergic inflammation, mice deficient in
M2 polarization (myeloid-specific IL-4Rα-/-), showed few differences in allergic
antibody and cytokine production, mucus secretion, and eosinophil infiltration
that are detrimental during allergic responses (Heller et al. 2007). Other studies
have shown that M2 macrophages can contribute to eosinophil recruitment
(Falcone et al. 2001; Huffnagle et al. 1998). In cases of asthma, by facilitating the
uptake and removal of fungal conidia, M2 macrophages have been shown to
inhibit asthma symptoms associated with chronic fungal infections (Moreira et al.
2010). In any event, the upregulation of IL-4 and IL-13 during allergy and
asthma contributes to accumulation of these cells.
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Helminth infection. Helminth infection in the GIT, pleural cavity and
peritoneal cavity elicit strong Type 2 immune responses that are required to expel
the worms. Infection leads to increased IL-4 and IL-13 production, proliferation
of macrophages, and upregulation of M2 phenotypic markers (Jenkins et al.
2011). IL-4 and IL-13 also promote IgE class switch, increased mucus production
and eosinophilia (Jenkins & Allen 2010). In the gut, Trichiuris muris infection
results in monocyte recruitment that ultimately contributes to macrophage
accumulation and obtain an M2 macrophage phenotype (Little et al. 2014).
Although robust Type 2 immune responses can be detrimental in the case of
allergy, these responses are necessary to clear helminth infection and limit
detrimental responses. Deficiency of IL-4 receptor α (IL-4Rα)-signaling
specifically in myeloid cells results in early mortality to Schistosoma mansoni,
due in part to exacerbated disease pathology from Th1 cells (Herbert et al. 2004),
and Th2 inflammation and fibrosis, which are limited by Arg-1 (Pesce et al.
2009). Infection with other helminthes can impair eosinophil recruitment and
tissue repair, but worms are cleared normally, suggesting that M2 macrophages
play different roles in various helminth infection models (Martinez et al. 2008).
Mechanisms of Inhibition by M2 Macrophages.
In addition to Arg-1, M2 macrophages produce several other inhibitory
molecules including IL-10, PD-L2, and TGF-β. These molecules can potentially
inhibit a variety of cell types, but their inhibitory properties have been primarily
studied with T cells.
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Interleukin-10. IL-10 potently inhibits T cell cytokine production and
proliferation, rendering the T cells unresponsive, or anergic. IL-10 also
downregulates MHC class II and co-stimulatory molecules on APCs (A. Taylor et
al. 2006), and induces immunoregulatory phenotypes, i.e. M2 macrophages,
iTregs (Murai et al. 2009; Italiani & Boraschi 2014). Administration IL-10 to
mice alleviates a plethora of diseases, including colitis, graft-versus-host disease
(GVHD), and allergic responses to name a few, however clinical trials in humans
have not been as successful (Min et al. 2007; Murai et al. 2009). Induction of IL10 within a given cell-type or tissue versus administration of recombinant IL-10
may have better therapeutic effects.
Programmed death-ligand 1/2. Immune checkpoints are critical for
maintaining self-tolerance, and much of this is mediated by membrane receptorligand interactions. Programmed cell death protein 1, PD-1, is an
immunooreceptor tyrosine-based inhibitory motif (ITIM)-containing receptors
expressed on T cells and B cells. PD-1 is upregulated in activated T cells and
binds to PD-L1 and PD-L2 (Latchman et al. 2001; Liang et al. 2003). PD-1
interacts with its ligands to prevent T cell activation and proliferation by
promoting apoptosis (Carter et al. 2002). Interestingly, PD-1/PD-L1 interactions
also maintain an anti-inflammatory environment by reducing apoptosis in Treg
cells (Carter et al. 2002). PD-L1 and PD-L2 are part of the B7 family of costimulatory molecules and are expressed on macrophages and dendritic cells. IL4 upregulates expression of PD-L2 on macrophages in a STAT6-dependent
manner (Liang et al. 2003). Inhibition of PD-L2 during infection with the
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helminth Nippostrongylus brasiliensis enhances Th2 responses in the lung,
demonstrating that PD-L2 is required to limit an exacerbated Th2 response
(Huber et al. 2010).
Transforming growth factor-β. TGF-β is a pleiotropic cytokine that
acts on virtually all cell-types. TGF-β potently inhibits T cells by blocking IL-2
production, a required growth factor for T cells, via smad3 signaling (A. Taylor et
al. 2006). This induces anergy, which is characterized by T cells that fail to
activate upon antigen-stimulation. TGF-β contributes to peripheral tolerance by
promoting Treg cell generation and increasing their suppressive function. In
combination with IL-6, TGF-β promotes differentiation to Th17 cells (Mangan et
al. 2006), whereas TGF-β promotes survival in memory T cells. In B cells, TGF-β
suppresses allergen-specific IgE and induces class-switch to allergen-specific IgA
(Mucida et al. 2005). Granulocytes, including mast cells and eosinophils, and NK
cells increase chemotaxis and often survival in the presence of TGF-β, which may
account for some detrimental effects of TGF-β in allergy models (Gorelik &
Flavell 2002). In NK cells, TGF-β also decreases cytokine production and their
cytolytic activity (Bellone et al. 1995). Dendritic cells and macrophages decrease
antigen presentation following TGF-β stimulation, but these cells can obtain
regulatory phenotypes and inhibit T cells and/or induce Treg cells (Gandhi et al.
2007; Jaensson et al. 2008). Several studies demonstrate that TGF-β drives M2
macrophage polarization and TAM development or mediate the antiinflammatory effects of M2 macrophages (Derynck et al. 2001; Calon et al. 2014).
M2 macrophages induced during infection with the nematode Litomosoides

sigmodontis suppress

CD4+
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T cell proliferation through production of TGF-β (M.

D. Taylor et al. 2006). Following phagocytosis of apoptotic cells, macrophages
upregulate TGF-β to suppress proinflammatory cytokine production that may
occur in response to the apoptotic bodies (Fadok et al. 1998). Additionally,
macrophages promote wound healing and repair through TGF-β production.
TGF-β has three subtypes, TGF-β1, TGF-β2 and TGF-β3, all with similar
functions, that are synthesized as precursor molecules containing a propeptide
region and the TGF-β homodimer (Gorelik & Flavell 2002). TGF-β noncovalently associates with a latency-associated peptide (LAP). This complex
binds to Latent TGF-β-binding Protein (LTBP), forming a large complex that gets
deposited on the extracellular matrix. TGF-β can also be expressed on the cell
surface when associated with LAP; this form mediates TGF-β suppression of T
cells by Treg cells (Nakamura et al. 2001). TGF-β remains inactive when bound
by LAP and LTBP; these molecules must be cleaved to release active TGF-β, but
the mechanisms by which activation occurs are poorly defined. Components of
the extracellular matrix including proteases release active TGF-β, as do pH
changes, ROS and thrombospondin in serum (Nunes et al. 1995; Hyytiäinen et al.
2004; Taylor 2009). Cell-surface bound TGF-β in complex with LAP mediates T
cell suppression and Treg induction by dendritic cells, but how TGF-β is activated
on cell surfaces is unknown (Gandhi et al. 2007). Integrins on epithelial cells also
cleave LAP from TGF-β and could potentially contribute on cell surfaces (Taylor
2009).
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T cell responses in disease. Maintaining a balance between induction
and inhibition of T cell responses is vital to the health of the host. Immunity to
several pathogens requires Th1 and Th17 responses, but excessive responses can
contribute to pathology, as is the case in colitis (Giacinto et al. 2005; Higgins et
al. 1999; Yang et al. 2014). Similarly, exacerbated Th2 responses, or
inappropriate responses to antigens, lead to allergy and asthma, but Th2
inflammation is required to clear helminth infections (Paula et al. 2013). M2
macrophages possess the capabilities to dampen excessive immune responses
through several different mechanisms, and can also promote tolerance through
induction of Treg cells.
Unchecked, T cells are main drivers of autoimmune disorders, multiple
sclerosis (MS) and colitis. EAE, an animal model of MS, is driven by pathogenic
Th1 and Th17 responses that target the central nervous system (Langrish et al.
2005). The therapeutic agent, fasudil, alleviates the symptoms of EAE by
promoting M2 macrophages that inhibit pathogenic T cell responses and
increasing Treg cells (Liu et al. 2013; Liu et al. 2015). However, many of the
factors produced by M2 macrophages to inhibit inflammatory responses have
been implicated in tumorigenesis, demonstrating the importance of the inducible
and reversible nature of M2 macrophages. Within the tumor microenvironment,
M2 macrophages or TAM that develop within the tumor suppress cytotoxic T
cells and NK cells that could help to eliminate the tumor (Noy & Pollard 2014).
Further, M2 macrophage functions that normally contribute to wound healing
and tissue repair promote tumor growth and metastasis through increased
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stroma remodeling and angiogenesis (Martinez et al. 2008). Treg cells are also
increased in the tumor microenvironment. M2 macrophages may directly induce
these cells, or enhance their suppressive functions within the tumor.
The microbiota alters and induces development of several subsets of T
cells, and perhaps others that induce inflammation and alter inflammation.
Understanding the balance of T cell responses during infection and disease will
help us determine how specific microbes can augment or limit certain responses.
Concluding Remarks.
The microbiota is vital to the development of lymphoid tissues and
immune responses, the induction of tolerance, and disease prevention. The
molecular mechanisms by which intestinal bacteria guide these beneficial
responses are just beginning to be discovered. Continued research into the
interactions between specific bacteria and the immune system will undoubtedly
uncover novel interactions that contribute to homeostasis in the gut, and other
microbiota/host interfaces such as the skin, eyes, lung, vagina and bladder.

CHAPTER TWO
MATERIALS AND EXPERIMENTAL METHODS
Mice.
All animal experiments were performed according to protocols approved
by the Institutional Animal Care and Use Committee at Loyola University
Medical Center (Maywood, IL). Specific pathogen–free (SPF) C57BL/6, TLR4-/-,
TLR2-/-, CD4-/-, and OT-II transgenic mice founders were purchased from The
Jackson Laboratory (Bar Harbor, ME) and bred in-house. Mice lacking MyD88
in myeloid cells were generated by crossing Lyz2-Cre transgenic mice to MyD88floxed mice as described (Gais et al. 2012). Sterile standard chow and tap water
were given to mice ad libitum.
Reagents.
All base media and supplements were from Life Technologies (Grand
Island, NY). All antibodies were from Biolegend (San Diego, CA) unless otherwise
indicated. The fluorescent antibodies used for flow cytometry include antiCD16/32 (FC block), anti-F4/80 (BM8), anti-CD25 (PC61), anti-CD4 (GK1.5),
anti-CD8 (53-6.7), anti-CD11b (M1/70), anti-CD44 (IM7), anti-IL-4Rα (I015F8),
anti-CD206 (C068C2), anti-CD80 (16-10A1), anti-CD86 (GL-1), anti-PD-L1
(10F.9G2), anti-CD11c (N418), anti-siglecF (1RNM44N, eBioscience, San Diego,
CA), anti-Ly6G (1A8), anti-Ly6C (HK1.4), anti-MHCII (M5/114.15.2), anti-PD-L2
(TY25), anti-IgM (RMM-1), anti-IL-4 (11B11), anti-IL-13 (eBio13A, eBioscience,
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San Diego, CA), anti-IFN-γ (R4-6A2), anti-LAP (TW7-16B4), anti-Foxp3 (FJK16s, eBioscience, San Diego, CA), anti-CD68 (ICFC), anti-CD80 (human, 2D10),
anti-CD163 (GHI/61), anti-PD-L1 (human, 29E.2A3) and sheep antimouse/human arginase-1 (R&D systems, Minneapolis, MN). Enzyme-Linked
Immunosorbent Assay (ELISA) reagents for quantitation of IL-10, IFN-γ, TNF-α,
and KC/CXCL1 were from R&D Systems; IL-17A, IL-2, IL-13 and TGF-β
matched-pair reagents were from Biolegend. Clodronate and PBS liposomes
were from VU medisch centrum (Amsterdam, The Netherlands). The anti-CD3ε
(145-2C11) for in vivo experiments was from Leinco Technologies, Inc, (St. Louis,
MO). The anti-CD3ε used for in vitro experiments was LEAF-purified anti-CD3ε
(145-2C11, Biolegend). Cytochalasin D, NS-398, and SB-431542 were from Sigma
(St. Louis, MO). All primers were from IDT (Coralville, IA). Apoptosis reagents
were from BioLegend (San Diego, CA). The MFB-F11 cell-line and RAW264.7
cell-line were generous gifts from the Iwashima and Weithoff laboratories,
respectively. QUANTI-blue reagent was from Invitrogen (Carlsbad, CA).
Cytokines for in vitro assays were from Peprotech (Rocky Hill, NJ).
The following neutralizing antibodies were used for in vitro assays: TGF-β
inhibition, 5 µg/mL anti-TGF-β (1D11, R&D Systems, Minneapolis, MN) or
equivalent concentration of LEAF-purified mouse IgG1 isotype control; PD-L2
inhibition, 3 µg/mL anti-PD-L2 (TY25) or isotype control LEAF-purified rat
IgG2a; PD-L1 inhibition, 5 µg/mL anti-PD-L1 (10F.9G2) or isotype control LEAFpurified rat IgG2b. Experiments with blocking antibody included the addition of 1
µg/mL LEAF-purified anti-CD16/32 (FcγRII/III) to all wells. For small molecule
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inhibitors, the following concentrations were used: Nor-NOHA (12 µM),
exogenous L-arginine (2 mM), NS-398 (1 µM).
Purification of Exopolysaccharide.
Exopolysaccharide was isolated from B. subtilis DS991 (ΔsinRtasA
mutant), a strain that produces and secretes large amounts of EPS (Guttenplan et
al. 2010). The negative control, designated ΔEPS, DS5187 (sinRtasAepsH
mutant), does not produce EPS and does not protect from C. rodentium-induced
disease (Jones et al. 2014). EPS was isolated from stationary phase supernatants
of bacteria grown in Luria–Bertani (LB), BHI (brain-heart infusion) or MSgg
medium isolated by 50% EtOH precipitation at -20o C. The precipitate was
pelleted (15,000xg, 4˚C, 20 min), and resupended in 0.1 M Tris (pH 8.0) and
samples were treated with DNase (67 mg/ml) and RNase (330 mg/ml) at 37˚C
for 2 h followed by proteinase K (40 mg/ml) digestion at 55˚C for 3 h. EPS was
further purified by gel filtration on an S1000 column. Dialyzed EPS was
quantified by dry weight and phenol sulfuric acid assay.
Generation of EPS-specific Antibodies.
A New Zealand White rabbit was bled for preimmune serum then
immunized by intramuscular and subcutaneous injection of 100 µg EPS from
BHI medium in TiterMax Gold adjuvant. Three weeks post primary
immunization, the rabbit was boosted with 100 µg EPS in adjuvant. Eight days
later, serum was collected. We assessed antibody recognition of EPS and EPS
purity by immunoelectrophoresis and western blot. For immunoelectrophoresis,
EPS from BHI was electrophoresed in a 0.9% agarose gel, then anti-EPS and
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preimmune serums were loaded into troughs and incubated o/n in a humidity
chamber. The gel was dehydrated and stained with Coomassie brilliant blue to
visualize antigen/antibody arcs of precipitation. We found one arc of
precipitation between anti-EPS serum and EPS and no precipitation occurring
between the EPS and preimmune serum, or elsewhere on the gel (Figure 2.1A).
Also, we see little migration of EPS through the gel. These data demonstrate that
anti-EPS serum recognizes EPS and neither serum recognizes other material in
the sample at the level of detection. For western blot analysis, EPS and ∆EPS
from BHI were electrophoresed on a 10% SDS-PAGE gel for 3 h at 80 Volts and
transferred to nitrocellulose overnight at 100 milliamps. The blot was incubated
with rabbit anti-EPS serum for 2 h, then the secondary reagent, donkey antirabbit IgG (H&L)-HRP (The Jackson Laboratory, Bar Harbor, ME). Similar to
our immunoelectrophoresis results, we find that EPS does not migrate in
polyacrylamide either, but by western we do see faint bands of contamination in
EPS (Figure 2.1B). Importantly, the EPS smeared band is not present in the
∆EPS sample. Further, the EPS band is comparable to published results from the
Kearn’s laboratory of EPS purified from the B. subtilis 991 strain assessed on an
agarose gel with StainsAll (Guttenplan et al. 2010). For certain experiments,
anti-EPS IgG was purified from anti-EPS serum using protein G beads and
biotinylated using NHS-EZ-Link.
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Figure 2.1. Recognition of EPS by anti-EPS rabbit serum.
A. Immunoelectophoresis of EPS. EPS (BHI) was electrophoresed on 0.9%
agarose. Troughs were cut for anti-EPS and pre-immune serum. Troughs were
loaded with either serum and incubated in a humidity chamber overnight. The
gel was dehydrated and stained with Coommassie blue. B. Western blot of EPS
and ΔEPS (BHI). EPS and ΔEPS were loaded into a 10% SDS-PAGE gel and
electrophoresed for 3 h at 80 Volts. The gel was transferred to nitrocellulose o/n
at 100 milliamps, and blotted the next day with rabbit anti-EPS serum, detected
using goat-anti-rabbit Ig – HRP.

B. subtilis Spore Preparation.
B. subtilis wild-type 3610, DS76 (espH mutant) were germinated via
exhaustion as described previously (Jones & Knight 2012). On the day of
administration, B. subtilis spores were washed with ice-cold water, resuspended
in 100 mL PBS, and administered to mice via oral gavage. Cells were isolated 4-6
days post-gavage for analysis.
EPS Binding and Internalization.
Peritoneal cells were obtained from mice (4–6 weeks of age) by peritoneal
lavage with 5 ml DMEM (10% FBS). It is imperative that these experiments were
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performed with cells on ice at all times or at

4oC

in the centrifuge for washes.

After lysing RBCs, cells were incubated with EPS (10 µg) on ice for 1h, washed,
and then incubated with anti-F4/80 (clone BM8), anti-CD11b (clone M1/70), or
rabbit anti-EPS serum, followed by donkey anti-rabbit Ig as secondary antibody.
In some experiments, purified IgG anti-EPS that was biotinylated was used. For
internalization experiments, cells were incubated with Cytochalasin D (5 µM) for
20 minutes on ice. EPS was added to cells, incubated on ice for 30 minutes, then
experimental tubes were shifted to 37oC for 15 minutes and returned to 4oC to
stain for EPS, as described. Fluorescence intensity was assessed by flow
cytometry.
Adoptive Transfer Studies.
For adoptive transfer, peritoneal cells were isolated by lavage (with
RPMI/50%FCS) from mice 3 days post-treatment with EPS (i.p.). Cells in the
granulocyte and lymphocyte gates were FACS-sorted based on forward scatter
(FSC) and side scatter (SSC) and injected i.p. into mice. For macrophage
depletion studies, mice were injected i.p. with 200 µL clodronate-loaded or PBSloaded liposomes (Stock 5 mg/mL). Four to 6 h later, mice were treated with
EPS, and then 3 days later, peritoneal cells were isolated by PBS lavage. By flow
cytometry, less than 1% of the transferred cells were macrophages.
C. rodentium ATCC 51459 was cultured 16 hr in LB medium and washed
once in PBS. An infectious dose (5x108 CFUs) was resuspended in 100 µL sterile
PBS and administered to mice by oral gavage. Disease was assessed 11 days postinfection (dpi). Serum cytokine levels were assessed by ELISA and distal colons
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were collected and processed for histological analysis as described (Jones &
Knight 2012). To assess diarrhea, feces were examined and scored 1–4 (Jones &
Knight 2012): 1, no diarrhea (hard, dry pellets); 2, slightly soft stool (mild
diarrhea); 3, very soft stool (moderate diarrhea); and 4, unformed stool (severe
diarrhea).
Flow Cytometry.
For flow cytometry, cells were treated with anti-CD16/32 Fc Block and
then stained with surface antibodies. To assess intracellular cytokines, cells were
fixed using perm/fix reagents from BD Biosciences according to manufacturer’s
protocol. For Foxp3 staining, cells were fixed using Foxp3/ Transcription Factor
Staining Buffer Set (Ebioscience, San Diego, CA). Cells were fixed for 16 h, then
permeabilized as per manufacturer’s protocol. Anti-Foxp3 antibody was added to
cells for 1 h at room temperature. Cells were analyzed on FACSCanto II or
LSRFortessa flow cytometers; cell sorting was performed on a FACSAria cell
sorter (BD Biosciences). Analyses were performed using FlowJo software (Tree
Star, Ashland, OR) by first gating on single cells, and then analyzing each
population as described.
In vitro and in vivo Treatment with EPS.
For in vitro treatment of peritoneal cells, total peritoneal cells were
isolated by lavage with 5 mL PBS and plated in 24-well plates for 2 h to allow
macrophages to adhere. Non-adherent cells were aspirated and washed away.
The remaining cells were 80-90% F4/80+CD11b+ macrophages. Peritoneal cells
or RAW264.7 cells were treated for 16 h with 5 µg/mL EPS purified from DS991
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B. subtilis grown in MSgg medium. For intracellular cytokine analysis, cells were
cultured for an additional 2 h with Brefeldin A, and analyzed by flow cytometry.
For in vivo treatment, mice were injected i.p. with EPS (200 µg) and 3 days later,
peritoneal cells obtained by lavage as described (Jones et al. 2014). The level of
TGF-β production in serum (1:100) was determined by ELISA after activating
TGF-β with 5 µL 1 N HCL/100 µL for 15 min at RT, followed by neutralization
with 1 N NaOH.
T cell Proliferation Assay.
Splenocytes were labeled with 5 µM CellTrace Violet (Life Technologies)
according to manufacturer’s directions and cultured either alone (3x105 cells) or
with total peritoneal cells (104) or purified macrophages (5x103) in 96-well flatbottom tissue culture plates coated with 2 µg/mL anti-CD3. Plates were coated
with anti-CD3 using borate buffer pH 8.5 for at least 1 h at 37oC or room
temperature o/n. Three days later, non-adherent cells were collected, stained
and analyzed by flow cytometry. For Treg cell induction experiments, this same
assay was performed with the addition of IL-2 (50 µg/mL). For transwell
experiments, 1x106 splenocytes were cultured in anti-CD3-coated 24-well plates
with or without transwell inserts (Corning) containing 5x105 peritoneal cells. For
antigen-specific T cell proliferation assay, peritoneal cells were pulsed o/n with 1
mg/mL ovalbumin (OVA). CD4+ were purified by positive selection from OT-II
mouse spleen using magnetic beads (Streptavidin Particles Plus-DM, BD
Biosciences, San Jose, CA) using biotinylated anti-CD4. Purified cells were
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labeled with CTV and incubated with OVA-pulsed peritoneal cells in anti-CD3 (2
µg/mL)-coated wells with soluble anti-CD28 (5 µg/mL) for 6 d.
Cell Purification using Magnetic Beads.
F4/80+ and CD4+ cells were isolated, as indicated, by positive selection
using magnetic beads, Streptavidin Particles Plus-DM (BD Biosciences, San Jose,
CA) as per manufacturers protocol. Total cells were incubated with anti-CD16/32
(Fc Block) for 15 minutes on ice, then incubated with biotinylated antibodies.
Cells were then washed twice and magnetic beads were added based on cell
numbers (15 µL per 5x106 cells) and incubated on ice for 30 minuntes. Without
washing, samples are place on the BD IMag Cell Separation Magnet for 8
minutes. Negatively-selected cells are collected in the supernatants, and
positively-selected cells are resuspended in PBS and placed on the magnet two
more times.
Real-time Quantitative PCR.
RNA was isolated from flow cytometry–sorted F4/80+CD11b+
macrophages using TRIzol reagent (Invitrogen, Carlsbad, CA), and cDNA was
prepared. PCR was performed on a C1000 thermal cycler with CFX96 real-time
detection system (Bio-Rad, Hercules, CA) using the following primers (forward
and reverse): Arg1, 5′-AGACCACAGTCTGGCAGTTG-3′ and 5′CCACCCAAATGACACATAGG-3′; Nos2, 5′-CAGCTGGGCTGTACAAACCTT-3′
and 5′-CATTGGAAGTGAAGCGTTTCG-3′; Ym-1, 5’ –
CATGAGCAAGACTTGCGTGAC-3’ and 5’ – GGTCCAAACTTCCATCCTCCA-3’;
FIZZ-1, 5’ – TCCCAGTGAATACTGATGAGA-3’ and 5’ –
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CCACTCTGGATCTCCCAAGA-3’; IL-12p40, 5’ GAAGTTCAACATCAAGAGCAGTAG-3’ and 5’ – AGGGAGAAGTAGGAATGGGG3’; Actb (β-actin), 5′-GGCTGTATTCCCCTCCATCG-3′ and 5′CCAGTTGGTAACAATGCCATGT-3′. Expression of each target gene was
normalized to β-actin expression, and data are presented relative to
F4/80+CD11b+ cells isolated from untreated mice.
TGF-β Bioassay.
MFB-F11 cells (2x104) were seeded into 96-well plates in RPMI with 10%
FCS. The next day, cells were washed extensively with PBS and co-cultured with
peritoneal cells (1x105) in serum-free RPMI for 24 h. Recombinant human TGF-β
(Biolegend, San Diego, CA) was used as a positive control. Supernatants (30 µL)
were mixed with QUANTI-blue reagent (170 µL) and incubated at 37oC for 24 h
until A630 was measured. Background absorbance (PBS-treated cell
supernatants) was subtracted from all samples. Data are represented as foldincrease over peritoneal cells from untreated mice.
Apoptosis Analysis.
For apoptosis staining, cells were collected from the T cell proliferation
assay after 1 d of culture. Following extracellular cell-surface staining, cells were
resuspended in Annexin V Binding Buffer (BioLegend, San Diego, CA) and 3 µL
of Annexin V and 3 µL of 7-AAD were added to 1x106 cells for 15 minutes at room
temperature. Cells were then analyzed by flow cytometry without washing.
Statistical Analysis.
Statistical significance was determined by unpaired two-tailed Student’s t

71
test unless otherwise indicated using Prism software (GraphPad Software; La
Jolla, CA). A p value <0.05 was considered statistically significant with p<0.001
denoted as ***, p = 0.001 to 0.01 denoted as **, and p = 0.01 to 0.05 denoted as
*. Not significant denoted as ns (p > 0.05).

CHAPTER THREE
EXPERIMENTAL RESULTS
Section 1: Identification of Cell(s) Required for EPS-mediated
Protection from Disease
Binding of EPS to Peritoneal Cells.
EPS administered via intraperitoneal (i.p) injection prevents disease
associated with C. rodentium. Additionally, adoptive transfer of total peritoneal
cells from EPS-treated mice into recipient mice prevents disease (Jones et al.
2014). We therefore hypothesized that EPS modulates a cell within the
peritoneal cavity to exert a protective effect. The peritoneal cavity is comprised of
a large number of innate-like B1 cells, macrophages, and a small percentage of T
cells, DCs, and eosinophils. To determine which cell-type is involved in EPSmediated protection, we tested which cells bind EPS by incubating peritoneal
cells from a wild-type (WT) untreated mouse with EPS. We then identified cells
bound to EPS using antiserum from rabbits immunized with EPS, detected with
fluorescent goat anti-rabbit Ig antibody and cell-specific antibodies. As a
negative control, cells were incubated with material derived from the mutant B.
subtilis (ΔEPS) that does not produce EPS. These strains are described in greater
detail in Chapters One and Two. This mutant strain of B. subtilis produces 5 to
10-fold less total polysaccharide compared to the hyper-producing strain used to
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isolate EPS, but the background polysaccharide levels are the same. We added a
volume of ΔEPS equivalent to the volume of EPS added, relative to the starting
cultures of each strain. E.g., we purify both EPS and ΔEPS from 500 mL starting
cultures; if we need 10 µL of EPS for a final concentration of 5 µg/mL, we add 10
µL of ΔEPS, even though the actual polysaccharide concentration of this material
is less. By flow cytometry, we found an increase in EPS binding on
F4/80+CD11b+ macrophages (Figure 3.1A), with little to no binding to other celltypes within the peritoneal cavity (Figure 3.1). As negative controls, we do not
see any increase in fluorescence intensity by ΔEPS or by preimmune rabbit
serum. These data show that EPS binds F4/80+ cells and suggest that
macrophages may be involved in EPS-mediated protection from C. rodentiuminduced disease.
Macrophages rapidly internalize antigens that bind to the cell surface,
leading us to test if macrophages internalize EPS. To test this, cells were
incubated with EPS as described above at 4oC, and then experimental tubes were
shifted to 37oC for 15 minutes; cells were then returned to 4oC. Purified,
biotinylated anti-EPS IgG was added to cells and the presence of EPS on the cell
surface was assessed by flow cytometry. If macrophages internalize EPS, we
would expect to see a decrease in surface EPS following incubation at 37oC.

A

F4/80+CD11b+ B
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Lymphocytes
EPS
ΔEPS
Anti-EPS

EPS

EPS
CD11c+

C

EPS
Anti-EPS

EPS

D

EPS

SiglecF+
E
EPS
Anti-EPS

F4/80+CD11b+
EPS
Preimmune

EPS

Figure 3.1. EPS binding to peritoneal cells. EPS (10 µg) or an equal
volume of ΔEPS purified from BHI media was added to total peritoneal cells
from untreated WT mice for 1 h. EPS binding was detected using anti-EPS
rabbit serum and goat FITC-anti-rabbit-Ig antibody. Fluorescence Intensity
was measured by flow cytometry gated on specific subsets of cells. A.
F4/80+CD11b+ macrophages. B. Lymphocyte gate. C. CD11c+ dendritic cells.
D. SiglecF+ eosinophils. E. EPS, total peritoneal cells, and preimmune serum
gated on F4/80+CD11b+ macrophages. Representative flow cytometric profiles
from 5 independent experiments.
As expected, we found a decrease in surface EPS in samples incubated at 37oC
(green line) compared to samples that remained at 4oC (red line) for the duration
of the experiment (Figure 3.2), suggesting that EPS was internalized by the
macrophages. To confirm this idea, we inhibited phagocytosis by adding
Cytochalasin D (5 µM), a small molecule inhibitor of actin polymerization, to cells
before incubation with EPS. We expected that Cytochalasin D would block

75
internalization of EPS at

37oC,

and we would see similar levels of surface EPS

comparable to samples that remained at 4oC. As shown in Figure 3.2,
Cytochalasin D blocks much of the internalization of EPS at 37oC (yellow line),
although some EPS may still be internalized as surface levels of EPS are not as
high as cells that remain at 4oC. Biotinylated anti-EPS IgG with streptavidin-PE
(present in each tube) alone serves as the negative control (blue line). These data
suggest that peritoneal macrophages bind and rapidly internalize EPS.
+ EPS 4oC
+ EPS 37oC + Cytochalasin D
+ EPS 37oC
Anti-EPS

EPS
Figure 3.2. Internalization of EPS by peritoneal macrophages. EPS
(10 µg) was added to total peritoneal cells and incubated at 4oC for 30 minutes.
Indicated samples were then shifted to 37oC for 15 minutes. Binding was
detected using purified, biotinylated anti-EPS IgG and streptavidin-PE.
Fluorescence Intensity was measured by flow cytometry of granulocyte-gated
cells. Representative flow cytometric profiles from 4 independent experiments.

Pattern recognition receptors, including Toll-like Receptors, NOD-like
receptors, and C-type lectins, etc., recognize bacterial and viral products, leading
to activation or inhibition of innate immune responses. Our lab has previously
shown that EPS does not protect TLR4-deficient mice from disease (Jones et al.
2014), suggesting that EPS utilizes TLR4 to induce a protective response. Since
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TLRs are highly expressed on peritoneal macrophages, we hypothesized that EPS
binds to TLR4 on peritoneal macrophages. To test this hypothesis, we incubated
peritoneal macrophages from TLR4-/- mice with EPS and anti-EPS IgG, and
assayed for an increase in fluorescence intensity by flow cytometry. If EPS binds
to TLR4 on macrophages, we do not expect to see an increase in fluorescence in
TLR4-/- macrophages compared to WT macrophages. Surprisingly, EPS binds
TLR4-/- F4/80+CD11b+ cells (Figure 3.3A) to the same extent as we see in WT
F4/80+CD11b+ cells (Figure 3.1A). We also assessed EPS binding to TLR2-/macrophages and found that EPS binds macrophages in the absence of TLR2
(Figure 3.3B). These data suggest that EPS does not directly bind to TLR4 or
TLR2 and perhaps utilizes a co-receptor of the TLR4 signaling complex, such as
carbohydrate-binding lectins, to bind to macrophages.
TLR4-/B
EPS
Anti-EPS

A

EPS

TLR2-/EPS
Anti-EPS

EPS

Figure 3.3. EPS Binding to peritoneal cells from TLR2- and TLR4deficient mice. EPS was added to total peritoneal cells from untreated mice,
and binding was detected using rabbit anti-EPS anti-serum and FITC-goat
anti-rabbit-Ig antibody. Fluorescence Intensity was measured by flow
cytometry. A. F4/80+CD11b+ macrophages from TLR4-/- mice. B.
F4/80+CD11b+ macrophages from TLR2-/- mice. Representative of 4
independent experiments.
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Requirement of Macrophages for EPS-mediated Protection from C.
rodentium-induced Disease.
Since EPS binds to peritoneal macrophages and total peritoneal cells from
EPS-treated mice prevent disease caused by C. rodentium, we next asked if
macrophages purified from the peritoneal cavity of EPS-treated mice prevent
disease. Macrophages are readily activated by antibodies or magnetic beads;
therefore, we decided to purify macrophages by FACS-sorting the granulocyte
gate and the lymphocyte gate based on forward scatter (FSC) and side-scatter
(SSC) in order to minimally manipulate the cells. Cells within the granulocyte
gate are 80-90% macrophages (Figure 3.4), therefore we expect that the
granulocyte population will prevent disease, but the lymphocyte population will
not (<5% macrophages, Figure 3.4). Sorted cells (3x104) were adoptively
Pre-sort

Granulocyte gate

4.39

80.2

SSC

63.5

Lymphocyte gate

F4/80

Figure 3.4. F4/80 expression on sorted peritoneal cells. Peritoneal
cells were sorted using FACS based on FSC and SSC from the lymphocyte and
granulocyte gates from untreated or EPS-treated mice. F4/80 expression on
total peritoneal cells prior to sort (left), or cells obtained from the sort in the
lymphocyte gate (center), or granulocyte gate (right). Representative of 3 sorts
in each of 2 independent experiments.
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Figure 3.5. Assessment of C. rodentium-induced disease following
adoptive transfer of peritoneal cells from EPS-treated mice. Crypt
height (left), diarrhea score (center), and serum CXCL1 (right) on day 11 post C.
4
rodentium infection. Peritoneal cells (3x10 ) from EPS-treated mice were
transferred days -1, +1, and +3 relative to C. rodentium infection. (n) PBSinjected mice, no cell transfer (- control); (☐) EPS-injected mice, no cell transfer
(+ control); ( ) cells transferred from EPS-injected mice, total unsorted
(total), granulocytes (Gr), lymphocytes (Lym). Data are from 2 independent
experiments; N = 5-7 mice total per treatment. Statistical significance
determined by Student’s t test. p<0.001 denoted as ***, p = 0.001 to 0.01
denoted as **, and p = 0.01 to 0.05 denoted as *.

transferred to recipient mice -1, +1, and +3 days post-infection (dpi) with C.
rodentium, and disease was assessed 11 dpi. The cells in the granulocyte gate
protected recipient mice from disease, whereas lymphocytes did not, as
evidenced by increased colonic crypt heights, loose stool, and increased levels of
serum pro-inflammatory chemokine CXCL1 (Figure 3.5). These data suggest that
cells in the granulocyte gate, which are predominately macrophages, mediate
protection by EPS.
We further assessed the requirement of macrophages in EPS-mediated
protection using clodronate liposomes. Macrophages phagocytose the liposomes,
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releasing clodronate inside the cells, which induces apoptosis (Rooijen & Sanders
1994). Intraperitoneal injection of the liposomes results in rapid depletion of
peritoneal macrophages. The liposomes gradually disseminate and deplete
macrophages in the spleen, liver, and bone marrow (van Rooijen & Hendrikx
2010).
Mice were injected with clodronate liposomes to deplete macrophages, or
PBS liposomes as a control, 4-6 hr prior to EPS treatment. Three days later, we
adoptively transferred peritoneal cells (6x104) to naïve recipients -1, +1, and +3
dpi with C. rodentium; disease was assessed 11 dpi. If macrophages are required
for EPS-mediated protection, we would expect that in the absence of
macrophages, peritoneal cells would no longer protect mice from disease. As
expected, all mice that received macrophage-depleted peritoneal cells from EPSinjected mice had evidence of disease, whereas only 1 of 7 that received peritoneal
cells from EPS-injected mice treated with PBS liposomes developed disease
(Figure 3.6). These data indicate that macrophages are required for EPSmediated protection from C. rodentium-induced inflammation.
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HowN=
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with
7-9EPS
micealter
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per treatment.to induce protection? Macrophages are
classified into two main subsets. M1, classically-activated, macrophages
differentiate in response to TLR stimulation and IFN-γ, and are proinflammatory and highly phagocytic. They produce effector molecules including
IL-12p40 and iNOS. In contrast, M2, alternatively-activated, macrophages are
anti-inflammatory, and involved in immunity to parasites and wound-healing
responses. They differentiate in response to glucocorticoids, TLR stimulation,
the anti-inflammatory cytokines IL-10 or TGF-β, or more traditionally, IL-4 and
IL-13. We hypothesize that EPS induces M2 macrophages, which prevent disease
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by providing an anti-inflammatory environment that diminishes a hyperinflammatory immune response induced by, for example, C. rodentium.
Following M2 macrophage polarization, macrophages upregulate
expression of CD206, IL-4Rα, arginase-1, FIZZ-1, and Ym-1 (Table 1.2). To
determine if EPS induces an M2 macrophage phenotype, we took a step back
from the C. rodentium model and asked how EPS modules the immune system in
naïve, uninfected mice. We examined peritoneal cells from mice 3 days after i.p.
injection with EPS, and we expected to find an increase in M2 macrophages at
this time point since total peritoneal cells 3 days post-EPS treatment protect
recipients from disease. We found increased M2 macrophage marker expression
on F4/80+CD11b+ cells compared to treatment with the negative control, ΔEPS
(Figure 3.7A). Additionally, we FACS-purified F4/80+CD11b+ macrophages from
EPS-injected mice and found that transcripts of Ym-1 and FIZZ-1 were

Figure 3.7. EPS-induced changes in phenotype of peritoneal
macrophages in vivo. WT mice were injected with EPS and 3 days later
peritoneal cells were examined by flow cytometry and qRT-PCR. A.
Representative flow cytometric profiles of M2 macrophage marker
expression (Arg-1, CD206, and IL-4Rα) on F4/80+CD11b+ cells from WT
mice. B. Fold change by qRT-PCR of Ym-1, FIZZ-1, IL-12p40 and Nos2
expression in F4/80+CD11b+ cells in WT mice injected with EPS (relative to
mice injected with ΔEPS) (average of 4 independent experiments, N = 7 mice
total per group). ND = not detectable.
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upregulated 5-fold and 9-fold, respectively, compared to macrophages from
ΔEPS-treated mice. In contrast, no upregulation of the M1 macrophage markers
IL-12p40 or Nos2 (iNOS) occurs (Figure 3.7B). We conclude that administration
of EPS induces cells with an M2 macrophage phenotype in peritoneal
macrophages.
The peritoneal cavity is a dynamic environment with cells continuously
entering, surveying, and trafficking to other parts of the body. We sought to
characterize the distribution of cells in the peritoneal cavity in response to EPS to
better understand when M2 macrophage induction occurs. We performed a
time-course study and analyzed the cells present in the peritoneal cavity 1, 2, and
3 days following EPS treatment. Previous reports have shown that regardless of
what material is administered, an i.p. injection results in an influx of monocytes
and neutrophils and an efflux of B1 cells (Doherty et al. 1995; Ghosn et al. 2010; F
et al. 2012). Similar to these findings, we find a rapid increase in Ly6C+
monocytes 1 day after treatment with EPS and ∆EPS (Figure 3.8). By day 2, the
percentage of macrophages increases in both treatment groups, which may be
attributed to the differentiation of infiltrating monocytes into macrophages.
Further, the majority of F4/80+ cells are CD11b+F4/80lo and have yet to reach full
differentiation into CD11b+F4/80hi macrophages that bear the M2 phenotype in
EPS-treated mice (Figure 3.8). By day three, the peritoneal cell composition in
∆EPS-treated mice looks similar to an untreated mouse, whereas EPS-treated
mice display an increase in M2 macrophages, as described in Figure 3.7. These
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data suggest that it takes 3 days to fully restore macrophages to the peritoneal
cavity and induce an M2 phenotype following an i.p. injection. Although the
small percentage of macrophages at two days bear the M2 phenotype, the influx
of other cell types that occurs due to the injection drowns out the number of

Ly6C

CD11b

macrophages within the peritoneal cavity.

F4/80

Day 0

Day 1 EPS

Day 1 ΔEPS

Ly6G

Ly6C

CD11b
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F4/80

Ly6G

Day 2 EPS

Day 2 ΔEPS

Day 3 EPS

Day 3 ΔEPS

Figure 3.8. Kinetics of macrophage accumulation following i.p.
injection with EPS. Macrophages (F4/80+CD11b+), monocytes (Ly6C+) and
neutrophils (Ly6G+Ly6Clo) present in the peritoneal cavity were assessed in
untreated (day 0) or days 1-3 post-injection with EPS or an equal volume of
ΔEPS. Representative of 3 independent experiments, 2 mice per group per
experiment.
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Does EPS act directly on macrophages? Although most reports suggest
that M2 macrophages develop in response to IL-4 and IL-13 produced by a
variety of cell types, a diverse set of activators including cytokines, immune
complexes, and glucocorticoids have been shown to induce an M2 phenotype.
Since EPS binds to macrophages, we expect EPS to directly induce M2
macrophage polarization. We tested if EPS acts directly on macrophages to
induce the M2 macrophage phenotype in vitro by culturing peritoneal F4/80+
cells overnight with EPS (1 µg/mL) or an equal volume of ∆EPS, with the
expectation that we would see upregulation of the markers listed in Table II in
EPS-treated cells. By flow cytometry, we found upregulation of Arg-1, CD206
and IL-4Rα in EPS-treated cells compared to untreated cells (Figure 3.9A).

A

ΔEPS
EPS

Arg-1

CD206

Arg-1

CD206

IL-4Rα

B

IL-4Rα

Figure 3.9. EPS-induced changes in phenotype of macrophages in
vitro. Peritoneal F4/80+ macrophages (A) or RAW264.7 cells (B) were
incubated 16 h with EPS or ∆EPS in vitro and analyzed by flow cytometry for M2
marker expression (Arg-1, CD206 and IL-4Rα). Data are representative of 5
independent experiments.
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These data indicate that EPS induces M2 macrophages in vitro by acting directly
on macrophages.
To confirm that EPS acts directly on macrophages, we cultured RAW264.7
cells, a mouse macrophage cell line, with EPS (1 µg/mL) or ∆EPS for 16 h in vitro
and assessed upregulation of M2 macrophage markers. By flow cytometry, we
found that the expression of these markers was upregulated in EPS-treated cells
compared to cells treated with ∆EPS (Figure 3.9B). These data further
demonstrate that EPS acts directly on macrophages to induce M2 macrophages.
We further characterized the phenotype of M2 macrophages by assessing
the expression of co-stimulatory or co-inhibitory molecules CD80, CD86, PD-L2

EPS
NT

MHCII

PD-L1

CD80

CD86

PD-L2

Figure 3.10. EPS-induced changes in macrophage receptor
expression. Peritoneal cells were isolated from untreated, or EPS-treated
mice 3 days post-treatment (dpt). Expression of MHC class II, CD80, CD86,
PD-L1 and PD-L2 on F4/80+ macrophages was assessed by flow cytometry. Data
are representative of 5 independent experiments.
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and PD-L1, as well as MHC class II. These molecules could influence the antiinflammatory response of M2 macrophages and interactions with target cells.
We examined expression of these markers on peritoneal macrophages from EPStreated mice 3 days post-treatment (dpt), as well as peritoneal macrophages and
RAW264.7 cells treated in vitro with EPS. By flow cytometry, we find
upregulation of CD80 and PD-L1 on macrophages from mice treated in vivo with
EPS (Figure 3.10). In contrast, we find downregulation of CD86 in peritoneal
macrophages from EPS-treated mice. MHC class II expression is slightly
upregulated, but does not occur on all macrophages following EPS treatment.
We do not find changes in PD-L2 expression.
Similar to peritoneal macrophages from EPS-treated mice, peritoneal cells
and RAW264.7 cells treated with EPS in vitro upregulate CD80 and PD-L1
ΔEPS
EPS

MHCII

CD80

CD86

PD-L1

MHCII

CD80

CD86

PD-L1

Figure 3.11. EPS-induced changes in macrophage co-stimulatory
molecules in vitro. Peritoneal macrophages (top) or RAW264.7 cells
(bottom) were incubated 16 h with EPS 5 µg/mL or an equal volume of ΔEPS in
vitro and analyzed by flow cytometry. Expression of MHC class II, CD80, CD86,
PD-L1 and PD-L2 on F4/80+ macrophages was assessed by flow cytometry.
Data are representative of duplicate wells in 4 independent experiments.
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(Figure 3.11). EPS decreases expression of CD86 and does not alter MHCII in
peritoneal macrophages treated in vitro, however, CD86 expression slightly
increases, as does MHC class II in RAW264.7 cells treated with EPS. These data
suggest that peritoneal macrophages respond similarly to macrophages from
mice treated with EPS, but RAW264.7 cells are slightly altered in their response
to EPS.
EPS-induced M2 Macrophage Localization in vivo.
Thus far, we have examined the generation of M2 macrophages in vitro in
response to EPS and in vivo in the peritoneal cavity, but does EPS induce
development of M2 macrophages in other organs and locations of the mouse?
Further, can M2 macrophages induced in the peritoneal cavity travel to other
locations, i.e., the colon, to protect from C. rodentium-induced disease?
To address these questions, we first examined the spleen and MLN of EPStreated mice for the presence of M2 macrophages. The number of macrophages
PBS
EPS

PBS
EPS

CD206

IL-4Rα

Figure 3.12. M2 macrophage development by intravenous injection
with EPS. Mice were injected with 100 µg of EPS in 100 µL of PBS, or PBS
alone, by tail vain injection. The phenotype of peritoneal macrophages (CD206
and IL-4Rα) was assessed by flow cytometry 2 dpt. Representative data of 2
independent experiments with 2 mice per group in each experiment.
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is small in both the spleen and the MLN. Although we sometimes find a slight
increase in M2 macrophage phenotypic markers on macrophages in these organs
following EPS treatment, the increases are not reproducible (data not shown). To
verify that the injection site did not restrict the development of M2 macrophages,
we injected mice with EPS by intravenous (i.v.) injection and examined the
peritoneal cavity 2 dpt for M2 macrophages and found that M2 macrophages still
develop when using an alternate route of injection (Figure 3.12).
To determine if EPS-induced M2 macrophages traffic to other organs from
the peritoneal cavity, we isolated peritoneal cells from EPS-treated mice 3 dpt
and adoptively transferred them to recipient mice by i.p. injection. Prior to
transfer, the cells were labeled with the fluorescent dye, carboxyfluorescein
succinimidyl ester (CFSE), that covalently binds free amines on the surface and
within the cell. This allows us to track the transferred cells in the recipient mice.
Spleen

MLN

F4/80

Peritoneal Cavity

CFSE

Figure 3.13. Trafficking of peritoneal macrophages from EPS-treated
mice. Peritoneal cells were isolated from EPS-treated mice 3 dpt, labeled with
CFSE and 106 transferred (i.p.) into naïve mice. After 24 hours, peritoneal cells,
spleen and MLN were isolated from recipient mice and analyzed for transferred
CFSE+F4/80+ macrophages by flow cytometry. Representative flow cytometric
profiles from 3 independent experiments.

At 24 h post-transfer, we analyzed the presence of

CFSE+
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cells in various organs

by flow cytometry. As is shown in Figure 3.13, we find a small percentage of
CFSE+F4/80+ cells that remain in the peritoneal cavity following injection, with a
small percentage trafficking to the MLN at 24 h post-treatment. Very few
transferred macrophages are found in the spleen. The majority of CFSE+F4/80cells in the peritoneal cavity and MLN are IgM+ B cells (data not shown). Since
the MLN drains from the colon, we conclude that the macrophages from i.p.treated EPS mice can migrate from the peritoneum and traffic to the MLN.
Future experiments will determine if infection or injury enhance recruitment to
various organs.
Mechanism by which EPS Induces M2 Macrophages.
Previously, we showed that TLR4 is required for EPS protection from C.
rodentium-induced disease and that transfer of peritoneal cells from TLR4-/mice into WT mice did not prevent disease (Jones et al. 2014). These findings
suggest that TLR4 signaling is required for the generation of EPS-induced M2
macrophages. To test this, we injected TLR4-/- mice and TLR2-/- mice with EPS,
with the expectation that M2 macrophages would not develop in TLR4-/- mice but
would develop normally in TLR2-/- mice. After injecting TLR4-/- mice with EPS,
we found no upregulated expression of the M2 markers IL-4Rα, CD206, Arg-1,
CD80, CD86 or PD-L1 by flow cytometry (Figure 3.14), whereas TLR2-/- mice
show upregulated expression of M2 macrophage markers, similar to WT mice
(Figure 3.14, 3.9). Similarly, little to no upregulation of FIZZ-1 and Ym-1
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Figure 3.14. Induction of M2 macrophages in TLR-deficient mice.
TLR2-/- and TLR4-/- mice were injected with EPS and 3 days later peritoneal cells
were examined by flow cytometry. Representative flow cytometric profiles of M2
macrophage marker expression (Arg-1, CD206, IL-4Rα, CD80, CD86 and PD-L1)
on F4/80+CD11b+ cells from TLR2-/- mice (top) or TLR4-/- mice (bottom).
Representative flow cytometric profiles of 6 independent experiments, at least
two mice per group in each experiment.
transcripts occurs in macrophages from EPS- injected TLR4-/- mice compared to
WT mice, as well as no detectable levels of M1 macrophage markers (Figure 3.15).
We also tested if upregulation of M2 markers by EPS treatment of
macrophages in vitro requires TLR4 signaling. Macrophages from WT, TLR2-/or TLR4-/- mice were culture for 16 h with EPS and IL-4Rα and PD-L1 expression
was assessed by flow cytometry. We expected to find upregulation of these
markers in WT and TLR2-/- macrophages, but not in TLR4-/- macrophages. As
expected, EPS upregulated expression of IL-4Rα and PD-L1 on WT and TLR2-/cells, but not on TLR4-/- cells (Figure 3.16). These data suggest that the induction
of M2 macrophages by EPS, both in vitro and in vivo requires TLR4 signaling.
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Figure 3.15. qRT-PCR analysis for M2 macrophage markers on TLR4-/macrophages after i.p. injection of EPS. Fold change by qRT-PCR of Ym-1,
FIZZ-1, IL-12p40 and Nos2 expression in F4/80+CD11b+ cells in WT (n) and
TLR4-/- (☐) mice injected with EPS (compared to mice injected with ΔEPS)
(average of 4 independent experiments, N = 7 mice total per group). ND = not
detectable.
TLR4 signals through two downstream adapter molecules: TRIF and MyD88.
Our lab previously showed that mice lacking MyD88 signaling specifically in
myeloid cells are not protected from disease by EPS (Jones et al. 2014), which
supports our conclusions that macrophages, a myeloid lineage cell, mediates
protection, and that EPS signals through TLR4. Given these results, we asked if
EPS induces M2 macrophages in myeloid-specific MyD88-/- mice. Since these
mice are not protected from EPS, we would not expect to see induction of
protective M2 macrophages. As expected, no M2 macrophages were found in the
peritoneal cavity of EPS-injected myeloid-specific MyD88-/- mice (Figure 3.17).
Taken together, these data suggest that both TLR4 and MyD88 in myeloid cells
are required for the polarization of M2 macrophages by EPS.
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Figure 3.16. in vitro induction of M2 macrophages by EPS in TLRdeficient mice. Peritoneal macrophages from WT, TLR4-/- or TLR2-/- mice
were incubated 16 h with EPS (5 µg) in vitro and analyzed by flow cytometry.
Expression of IL-4Rα and PD-L1 were assessed by flow cytometry.
Representative flow cytometric profiles of duplicate wells in 3 independent
experiments.
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Figure 3.17. Flow cytometric analysis of M2 macrophage markers
on peritoneal macrophages from EPS-treated myeloid MyD88-/mice. Representative profiles of 4 independent experiments; N = 8 mice
total per treatment.
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Polarization of M2 macrophages often requires IL-4 and IL-13, IL-10, or
TGF-β. We find upregulation of IL-4Rα on EPS-induced M2 macrophages, as
well as increased levels of genes expressed downstream of IL-4 and IL-13
signaling, including CD206, Ym-1, and arginase-1, leading us to hypothesize that
EPS induces M2 macrophages by upregulating IL-4 and IL-13 production in
macrophages. To test if macrophages express IL-4 and IL-13 in response to EPS,
we cultured total peritoneal cells with EPS overnight, and then added brefeldin A
(5 µg/mL) for 3 h to allow for retention of the cytokines intracellularly, and
analyzed by flow cytometry. If EPS induces M2 macrophages using IL-4 and IL13, we expect to see increased expression of these cytokines in macrophages in
response to EPS. Figure 3.18 shows that F4/80+ peritoneal cells upregulate both
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Figure 3.18. EPS-induced changes in cytokine phenotype of
peritoneal cells in vitro. Peritoneal cells were incubated 16 hr with EPS
in vitro and analyzed by flow cytometry. IL-13, IL-4, or IFN-γ expression in
F4/80+ cells (A) IL-13 and IL-4 expression in CD3+ or IgM+ cells (B). Data are
representative of duplicate wells in 4 independent experiments.

IL-4 and IL-13, whereas no increase in cytokine expression is seen in

CD3+
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T cells

or IgM+ B cells, (Figure 3.18). Further, we find no changes in the M1 macrophage
cytokine, IFN-γ. Consistent with this finding, EPS induces M2 macrophages in
CD4-/- mice (Figure 3.19), suggesting that macrophages to not require CD4+ T
cells for M2 polarization in response to EPS. Taken together, these in vitro and
in vivo data support the hypothesis that EPS directly drives M2 macrophage
polarization by upregulating IL-4 and IL-13, although we cannot rule out the
contribution of other type-2 immunity promoting cells, including ILC2s (innate
lymphoid cells), DCs, and eosinophils, in helping to maintain these cells in vivo.
Recent studies have demonstrated that macrophages self-sustain within
tissues by proliferating (Jenkins et al. 2011; Yona et al. 2013). Additionally,
tissue-resident macrophages proliferate in response to M2 macrophagepolarizing conditions (Jenkins et al. 2013). We hypothesized that since EPS
upregulates M2 macrophage-inducing cytokines, EPS will induce macrophage

EPS
NT

IL-4Rα

PD-L1

Figure 3.19. M2 macrophage induction in CD4-/- mice. CD4-/- mice
were injected with 100 µg of EPS and 3 dpt peritoneal F4/80+ macrophages
were assessed by flow cytometry for M2 macrophage markers. Data are
representative flow cytometric profiles of 8 independent experiments, 1-3 mice
per group per experiment.

96
proliferation within the peritoneal cavity. To test this hypothesis, we isolated
peritoneal cells from mice 3 dpt with EPS and labeled them with CellTrace Violet
(CTV), a highly stable membrane-permeable fluorescent dye. As cells proliferate,
CTV dilutes, which can be measured by flow cytometry. Once labeled with CTV,
cells were transferred into naïve mice, and 48 h later, peritoneal cells were
isolated and analyzed for proliferation by flow cytometry. If EPS stimulates
macrophage proliferation, we expect to find increased dilution of CTV in
peritoneal cells from mice treated with EPS compared to cells from untreated
mice. As expected, in F4/80+ cells from donor mice treated with EPS, we find
increased decreased levels of CTV, and hence increased proliferation compared to
F4/80+ cells from untreated donor mice (Figure 3.20). CD3+ T cells and CD19+ B
cells from either group of mice did not proliferate. In CD11c+ DCs, we find two
peaks in CTV staining from EPS-treated cells, compared to only one peak from
untreated cells (data not shown). Because only a few DCs are present within the
peritoneal cavity and the population is fairly heterogeneous, it is difficult to draw
a conclusion about these cells. In vitro, we do not find increases in macrophage
proliferation following EPS treatment (data not shown). Macrophages tightly
adhere to plastic in tissue-culture dishes; the vastly different environment in
vitro compared to in vivo conditions, including infiltrating monocytes, may
explain the differences in proliferation. Further studies are needed to optimize in
vitro conditions to determine if macrophages proliferate in vitro and if DCs
proliferate in response to EPS.
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Figure 3.20. Proliferation of peritoneal macrophages following EPS
treatment. Peritoneal cells were isolated from untreated or EPS-treated mice
3 dpt, labeled with CTV, and transferred (i.p.) into untreated recipient mice.
Two days post-transfer, CTV dilution was assessed in CTV+F4/80+ macrophages
by flow cytometry. Data are representative flow cytometric profiles of 2
independent experiments with 2 mice per group.
Conclusions from Section 1.
EPS induces M2 macrophages. These macrophages are required for
protection from C. rodentium-induced disease and transfer of these cells to
recipient mice prevents disease. EPS acts directly on macrophages to induce an
M2 macrophage phenotype and also upregulates IL-4 and IL-13. Induction of
M2 macrophages requires TLR4 and MyD88 signaling in myeloid cells.
Section 2. Mechanism by which EPS-induced M2 Macrophages Exert
Anti-inflammatory Effect
Inhibition of T cell Responses in vitro.
EPS induces M2 macrophages, and adoptive transfer of these
macrophages prevents disease associated with C. rodentium. Further, depletion
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of macrophages alleviates these protective effects. How do EPS-induced M2
macrophages prevent inflammation induced by C. rodentium? M2 macrophages
exert anti-inflammatory effects through a variety of different mechanisms, one of
which is through inhibition of T cells. Because much of the damage caused by C.
rodentium is due to a hyper-reactive CD4+ T cell response, as discussed in
Chapter 1, we hypothesized that EPS prevents C. rodentium-induced
inflammation by inducing M2 macrophages, which inhibit T cell responses.
To test this possibility, we developed an in vitro T cell proliferation assay.
T cells proliferate in vitro in response to anti-CD3 and co-stimulation. T cells can
be labeled with CTV for the purpose of tracking proliferation. Following
activation with anti-CD3, T cells upregulate activation markers including CD25,
the IL-2Rα chain, and CD44, a glycoprotein involved in cell-to-cell adhesion,
cytokine production increases, especially IL-2 and IFN-γ, and then the T cells
proliferate rapidly. As the cells proliferate, the fluorescent dye associated with
each cell is decreased, and this decrease can be measured by flow cytometry. We
hypothesized that co-culture of T cells with peritoneal cells from EPS-treated
mice would result in decreased T cell proliferation. To test this hypothesis, we
labeled total splenocytes with CTV and added the cells to anti-CD3ε-coated wells.
The anti-CD3ε stimulates the TCR, and B cells present in the splenocytes provide
co-stimulation. We then added peritoneal cells from EPS- or ΔEPS-treated mice
and tested for a decrease in T cell proliferation, activation and cytokine
production. If EPS-induced M2 macrophages are inhibitory, we expected to see a

decrease in

CD4+
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T cell activation and proliferation in co-cultures with peritoneal

cells from EPS-treated mice. By flow cytometry, we found a decrease in activated
CD4+CD44+CD25+ T cells (Figure 3.21A, C middle) in co-cultures with peritoneal
cells from EPS-treated mice compared to peritoneal cells from ΔEPS-treated
mice. Further, CD4+ T cells do not proliferate when cultured with peritoneal cells
from EPS-treated mice compared to cultures with peritoneal cells from ΔEPStreated mice or splenocytes alone (Figure 3.21B, C left). Additionally, total IFN-γ
levels are decreased in the supernatant of the cultures containing peritoneal cells
from EPS-treated mice compared to peritoneal cells from ΔEPS-treated mice or
splenocytes alone (no peritoneal cells) (Figure 3.21C right). These data indicate
that peritoneal cells from EPS-treated mice inhibit CD4+ T cell responses.
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Figure 3.21. Inhibition of anti-CD3-stimulated CD4 T cell
proliferation by peritoneal cells from EPS-treated mice. CTV-labeled
spleen cells were stimulated with anti-CD3, cultured with total peritoneal cells
from EPS or ΔEPS-treated mice, and analyzed by flow cytometry. A.
CD4+CD44+CD25+ Activated T cells. B. Proliferation of CD4+ T cells; Horizontal
bar = % proliferating cells. C. (Left) % proliferating CD4+ T cells; (center) %
activated CD4+ T cells (CD44+CD25+); (right) concentration of IFN-γ in culture
supernatants as determined by ELISA. Average of 10 independent experiments;
N = 15 mice total per group. Statistical significance determined by Student’s t
test. p<0.05 denoted as *.
Since peritoneal cells from EPS-treated mice were co-cultured with total
splenocytes (containing both CD4+ and CD8+ T cells), we also tested if CD8+ T
cell responses were suppressed. We found that, like CD4+ T cells, CD8+ T cell
activation was decreased in co-cultures with peritoneal cells from EPS-treated
mice compared to peritoneal cells from ΔEPS mice (Figure 3.22A), although the
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Figure 3.22. Inhibition of anti-CD3-stimulated CD8 T cell
proliferation by peritoneal cells from EPS-treated mice. CTV-labeled
spleen cells were stimulated with anti-CD3 and cultured with total peritoneal
cells from EPS or ΔEPS-treated mice. A. Activated CD8+ T cells (CD44+CD25+) in
co-cultures with peritoneal cells from ΔEPS-treated mice (left) or EPS-treated
mice (center); % Activated CD8+ T cells (CD44+CD25+) in 3 independent
experiments; N = 7 mice total per group. B. Proliferation of CD8+ T cells;
Horizontal bar = % proliferating cells; (right) % proliferating CD8+ T cells in 3
independent experiments; N = 7 mice total per group. Statistical significance
determined by Student’s t test. p<0.001 denoted as ***, p = 0.001 to 0.01
denoted as **, and p = 0.01 to 0.05 denoted as *.
reduction was not as much as for the CD4+ T cells. CD8+ T cell proliferation is
also greatly reduced in co-cultures with EPS-treated mice compared to peritoneal
cells from ΔEPS mice (Figure 3.22B). Since IFN-γ was measured in culture
supernatants, the reduction in IFN-γ production in Figure 3.20C is likely due to

decreased expression by both

CD4+

and

CD8+
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T cells. Taken together, these data

demonstrate that peritoneal cells from EPS-treated mice inhibit both CD4+ and
CD8+ T cell responses.
Although unlikely that EPS would be present in the peritoneal cavity 3 dpt,
we verified that EPS doesn’t directly inhibit T cell proliferation by culturing with
purified CD4+ T cells with EPS or ΔEPS for 16 h, then stimulated the cells with

ΔEPS
EPS 5 µg/mL

CTV

Figure 3.23. T cell proliferation following in vitro treatment with EPS.
CTV-labeled CD4+ T cells were co-cultured with EPS (20 µg/mL) or an equal
volume of ΔEPS for 16 h, then added to anti-CD3-coated plates with soluble antiCD28. Three days later, proliferation was assessed by flow cytometry.
Representative profile of duplicate wells in 3 independent experiments.
anti-CD3 and anti-CD28. Three days later, we assessed proliferation by flow
cytometry and found no differences in CD4+ T cell proliferation in cells treated
with EPS compared to ΔEPS-treated cells (Figure 3.23).
Anti-CD3 strongly stimulates T cells activation and proliferation. We
asked if peritoneal cells from EPS-treated mice inhibit antigen-specific T cell
proliferation, which is a more physiologically-relevant analysis. To do this, we
utilized OT-II transgenic mice in which CD4+ T cells express an ovalbumin-
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specific αβTCR. Peritoneal cells were isolated from PBS- or EPS-treated WT mice
3 dpt and pulsed overnight with ovalbumin (OVA). CD4+ T cells were purified
from OT-II mice and co-cultured with OVA-pulsed peritoneal cells for 6 days.
We found that peritoneal cells from EPS-treated mice inhibit CD4+ T cells
proliferation compared to proliferation of T cells in culture with peritoneal cells
from PBS-treated mice (Figure 3.24). Peritoneal cells from EPS-treated mice also
inhibitit of OVA-specific T cell prolifeartion using bone marrow-derived dendritic
cells as the antigen-presenting cell (APC) (data not shown). This experiment

PBS
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CTV
Figure 3.24. Inhibition of antigen-specific T cell proliferation by
EPS-induced M2 macrophages. Anti-CD3-stimulated, CTV-labeled CD4+ T
cells from OT-II transgenic mice were co-cultured with OVA-pulsed peritoneal
cells from PBS-treated or untreated mice. Three days later, proliferation was
assessed by flow cytometry. Representative data from 3 independent
experiments.
demonstrates that reduced proliferation was not due to decreased antigen
presentation by peritoneal cells from EPS-treated mice, although we have not
ruled out this possibility. These data suggest that peritoneal cells from EPStreated mice inhibit antigen-specific T cell proliferation.

104
Since we hypothesize that EPS-induced M2 macrophages within the
peritoneal cavity exert this anti-inflammatory effect, we next tested if purified
macrophages from EPS-treated mice inhibit T cell proliferation. We FACS-sorted
F4/80+CD11b+ cells from the peritoneal cavity of EPS-treated or ΔEPS-treated
mice and co-cultured them in the T cell proliferation assay. We expected that if
macrophages mediate the inhibitory activity within the peritoneal cavity in this
assay, that macrophages would inhibit T cell responses and F4/80- cells would
not. As expected, macrophages from EPS-treated mice inhibited CD4+ T cell
proliferation (18% proliferation), compared to F4/80+CD11b+ cells from ΔEPStreated mice, which did not inhibit proliferation (75% proliferation). Further,
FACS-sorted T cells (CD3+) and B cells (IgM+) from EPS-treated mice did not
inhibit T cell proliferation (Figure 3.25).

Figure 3.25. Proliferation of CD4+ T cells in co-cultures with FACSpurified peritoneal cell populations. CTV-labeled spleen cells were
stimulated with anti-CD3 in c0-cultures with FACS-purified cells from EPS or
ΔEPS-treated mice. Proliferation of CD4+ T cells with F4/80+CD11b+ cells (left);
CD3+ T cells (center) or IgM+ B cells (right). Horizontal bar = % proliferating
cells. Representative flow cytometric profiles from 3 independent experiments;
N = 7 mice total per group.
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To further test if M2 macrophages are required for T cell inhibition, we cocultured proliferating T cells with peritoneal cells from EPS-treated mice that
were depleted of macrophages by clodronate liposomes. As a control, we cocultured T cells with peritoneal cells from EPS-treated mice that were treated
with PBS liposomes, with the expectation that peritoneal cells from these mice
would inhibit proliferation. Further, we expected the cells from mice treated with
clodronate liposomes and EPS would no longer inhibit proliferation. As
expected, peritoneal cells from PBS liposome-EPS-treated mice inhibited CD4+ T
cell proliferation, whereas peritoneal cells from EPS-treated mice depleted of
macrophages did not inhibit proliferation (Figure 3.26).

PBS-L 11%
Clod-L 85%
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Figure 3.26. Proliferation of CD4 T cells in co-cultures with
peritoneal cells from macrophage-depleted mice. Mice were treated
with EPS 4-6 h post-treatment with PBS liposomes (PBS-L) or clodronate
liposomes (Clod-L). Peritoneal cells were co-cultured with CTV-labeled spleen
cells and stimulated with anti-CD3. Proliferation of CD4+ T cells, horizontal
bar = % proliferating cells. Representative flow cytometric profiles from 4
independent experiments; N = 6 mice total per group.

Similarly, peritoneal cells from EPS-treated

TLR4-/-
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or myeloid MyD88-/-

mice, which do not generate M2 macrophages, also did not inhibit T cell
proliferation, whereas peritoneal cells from TLR2-/-, which do develop M2
macrophages, inhibit proliferation (Figure 3.27). We conclude that EPS induces
anti-inflammatory M2 macrophages that inhibit T cell responses in vitro.

C

TLR2-/-

EPS 5%
TLR2-/- ΔEPS 86%

60
40
20

S

EP

N

on
Δ e
EP
S

0

CTV

100

ns

80
60
40
20
0

on
Δ e
EP
S
EP
S

ΔEPS 50%
EPS 46%

Mye- MyD88-/-

N

ns

80

% Proliferation (CD4+ T cells)

TLR4-/-

100

TLR2-/-

100
100
80
80

***

ns

60
60
40
20

0
oonn
e
ΔΔEE
PS
EEP
PSS

CTV

B
% Proliferation (CD4+ T cells)

WT EPS 18%
TLR4-/-EPS 62%

+
% Proliferation
cells)
% Proliferation (CD4
(CD4+ TTcells)

A

N
N

CTV
Figure 3.27. Proliferation of CD4+ T cells in co-cultures with
peritoneal cells from EPS-treated TLR-deficient mice. CTV-labeled
spleen cells were stimulated with anti-CD3 and cultured with total peritoneal
cells from EPS- or ΔEPS-treated mice. Proliferation of CD4+ T cells cultured
with peritoneal cells from TLR4-/- (A), myeloid MyD88-/- (B), or TLR2-/-(C)
mice. Horizontal bar = % proliferating cells. None = splenocytes alone. 4-6
independent experiments with N = 7-10 mice total per group. Statistical
significance determined by Student’s t test. p<0.001 denoted as ***, p = 0.001
to 0.01 denoted as **, and p = 0.01 to 0.05 denoted as *.

Inhibition of T cell Responses in vivo.
The data above indicate that EPS-induced M2 macrophages have the

capacity to inhibit T cells in vitro, but does this occur in vivo? Naïve

CD4+
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T cells

polarize into different T cell subsets based on their environment. Upon antigenspecific interactions, co-stimulation and the surrounding cytokine milieu, T cells
activate, proliferate, and produce effector cytokines, leading to inflammation. We
tested if EPS inhibited T cell responses in vivo by measuring levels of Th1, Th17,
and Th2 inflammatory cytokines, IFN-γ, IL-17A and IL-13, respectively, in
cultures of splenocytes from EPS- or ΔEPS-treated mice stimulated with antiCD3ε. The secretion of each of the cytokines was decreased in EPS-treated mice
compared to ΔEPS-treated mice (Figure 3.28), indicating that EPS induces a
systemic anti-inflammatory response that broadly suppresses Th1, Th17, and Th2
cytokine production.
To determine if EPS alters T cell responses during inflammation in vivo,
we administered EPS to mice and 3 days later, after induction of M2
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Figure 3.28. Inhibition of T cell responses in EPS-treated mice.
Quantification by ELISA of IFNγ, IL-17A, and IL-13 in culture supernatants of
anti-CD3-stimulated splenocytes from EPS- or ΔEPS-treated mice. Average of
4 independent experiments with N = 8 mice total per group. Statistical
significance determined by Student’s t test. p<0.001 denoted as ***, p = 0.001
to 0.01 denoted as **, and p = 0.01 to 0.05 denoted as *.

108

Fig. 3.29. Inhibition of T cell cytokine responses in serum from
EPS-treated mice. Quantification by ELISA of serum TNF-α, IFN-γ and
IL-2 in EPS-treated or untreated (NT) mice 2 h post-i.p. injection of antiCD3. Average of 3 independent experiments with N = 9 mice total per group.
Statistical significance determined by Student’s t test. p<0.001 denoted as
***, p = 0.001 to 0.01 denoted as **, and p = 0.01 to 0.05 denoted as *.
macrophages, injected them i.p. with anti-CD3ε, which induces potent T cell
activation and release of TNF-α and IL-2 (Ferran et al. 1991). We expected
decreased production of these cytokines in the blood of EPS-treated mice
compared to ΔEPS-treated mice. Indeed, we found a two-fold decrease in
production of serum TNF-α, IL-2 and IFN-γ in EPS-injected mice compared to
mice injected with ΔEPS (Figure 3.29). Together, these data indicate that EPS
inhibits T cell responses in vivo.
Mechanism by which EPS-induced M2 Macrophages Inhibit T cells.
Inhibitory molecules produced by EPS-induced M2
macrophages. M2 macrophages inhibit T cell responses by multiple factors,
including Arg-1, PGE2, IL-10, PD-L1/2 and TGF-β (Taylor et al. 2006; Pesce et al.
2009; Huber et al. 2010). In section 1, we established that EPS-induced M2
macrophages express Arg-1 and PD-L1, but these cells may also express other
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inhibitory cytokines, such as IL-10, known to inhibit T cell proliferation. We used
ELISA to test if EPS-induced M2 macrophages upregulate IL-10 production, and
found no increase in IL-10 levels in culture supernatants compared to
supernatants from untreated macrophages (Figure 3.30A).
TGF-β is secreted as a latent pro-peptide, and cannot interact with its
receptor unless cleaved. TGF-β associates with latency-associated peptide (LAP)
in the cytoplasm, but when associated with LAP, can be expressed on the cell
surface, although the process is not well understood. Cells and tissues rapidly
inactivate TGF-β following secretion making it difficult to detect; inactive TGF-β
can be activated with acid, allowing detection. To determine if EPS upregulates

Figure 3.30. Identification of inhibitory Molecules Produced by EPSinduced M2 macrophages. A. Quantitation of IL-10 in cell supernatants of
macrophages from untreated or EPS-treated mice. Average of 6 mice in 2
independent experiments. B. Quantification by ELISA of total TGF-β in serum
after EPS-treatment or no treatment (NT). N= 4-5 mice total per group. C. LAP
expression on F4/80+ macrophages 3 dpt with EPS compared to F4/80+ cells
from untreated mice. D. Fold change in TGF-β reporter activity in co-cultures of
MFB-F11 cells with peritoneal cells from EPS-treated relative to TGF-β activity in
untreated mice. rTGF-β= recombinant human TGF-β. Average of 6 mice from 2
independent experiments. Statistical significance determined by Student’s t test.
p<0.001 denoted as ***, p = 0.001 to 0.01 denoted as **, and p = 0.01 to 0.05
denoted as *.
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expression of TGF-β, we activated total TGF-β in serum by acid-treating with 1 N
HCl, and then neutralizing with 1 N NaOH. By ELISA, EPS upregulates total
TGF-β in serum compared to untreated mice (Figure 3.30B). To test if EPS
upregulates TGF-β in macrophages from EPS-treated mice, we assessed LAP
expression on F4/80+ cells from EPS-treated mice and untreated mice. Since
LAP, and not TGF-β, has a transmembrane domain, if EPS upregulates cellsurface TGF-β, we would expect to see LAP upregulated. We find a very slight
upregulation of LAP expression on the surface of macrophages following EPS
treatment. (Figure 3.30C).
We further tested for increased TGF-β expression by co-culturing
peritoneal cells from EPS-treated mice with MFB-F11 cells. This Tgf-b1-/fibroblast cell line stably expresses a reporter plasmid consisting of TGF-β
responsive Smad-binding elements coupled to a secreted alkaline phosphatase
reporter gene. Smad proteins are part of a signaling cascade activated upon TGFβ receptor signaling. Since this cell line originates from a Tgf-b1-/- mouse, the
assay has limited background activity. We expected that if EPS-induced M2
macrophages express TGF-β that we would see an increase in alkaline
phosphatase activity compared to cells from untreated mice. Relative to cells
from untreated mice, we find a 4-fold increase in Smad activity, and therefore
TGF-β activity, in cells from EPS-treated mice (Figure 3.30D). The 4-fold
increase in TGF-β was equivalent to 125 pg/mL of recombinant human TGF-β
added to MFB-F11 cells. These data suggest that EPS-induced M2 macrophages
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produce TGF-β, which is a potent inhibitor of T cell proliferation.
Since EPS-induced M2 macrophages express multiple inhibitory factors,
including Arg-1, PD-L1 and TGF-β, we next tested if EPS-induced M2
macrophages inhibit via a soluble factor or by cell-to-cell contact. We used
transwells to separate peritoneal cells from T cells. We expected that if inhibition
requires cell contact, the peritoneal cells from EPS-treated mice would no longer
inhibit T cell proliferation if placed in a transwell, separated from the
splenocytes. As is seen in Figure 3.31, EPS-induced M2 macrophages no longer
inhibited CD4+ or CD8+ T cell proliferation when separated from the T cells,
indicating that cell-to-cell contact is required for inhibition (Figure 3.31); this
finding does not rule out the possibility that soluble factors also contribute to the
inhibition.
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Figure 3.31. Proliferation of T cells in contact with, or separated
+
+
from peritoneal cells. Proliferation of CD4 (A) or CD8 (B) T cells cocultured with peritoneal cells from untreated (NT)- or EPS-treated mice in
direct contact (no transwell, left) or with peritoneal cells in a transwell insert
(right). Horizontal bar = % proliferation. Representative of three independent
experiments.
Restoration of CD4+ T cell proliferation by inhibitors of M2
macrophage function. To identify the molecule(s) produced by EPS-induced
M2 macrophages that prevents T cell activation, we added inhibitors to the T cell
inhibition assay, focusing on PD-L1 and TGF-β. To test if TGF-β is required for
inhibition of T cells by EPS-induced M2 macrophages, we added neutralizing
TGF-β antibody to co-cultures of peritoneal cells and proliferating T cells. If
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TGF-β mediates the anti-inflammatory effect of EPS-induced M2 macrophages,
we expected to find an increase in T cell proliferation in these co-cultures
compared to co-cultures with isotype control antibody. Whereas only 14% of
CD4+ T cells proliferated in cultures with peritoneal cells from EPS-treated mice,
proliferation was greatly increased by the addition of anti-TGF-β (69% CD4+ T
cells) (Figure 3.2A, B), indicating that EPS-induced M2 macrophages produce
TGF-β, which inhibits CD4+ T cell proliferation in vitro. We further tested the
importance of TGF-β signaling in EPS-induced M2 macrophage inhibition of T
cells by using a TGF-β receptor kinase inhibitor. This inhibitor, SB-431542,
blocks phosphorylation of Smad proteins, thereby inhibiting TGF-β signaling. In
accordance with TGF-β inhibition by antibody, we find a dose-dependent
restoration of T cell proliferation in the presence of SB-431542. Inhibition using
this small molecule also restores T cell activation, as expected; however, this
restoration occurs at all concentrations of the inhibitor (Figure 3.32C, D). These
data suggest that TGF-β mediates CD4+ T cell inhibition by EPS-induced M2
macrophages.
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Figure 3.32. Inhibition of TGF-β in co-cultures of proliferating T
cells and peritoneal cells. A. Proliferation of CD4+ T cells of anti-CD3
stimulated splenocytes cultured with peritoneal cells from untreated mice (left)
or EPS-treated mice (right) in the presence of neutralizing anti-TGF-β antibody
or mouse (Ms) IgG1 isotype control. Horizontal bar = % proliferation. B.
Average proliferation in three independent experiments. C and D.
Proliferation and activation of CD4+ T cells of anti-CD3 stimulated splenocytes
cultured with peritoneal cells from untreated mice (left) or EPS-treated mice
(right) and SB-431542 (C); data from 4 independent experiments (D) using
decreased amounts of SB-431542. Average proliferation (left) and activation
(CD44+CD25+) (right) of T cells. Statistical significance determined by Student’s
t test. p<0.001 denoted as ***, p = 0.001 to 0.01 denoted as **, and p = 0.01 to
0.05 denoted as *.

In contrast to TGF-β inhibition, addition of neutralizing antibodies to PDL2 (Figure 3.33A), PD-L1 (Figure 3.33B), and IL-10 (Figure 3.33C) did not
restore CD4+ T cell proliferation (Figure 3.34). Further, inhibition of Arg-1
activity by Nor-NOHA, or addition of exogenous L-arginine, did not restore T cell

115
proliferation (Figure 3.33D, E and Figure 3.34), even though we found increased
expression of Arg-1 in EPS-induced M2 macrophages (Figure 3.3). The addition
of NS-398, a COX2 inhibitor that prevents PGE2 production also had no effect on
T cell inhibition by EPS-induced M2 macrophages (Figure 3.33F). These data
suggest that TGF-β is responsible for the inhibitory effect of M2 macrophages on
CD4+ T cells (Figure 3.34).
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Figure 3.33. Restoration of T cell proliferation by inhibitors of M2
macrophage function. Proliferation of CD4+ T cells cultured with
peritoneal cells from EPS-treated mice and containing inhibitors of M2
macrophage function: blocking anti-PD-L2(A); blocking anti-PD-L1(B);
neutralizing anti-IL-10 (C); Nor-NOHA (D); L-Arginine (E); NS-398, a COX2
inhibitor (F). Representative flow cytometric profiles are from 3 independent
experiments each, N = 6 mice total per group.
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Figure 3.34. Restoration of T cell proliferation by inhibitors of M2
+
macrophage function. % Proliferation of CD4 T cells cultured with
peritoneal cells from EPS-treated mice and containing inhibitors of M2
macrophage function. (n) NT peritoneal cells alone (negative control); (☐)
peritoneal cells from EPS-treated mice (positive control); ( ) cultures with
inhibitors of M2 macrophages, anti-TGF-β, Nor-NOHA, L-Arginine, NS-398,
anti-PD-L2, anti-PD-L1, and anti-IL-10. Data are from 3 independent
experiments each, N = 6 mice total per group. Statistical significance
determined by one-way ANOVA in combination with Bonferroni’s test for
multiple comparisons. *** denotes p < 0.0001 by ANOVA.

Restoration of CD8+ T cell proliferation by inhibitors of M2
macrophage function. Since TGF-β acts on all T cells, we expected TGF-β to
mediate EPS-induced M2 macrophage inhibition of CD8+ T cells, as well of CD4+
T cells. Indeed, anti-TGF-β also partially restored CD8+ T cell proliferation
(Figure 3.35A). Interestingly, blocking anti-PD-L1 antibody also partially
restored CD8+ T cell proliferation (Figure 3.35B). The addition of both anti-PDL1 and anti-TGF-β antibodies resulted in complete restoration of CD8+ T cell
proliferation (Figure 3.35C), indicating that both TGF-β and PD-L1 contribute to
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the inhibition of

CD8+

T cells. We conclude that the EPS-induced M2

macrophages inhibit T cell responses through TGF-β and PD-L1.
TGF-β and PD-L1 inhibit T cells by inducing apoptosis, among other
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Figure 3.35. Restoration of CD8+ T cell proliferation by inhibitors of
M2 macrophages. A-C. Proliferation of CD8+ T cells of anti-CD3 stimulated
splenocytes cultured with peritoneal cells from EPS-treated mice in the presence
of neutralizing anti-TGF-β antibody or mouse (Ms) IgG1 isotype control (A);
blocking anti-PD-L1 or rat (rt) IgG2b isotype control (B); both inhibitory
antibodies or isotype controls combined (C). Horizontal bar = % proliferation. D.
Average % proliferation from 3 independent experiments each, N = 6 mice total
per group. (n) NT peritoneal cells alone (negative control): (☐) peritoneal cells
from EPS-treated mice (positive control); ( ) cultures of EPS peritoneal cells
with inhibitors of M2 macrophages. Statistical significance determined by oneway ANOVA in combination with Bonferroni’s test for multiple comparisons. ***
denotes p < 0.0001 by ANOVA.
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mechanisms (Gorelik & Flavell 2002; Zou et al. 2016). We tested if peritoneal
cells from EPS-treated mice induce apoptosis in co-cultures of proliferating T
cells by staining for Annexin V and 7-AAD. Annexin V binds to
phosphatidylserine that is exposed on the cell surface in cells undergoing
apoptosis. During the early stages of apoptosis, cells bind Annexin V, but exclude
the viability dye, 7-AAD. Once membrane integrity is lost, cells take up 7-AAD
and are positive for both stains. We expected to see an increase in apoptosis in
CD4+ and CD8+ T cells co-cultured with peritoneal cells from EPS-treated mice
compared to untreated mice. After one day of culture with peritoneal cells from
EPS-treated mice, 37% of CD4+ T cells and 16% of CD8+ T cells are apoptotic,
compared to only 7.9% and 7.2% of CD4+ and CD8+ T cells, respectively, in cocultures with peritoneal cells from untreated mice (Figure 3.36). These data
suggest that EPS-induced M2 macrophage induce apoptosis in T cells through
TGF-β and PD-L1. The increase in Annexin V and 7-AAD double positive cells
could possibly due to necrosis, and additional, earlier time points need to be
examined to address this possibility. Future experiments will determine if
induction of apoptosis is dependent on these molecules and if T cells are also
rendered anergic by EPS-induced M2 macrophages.

CD4+
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7-AAD
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ANNEXIN V
Figure 3.36. Apoptosis staining in co-cultures of proliferating T cells
and peritoneal cells from EPS-treated mice. CTV-labeled spleen cells were
stimulated with anti-CD3 and c0-cultured with peritoneal cells from untreated or
EPS-treated mice for one day. Annexin V and 7-AAD were assessed in CD4+ and
CD8+ T cells by flow cytometry. Representative data from 3 independent
experiments, 1-3 mice in each group per experiment.

Conclusions from Section 2.
EPS-induced M2 macrophages inhibit T cell responses both in vitro and in
vivo. This inhibition is mediated by TGF-β and PD-L1, in a cell contactdependent manner.
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Section 3. Induction of Regulatory T cells by EPS-induced M2
Macrophages
Induction of T Regulatory Cells in vivo.
Naïve CD4+ T cells polarize into effector T cell subsets according to
environmental conditions. In the presence of TGF-β, CD4+ T cells upregulate
expression of Foxp3 and become inducible Treg cells (iTreg). Additionally, PD1–PD-L1 interactions not only maintain peripheral tolerance by inhibiting
effector T cells, but also help to maintain iTreg cells. Since M2 macrophages
produce TGF-β and PD-L1, which inhibit T cell responses, we hypothesize that
production of TGF-β could also induce regulatory T cells. We examined Foxp3
expression in CD4+CD25+ T cells in the peritoneal cavity 3 days post EPStreatment and found an increase in the percentage of Foxp3+ cells in EPS-treated
mice (average of 12%) compared to untreated mice (average of 52%), although
the percentage of activated T cells (CD4+CD25+) in the peritoneal cavity is
reduced (Figure 3.37). We find little difference in the percentage of Treg cells in
the spleen (27% in untreated vs. 22% in EPS-treated) (Figure 3.38). The
percentage of Treg cells is so small, however, that small changes may be difficult
to quantify by flow cytometry. To efficiently assess the development and impact
of EPS in the induction and development of Treg cells in spleen as well as in the
MLN and GIT, a Foxp3 reporter mouse maybe a useful tool.
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Figure 3.37. Induction of Treg cells in the peritoneum of EPS-treated
mice. A. Representative example of Foxp3 expression in CD4+CD25+ T cells in
the peritoneal cavity of untreated (NT, top) or EPS-treated (EPS, bottom) mice 3
dpt. B. % CD4+CD25+Foxp3+ cells in 5 independent experiments, N = 7 mice per
group. Statistical significance determined by Student’s t test. p<0.001 denoted
as ***, p = 0.001 to 0.01 denoted as **, and p = 0.01 to 0.05 denoted as *.
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Figure 3.38. Induction of Treg cells in spleen of EPS-treated mice.
Representative example of Foxp3 expression in CD4+CD25+ T cells in the spleen
of untreated (NT, top) or EPS-treated (EPS, bottom) mice 3 dpt. B. %
CD4+CD25+Foxp3+ cells in 5 independent experiments, N = 7 mice per group.
Statistical significance determined by Student’s t test. p<0.001 denoted as ***, p
= 0.001 to 0.01 denoted as **, and p = 0.01 to 0.05 denoted as *.
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Induction of T Regulatory Cells in vitro by M2 Macrophages.
We also tested the capacity of EPS-induced M2 macrophages to induce
iTreg cells in vitro. Dendritic cells and M2 macrophages co-cultured with naïve
CD4+ T cells have the capacity to polarize cells to Treg cells in vitro. We
hypothesized that in our co-cultures of EPS peritoneal cells and proliferating T
cells, the M2 macrophages would provide the TGFβ necessary for polarization.
IL-2 is a growth factor required for Treg cell survival, therefore we also added in
IL-2 to the co-cultures. Following co-culture of peritoneal cells from EPS-treated
mice with anti-CD3 stimulated splenocytes and IL-2, we find an increase in the
percentage of CD4+CD25+Foxp3+ T cells compared to co-culture with peritoneal
cells from untreated mice (Figure 3.39). Taken together, these data suggest that
M2 macrophages have the capacity to induce Treg cells.
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Figure 3.39. Induction of Treg cells by EPS-induced M2
macrophages. A. CD4+CD25+Foxp3+ T cells found in co-cultures of anti-CD3
stimulated splenocytes, IL-2 (50 ng/mL), and peritoneal cells from EPS-treated
or untreated (NT) mice. B. % CD4+CD25+Foxp3+ T cells (of total CD4+CD25+ T
cells) in 4 independent experiments with N = 6 mice total per group. Statistical
significance determined by Student’s t test. p<0.001 denoted as ***, p = 0.001
to 0.01 denoted as **, and p = 0.01 to 0.05 denoted as *.
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Conclusions from Section 3.
EPS-induced M2 macrophages produce TGF-β and PD-L1, which inhibit T
cell responses and contribute to the development and maintenance of peripheral
T regulatory cells (Gandhi et al. 2007; Francisco et al. 2009). We find a slight
increase in the percentage of Treg cells in the peritoneal cavity of EPS-treated
mice, and in vitro, EPS-induced M2 macrophages directly induce Treg cells.
Future experiments will determine if EPS-induced M2 macrophages induce Treg
cells in other locations in the body.
Section 4: Potential of B. subtilis to Treat Human Disease
Purified EPS has been used to determine the mechanism by which B.
subtilis spores prevent inflammatory disease induced by an enteric pathogen. As
a therapeutic, EPS would be an ideal way to transiently treat different diseases,
especially in immunosuppressed individuals. However, since B. subtilis spores
are already available as a food and as a probiotic in many countries, B. subtilis
could easily be used therapeutically without the timely regulatory processes
required for use of purified EPS in humans. Although we hypothesize that B.
subtilis spores that protect in an EPS-dependent manner utilize that same
mechanism as EPS, we sought to determine if spores also induce antiinflammatory M2 macrophages.
Induction of M2 Macrophages by B. subtilis Spores.
We first tested if like EPS, B. subtilis induces an M2 macrophage
phenotype. Mice were treated with WT or epsH B. subtilis mutant spores by oral
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gavage. The epsH spores do not produce EPS and do not protect mice from C.
rodentium-induced disease (Jones & Knight 2012). On days 4 and 6 posttreatment, we isolated MLN and peritoneal cells from mice and assessed M2
macrophage phenotype by flow cytometry. In the peritoneal cavity at 4 dpt, we
found an increase in the expression of IL-4Rα, and a slight increase in CD206 on
macrophages in mice treated with WT B. subtilis spores compared to
macrophages from epsH B. subtilis spores (Figure 3.40A). The cells were not
examined for expression of CD80, CD86 or PD-L1. At this time-point, we did not
find changes M2 macrophage markers in the MLN (data not shown).
Interestingly, although the percentage of macrophages is only 1-4% of the
MLN, by day 6, we found upregulation of several M2 macrophage markers on
F4/80+ cells of mice orally gavaged with WT B. subtilis spores compared to mice
gavaged with epsH B. subtilis spores (Figure 3.40B). CD206 and PD-L1 are
upregulated and CD80 expression has a slightly larger peak, but no changes are
seen in IL-4Rα or CD86. At day 6, no changes are seen in macrophage phenotype
in the peritoneum. These data suggest that B. subtilis induces M2 macrophages
in the peritoneal cavity at 4 dpt and in the MLN by day 6. The location of M2
macrophage induction in B. subtilis-treated mice has not been exhaustively
studied. Future studies are needed to determine the dynamics of induction and
migration of M2 macrophages in these mice.
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Figure 3.40. Induction of M2 macrophages in MLN and the
peritoneum of B. subtilis-treated mice. Mice were gavaged with WT B.
subtilis spores or epsH B. subtilis spores. Peritoneal cells (A) and MLN (B)
were isolated 4 dpt and 6 dpt, respectively, and M2 macrophage markers were
assessed on F4/80+ cells by flow cytometry. Data are representative of 5
independent experiments with 6-8 mice per group.
Inhibition of T cell Responses by B. subtilis Spores.
We further assessed the potential of cells from the peritoneal cavity and
MLN of mice treated with B. subtilis spores for the capacity to inhibit T cell
proliferation. Similar to purified EPS, administration of B. subtilis spores (by
oral gavage) resulted in the generation of peritoneal cells (4 dpt) that potently
inhibit T cell proliferation (Figure 3.41A). In contrast, peritoneal cells from mice
gavaged with EPS-deficient epsH B. subtilis spores did not inhibit T cell
proliferation. Since we hypothesize that macrophages within the MLN of B.
subtilis-treated mice will inhibit T cells, and macrophages represent such a small
percentage of the MLN, we purified F4/80+ cells using magnetic beads. F4/80+
MLN cells from WT- or epsH B. subtilis-treated mice isolated 6 dpt were co-
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cultured with proliferating T cells and the capacity to inhibit proliferation was
assessed. As seen in Figure 3.41B, in cultures with F4/80+ cells from WT
B.subtilis-treated mice, we find reduced T cell proliferation (48% CD4+ T cells)
compared to proliferation in co-cultures with F4/80+ cells from epsH-treated
mice (94% CD4+ T cells). These reductions in proliferation are reproducible;
however, they are not statistically significant (p=0.06), potentially due to
variability in proliferation between experiments. From these data, we conclude
that both B. subtilis, like EPS, induces cells that inhibit T cell proliferation,
indicating that both B. subtilis and EPS induce systemic anti-inflammatory
responses. Further studies are needed to determine if the inhibitory cells
induced by B. subtilis are M2 macrophages, as is the case for EPS.

Figure 3.41. Inhibition of T cell proliferation by peritoneal and MLN
cells from B. subtilis treated mice. Proliferation of CD4+ T cells in cultures
of anti-CD3 stimulated splenocytes and peritoneal cells from mice gavaged with
WT or epsH B. subtilis spores. A. Representative flow cytometric profile of cocultures of peritoneal cells isolated 4 dpt (Left), and % proliferating T cells in 4
independent experiments; N = 6 mice per group (right). B. Magnetic beadpurified F4/80+ cells from MLN 6 dpt. Representative flow cytometric profile
(Left); % proliferating CD4+ T cells in three independent experiments, with N =
5 mice total per group (right). Horizontal bar = % proliferating cells; none =
splenocytes alone. Statistical significance determined by Student’s t test.
p<0.001 denoted as ***, p = 0.001 to 0.01 denoted as **, and p = 0.01 to 0.05
denoted as *.
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Induction of M2 Macrophages in Human Cells.
B. subtilis appears to induce M2 macrophages in an EPS-dependent
manner, similar to the effects seen with purified EPS, although we have not
determined if the inhibitory peritoneal cell type is a macrophage. To further
demonstrate if the model could be relevant to treat human disease, we asked if
EPS induces an M2 macrophage phenotype in human macrophages. Many of the
M2 macrophage markers we utilize, Arg-1, Ym-1 and FIZZ-1 are expressed in
mouse, and not human macrophages. The scavenger receptor, CD163, is
routinely used as a human M2 marker, and we used this marker to assess the
capacity of EPS to induce M2 macrophages. We also assessed CD80 and PD-L1
expression, because these markers are upregulated in mouse macrophages, and
they have homologs in humans. We generated human macrophages from human
cord blood by first allowing monocytes to adhere to plastic and washing away
non-adherent cells. We then treated the enriched monocyte population with MCSF (10 ng/mL) for 5 d. After treating the macrophages with 5 µg EPS or an
equal volume of ΔEPS for 3 d, the expression of CD80, PD-L1 and CD163 was
assessed on CD68+ cells, the human macrophage marker, by flow cytometry. If
EPS induces M2 macrophages in humans, we expect to find an increase in CD163
expression in CD68+ cells treated with EPS compared to untreated or ΔEPStreated cells. Indeed, we found an increase in CD80+CD163+ cells within CD68+
cells from EPS-treated cultures compared to CD68+ cells from untreated cultures,
or cultures treated with ΔEPS (Figure 3.42). Further, EPS-treated cells
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upregulate PD-L1 (Figure 3.42, right), consistent with observations in mouse
macrophages. These data suggest that EPS induces M2 macrophages in human
cells. Future studies will be needed to determine if these M2 macrophages
generated in human also inhibit T cell responses.
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Figure 3.42. M2 macrophage induction in human cells. Macrophages
were generated from cord blood monocytes using M-CSF (10ng/mL) for 5 d.
Cells were treated with 5 µg/mL EPS or an equal volume of ΔEPS for 3 d;
CD68+ macrophages were assessed for CD80, CD163 and PD-L1 expression by
flow cytometry. Representative of 3 independent experiments, each from a
different cord blood donor.

Conclusions from Section 4.
These studies show that B. subtilis, like EPS, induces an anti-inflammatory
state and is a potential treatment for inflammatory disorders in humans until we
identify the structure of EPS. Additionally, we found that EPS induces an M2
macrophage-like phenotype in human macrophages.

CHAPTER FOUR
DISCUSSION
Introduction.
Bacteria contribute to the development of many organ systems and
physiological processes. The microbiota is essential to train the immune system
to tolerate foreign and self-antigen and develop regulated immune responses.
Our health relies on maintaining a robust and diverse microbiota within our
gastrointestinal tract. Failure to establish a healthy microbiome at birth leaves
individuals with increased susceptibility to numerous diseases.
Not only are bacteria required for the proper development of the immune
system, but specific bacterial molecules appear to be essential to mediate these
effects. Studies of bacterial products that modulate the immune system have,
until recently, focused primarily on pathogenic molecules that elicit proinflammatory responses or contribute to evasion of the immune system. These
studies identified host pattern recognition receptors, such as TLRs and NODs
and their cognate ligands (e.g. LPS, lipoteichoic acid and flagellin) along with the
downstream signaling pathways. Less understood are the mechanisms by which
commensal bacteria and commensal-derived products circumvent proinflammatory responses, allowing select bacteria to live in homeostasis with the
host. The work in this thesis seeks to understand how commensal bacteria
protect the host from disease.
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We found that a single oral dose of the probiotic B. subtilis or a single i.p.
injection of B. subtilis EPS prevents inflammatory responses against the enteric
pathogen, C. rodentium. Additionally, we have identified that EPS from B.
subtilis exerts this anti-inflammatory response by inducing M2 macrophages.
This is the first demonstration of a probiotic molecule exerting anti-inflammatory
effects through M2 macrophages.
Mechanism by which B. subtilis Induces Anti-inflammatory
Response.
EPS binding to macrophages. Peritoneal macrophages bind and
rapidly internalize EPS (Figure 4.1). Macrophages throughout the body and
especially peritoneal macrophages highly express pattern recognition receptors.
Since, EPS does not protect TLR4-/- mice from disease caused by C. rodentium,
we suspected that EPS binds to TLR4, however, we find that EPS binds to
peritoneal macrophages in mice deficient in TLR4 and TLR2. We hypothesize
that EPS utilizes a co-receptor of the TLR4 signaling complex, similar to LPS,
which binds to the co-receptors CD14 and MD2 (Da Silva Correia et al. 2001). In
addition, EPS could bind C-type lectins or scavenger receptors, which serve as
carbohydrate-binding pattern recognition receptors, and can associate with TLR4
(Stewart et al. 2009; Mukhopadhyay et al. 2011; Amiel et al. 2009; Yu et al.
2012).
Based on binding, we think that EPS acts strictly on macrophages,
however, EPS may be internalized or phagocytosed by other cell types and elicit a
response. Some efforts to biotinylate EPS have been sucessful, however, the
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process seems to render the EPS inactive and may alter the structure. Once we
understand the composition of EPS, we can more rationally determine a way to
label EPS based on the polysaccharide chemistry, and effectively expore the effect
of EPS on other cell types that perhaps bind EPS at low levels. In fact, we have
observed alterations in dendritic cells function following EPS treatment.
Dendritic cells pulsed with ovalbumin stimulate CD4+ T cell proliferation in OVAspecific T cells. Following EPS treatment, OVA-pulsed dendritic cells no longer
stimilate T cells to proliferate. Although we don’t observe many alterations in the
expression of co-stimulatory or co-inhibitory molecules, we find increased
expression of IL-10 and TGF-β. Whether this is due to the upregulation of IL-10
and TGF-β following EPS treatment, or if EPS alters antigen presentation and costimulation has not been determined. Further studies will determine the
mechanism by which EPS modulates dendritic cells. Dendritic cells and
macrophages express many of the same PRRs and therefore, the signaling
cascade induced following EPS binding and internalization may be similar in
both cell types. In both cases, EPS seems to induce a regulatory phenotype.
What is EPS? Our lack of understanding of the basic biology of EPS
complicates our search for the ‘EPS receptor’. EPS is essential for B. subtilis
biofilm formation. Within the eps operon are four genes, epsH-K, required for
synthesis of β-1,6-linked N-acetylglucosamine, identified to be a major
component of EPS and thereby the B. subtilis biofilm. The epsH and epsJ genes
encode glycosyltransferases. The B. subtilis mutant used as a negative control for
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EPS production in all of our experiments is an epsH mutant, suggesting that Nacetylglucosamine may comprise some of our immunomodulatory EPS. If an
EPS mutant outside of the epsH-K locus does not protect mice from disease, EPS
is likely made up of an additional carbohydrate component.
In initial analyses of EPS composition, we determined that EPS purified
from B. subtilis grown in LB medium was comprised of 88.0% mannose, 11.9%
glucose, and 0.1% N-acetylglucosamine (Complex Carboydrate Research Center,
University of Georgia). In collaboration with Dr. Neil Price at the USDA, we
have determined that high amount of mannose in our EPS preparations was due
to yeast extract mannan present in LB broth that co-purifies with EPS. A small
amount of EPS preparation purified from LB broth, although active in vivo, is
actual EPS. To obtain a higher and more pure yield of EPS, we grew B. subtilis in
MSgg minimal medium to minimize polysaccharide background contamination.
Using EPS purified from MSgg medium, we find the same immunomodulatory
effects in vivo that we see with EPS purified from LB broth or BHI media, which
we had used in early binding experiments (Table 4.1). Interestingly, we can use
10-fold less EPS from MSgg to induce the same response observed with EPS
purified from LB broth. The only functional difference identified thus far
between EPS purified from LB and MSgg is that EPS from MSgg (and from BHI)
induces M2 macrophages in vitro, whereas no in vitro changes were ever
detected using the less-pure EPS from LB broth (Table 4.1). Although we have
yet to determine the composition of EPS prepared from MSgg, it is possible that
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the mannose and N-acetylglucosamine observed to be a small percentage
previously are the actual, functional EPS. Once we determine the composition
and structure of EPS, we can identify macrophage receptors that bind to the
identified polysaccharide.

Table 4.1. Functional properties of EPS
purified from different culture conditions
Experiment

Growth Medium
BHI
LB
MSgg

EPS binding

+

+/-

+

M2 induction (in vivo)

+

+

+

M2 induction (in vitro)

+

-

+

T cell inhibition by EPSinduced M2 macrophages

+

+

+

Anti-CD3 challenge in vivo

n.d.

+

+

Splenic T cell responses

n.d.

+

+

Induction of Treg cells

n.d.

+

+

Key: (+): EPS purified from specified medium functions in this assay; (-):
EPS purified from this medium does not function in this assay; (+/-):
Variable results. List of abbreviations: BHI – brain heart infusion media;
EPS – exopolysaccharide; LB – Luria-bertani; n.d. – not determined.

Induction of M2 macrophages. Even though EPS does not bind
directly to TLR4, induction of M2 macrophages requires this PRR. Canonical
TLR4 signaling through MyD88 leads to NF-κB activation, however this pathway
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is often thought of as an inflammatory pathway. M1 macrophage induction often
occurs by LPS signaling through TLR4. How then, does EPS drive an antiinflammatory response and induce anti-inflammatory M2 macrophages?
The dependency on TLR4 is not likely due to LPS because B. subtilis is
Gram (+) and produces little to no LPS. In contrast to other bacterial
polysaccharides, notably PSA from B. fragilis that signals through TLR2, EPS is
unlikely to function through TLR2 because EPS induces M2 macrophages in

Figure 4.1. Model of induction of M2 macrophages by EPS. EPS
binds to macrophages and is rapidly internalized. EPS upregulates
expression of M2 macrophage markers in a TLR-4 dependent manner.
These cells also upregulate IL-4 and IL-13 that further enhances activation of
M2-dependent genes. STAT6, PPAR-γ, or NF-κB potentially drive this
process.
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TLR2-/-

mice. We hypothesize that EPS binding to TLR4 co-receptors recruits

TLR4 and initiates a signaling cascade, directly modifying macrophages and
induces M2 macrophage-specific transcription factors (Figure 4.1). EPS binding
to these receptors could upregulate M2 macrophage-inducing transcription
factors such as STAT6, IRF4 and peroxisome proliferator-activated receptor
gamma (PPAR-γ), which regulate transcription of Arg-1 and CD206 (Lawrence &
Natoli 2011; Shirey et al. 2010). IL-4 and IL-13 activate STAT6 signaling through
IL-4Rα to induce M2 macrophages. Since we see increased IL-4 and IL-13
production by macrophages following EPS treatment, EPS may activate the
STAT6 pathway. An intriguing study by Shirey et al. determined that respiratory
syncytial virus (RSV) activates PPAR-γ to induce M2 macrophages. Similar to
EPS-induced M2 macrophages, RSV-induced M2 cells upregulate FIZZ-1, Ym1,
CD206 and Arg-1 in a TLR4-dependent manner, that also requires STAT6 (Shirey
et al. 2010). This study identifies TLR4-dependent transcription factors that
drive M2 induction that EPS could potentially utilize.
We have preliminary evidence that EPS treatment upregulates NF-κB
signaling in RAW264.7 cells that stably express an NF-κB luciferase reporter
(Wonbeom Paik). IL-10 activates STAT3 signaling in macrophages, leading to
M2 macrophage generation in a process that also activates NF-κB, but EPS does
not upregulate IL-10 in the conditions tested thus far. Interestingly, STAT3
activation in dendritic cells upregulates PD-L1 expression, similar to what we see
in macrophages in response to EPS (Wölfle et al. 2011). We have not yet
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determined the timing of NF-κB activation, or if it occurs in primary
macrophages. It is possible that NF-κB activation occurs downstream of the
initial signaling events induced by EPS. Further, the phenotype of RAW264.7
cells following EPS treatment is somewhat different than primary macrophages
treated with EPS. Studies of the signaling cascades induced by EPS will have to
be completed in both cell types to verify that the correct signaling cascade is
identified.
An intriguing alternate hypothesis is that EPS antagonizes TLR4 signaling
to induce an anti-inflammatory response. In adipose tissue, the absence of TLR4
drives macrophages towards an M2 phenotype (Orr et al. 2012). M2
macrophages present in adipose tissue highly express suppression of
tumorigenicity 2 (ST2), a negative regulator of TLR4 signaling (Westcott et al.
2009). Other negative regulators of TLR4 signaling, such as AP-1 (activator
protein 1), are stimulated by TLR4 activation (Patel et al. 2006). EPS could
activate M2 macrophage polarization by upregulating a negative regulator of the
inflammatory TLR4 signaling cascade.
EPS acts directly on macrophages to upregulate M2 macrophage markers.
Other cell types, however, potentially contribute to the maintenance of M2
macrophages within the peritoneal cavity. Type 2 immune responses are
characterized by IL-4, IL-5, IL-10 and IL-13 production. ILC2s, Th2 cells, B cells
and eosinophils are all activated by these cytokines, which leads to even greater
production of these cytokines (Figure 4.2). Although M2 macrophages may
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initiate the response to EPS, these other type 2 immune cells are present in the
dynamic environment of the peritoneal cavity and may be activated by
macrophage cytokines.

ILC2
Eosinophil

B cell

M2
Treg

Th2
DC

IL-13
IL-4
TGF-β
IL-10

Figure 4.2. Dynamics of EPS-induced type 2 Immunity within the
peritoneal cavity.
Induction of M2 macrophages by other probiotics. Our work is
the first to identify a probiotic molecule that suppresses pro-inflammatory
responses through M2 macrophages. Many bacterial species have been shown to
induce the generation of Treg cells to suppress inflammation, however it is
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unclear how much M2 macrophages facilitate this induction. The Mazmanian lab
identified DCs as the cell type driving Treg induction by PSA, and DCs likely
induce Treg cells in other probiotic models. Other bacteria potentially induce
anti-inflammatory macrophages and these cells may induce Treg cells in many
models, as well as DCs. One study on Clostridium butyricum identified a
population of IL-10+ macrophages in the GIT of mice treated with this probiotic.
This mechanism of induction is unique to that of B. subtilis EPS, given that C.
butyricum utilizes TLR2 signaling and upregulates IL-10 production. These cells
are required for protection from DSS-induced colitis, and Treg cells seem to be
partially required, however a direct connection between macrophages and Treg
cells in this model has not yet been established.
Trafficking of EPS-induced M2 macrophages. EPS induces M2
macrophages within the peritoneal cavity following intraperitoneal injection of
EPS. Increases in M2 macrophages are found both in the peritoneum after i.p. or
i.v. injection of EPS, as well as after oral administration of B. subtilis spores.
Does EPS travel systemically following injection, and/or do M2 macrophages
traffic to other locations in the body? Macrophages are highly prevalent in the
peritoneum and because they bind and internalize EPS, we expect a limited
amount of EPS leaves the peritoneal cavity. Once we can label EPS, we will be
able to track where EPS travels after injection.
The peritoneum contains two populations of macrophages: LPMs and
SPMs. These cells differ in size and CD11b expression, and other markers, but
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EPS binds to both LPMs and SPMs. We hypothesize that EPS induces an M2
phenotype in LPMs and SPMs. Following non-specific i.p. injection, the majority
of LPM traffic to milky spots in the omentum, but cytokines still interact with
peritoneal cells (Okabe & Medzhitov 2016). Meanwhile, monocytes infiltrate the
peritoneal cavity and differentiate into macrophages (Ghosn et al. 2010).
Although these infiltrating cells may not directly interact with EPS, the cytokine
environment induced by initial EPS binding to LPMs and SPMs polarizes these
new macrophages to an M2 macrophage phenotype. In fact, supernatants from
EPS-induced M2 macrophages polarize naïve macrophages to an M2 macrophage
phenotype (unpublished observations). F4/80+ cells proliferate in response to
EPS, but we have not determined if this population of proliferating cells is LPMs,
SPMs, or both. Further, these studies were done by adoptive transfer of EPSinduced M2 macrophages into naïve mice. An important study will be to
determine if the macrophages of mice fed Bromodeoxyuridine, BrdU, (in order to
label proliferating cells) proliferate in response to EPS.
In our in vitro experiments, EPS-induced M2 macrophages inhibit T cell
responses via direct cell contact, suggesting that M2 macrophages traffic to
inhibit T cell responses during disease. We do not know if in vivo, these cells can
produce soluble factors to inhibit cells. TGF-β activation is not well understood
and could occur differently in vivo compared to our in vitro co-culture
conditions. We do find increased serum levels of total TGF-β, suggesting that
TGF-β may be cleaved from the surface of M2 macrophages in vivo. We often
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find increases in M2 macrophages in MLN and spleen following EPS treatment
where they may interact with and inhibit T cells. These T cells are recruited to
the colon following epithelial damage induced by C. rodentium in the colon.
Since we do not see infiltration into the mucosa in mice treated with EPS prior to
C. rodentium infection, we hypothesize that M2 macrophages render the T cells
inactive or anergic in the spleen or MLN, blocking recruitment to the colon.
Additionally, damage caused by C. rodentium may enhance recruitment of M2
macrophages to the spleen, MLN, or the colon where they directly inhibit
inflammation. We have preliminary evidence that an increase in Arg-1+ cells
occurs in the colon of mice treated with EPS prior to infection compared to mice
infected with C. rodentium alone. We have not established if the Arg-1+ cells are
macrophages, but these data suggest that M2 macrophages are recruited to the
colon during enteric disease.
Peritoneal cells administered by i.p. injection traffic to the spleen and
MLN, and we expect that some EPS-induced M2 macrophages traffic to other
organs following EPS injection. In different diseases, damage in other organs
could recruit EPS-induced M2 macrophages and lead to protection from other
sources of inflammation. The mechanisms of macrophage egress from the
peritoneal cavity are not well defined. A recent study identified a CD44dependent mechanism by which peritoneal macrophage are recruited to the liver
following sterile inflammation (Wang & Kubes 2016). This may be a relevant
mechanism for direct influx into other organs from the peritoneum.
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Interestingly, peritoneal macrophages upregulate CD44 following EPS treatment,
suggesting EPS-induced M2 macrophage may use a similar mechanism to travel
to the liver and perhaps other organs (Wonbeom Paik, unpublished
observations).
Alterations in T cell Responses by EPS-induced M2 Macrophages.
M2 macrophages mediate an anti-inflammatory response not only by
TGF-β and PD-L1, but also by arginase-1, IL-10, and PD-L2 (Huber et al. 2010;
Gobert et al. 2004; Pesce et al. 2009; Yue et al. 2015). Such molecules protect
from colitis, promote tissue repair and metabolic homeostasis, and provide
protective immunity to helminth infections (Little et al. 2014). Even though EPSinduced M2 macrophages produce multiple anti-inflammatory molecules, in our
in vitro co-cultures of EPS-induced M2 macrophages and proliferating T cells, we
find restoration of CD4+ T cell proliferation only by interfering with TGF-β. In
contrast, CD8+ T cell restoration occurs through PD-L1, as well as TGF-β.
Inhibition of other molecules including arginase-1, PGE2, PD-L2 and IL-10 had
no effect on T cell inhibition. We conclude that TGF-β and PD-L1 are the main
inhibitory factors of the EPS-induced M2 macrophages (Figure 4.3). We cannot
rule out the contribution of other factors, potentially contributing to protection in
vivo. Arginase-1 inhibits TCR signaling, but also promotes wound healing and
fibrosis (Pesce et al. 2009), effects we have not examined following EPS
treatment. EPS-induced M2 macrophages increase expression of CD80, but
decrease expression of CD86. These molecules interact with CD28 to provide co-
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stimulation to T cells, but can also interact with CTLA-4 to strongly inhibit T cell
responses (Figure 4.3). Although these molecules don’t contribute in our in vitro
T cell proliferation assay, further studies are needed to determine the importance
of these molecules in our system with T cells and other cells.
Programmed death-ligand 1. T cells upregulate PD-1 following TCR
stimulation. Its ligands, PD-L1 and PD-L2 are expressed on dendritic cells and
macrophages. These ligands serve as co-inhibitory receptors that are part of the

Figure 4.3. Interactions between effector molecules of EPSinduced M2 macrophages and T cells. M2 macrophages produce
multiple factors to inhibit T cell responses (-), including arginase-1, PD-L1 and
TGF-β. CD80 provides co-stimulation when it interacts with CD28 (+), but
inhibits following interactions with CTLA-4.
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immune checkpoint during T cell activation (Freeman et al. 2000). PD-1
pathway interactions limit the positive signals that T cells receive from CD28 and
CD80/CD86. PD-1/PD-L1 signaling reduces cytokine production and halts T cell
proliferation by inducing T cell apoptosis and anergy (Freeman et al. 2000; Liang
et al. 2003). In studies of chronic viral infection, PD-1 is highly expressed on
exhausted T cells, suggesting that this pathway also promotes T cell exhaustion
(Barber et al. 2006). CD8+ T cells are more sensitive to PD-1 ligation (Carter et
al. 2002), which may explain why, in our system, that PD-L1 blockade increases
proliferation of CD8+ T cells, but not of CD4+ T cells. The levels of co-stimulatory
and co-inhibitory molecules determine if the interaction leads to inhibition or
activation. EPS-induced M2 macrophage upregulate CD80 and downregulate
CD86, both co-stimulatory molecule, and increase expression of inhibitory PDL1. In our in vitro T cell proliferation assay, inhibition of CD8+ T cells occurs in
an antigen-independent manner, but potentially inhibition could occur in an
antigen-specific interaction. EPS-induced M2 macrophages inhibit antigenspecific CD4+ T cell proliferation, presumably through TGF-β, but we have not
tested inhibition of CD8+ T cells in an antigen-specific system. Understanding
the balance of these signals from M2 macrophages will help us determine how
EPS could be used in other disease states to inhibit CD4+ and CD8+ T cell
responses.
Transforming growth factor-β. TGF-β inhibits T cell responses by
inducing apoptosis and T cell anergy, but also promotes immune responses in
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other cells (Gorelik & Flavell 2002). As discussed above, although we see cell
contact-dependent inhibition via TGF-β signaling in vitro, activation may occur
differently in vivo. Integrins, matrix metalloproteinases (MMPs), and other
proteases present in the extracellular matrix activate TGF-β (Hyytiäinen et al.
2004). Peritoneal macrophages express integrins, including CD11b, and MMPs
that may activate TGF-β, but some macrophage functions require tissue-specific
signals for expression (Okabe & Medzhitov 2016). It is unclear if TGF-βexpressing macrophages interact with cells other than T cells in vivo. If TGF-β is
cleaved and activated from macrophages in vivo, it could act on a variety of
downstream cells. TGF-β signaling in DCs decreases maturation and antigen
presentation and decreases cytokine production and cytotoxicity of NK cells.
Additionally, it increases chemotaxis of eosinophils, granulocytes, mast cells, and
monocytes and macrophages. TGF-β also decreases activation, proliferation and
survival in B cells, but interestingly, it promotes class switching to IgA (Gorelik &
Flavell 2002). This would be beneficial in C. rodentium infection, where IgA
production is required for clearance of the pathogen. This also supports the use
of EPS treatment for disease in other mucosal tissues, such as the lung.
Additionally, if EPS can promote class switch to IgA, it could prevent
development of unwanted isotypes, such as IgE in the case of allergic responses,
from being generated. In certain diseases, decreased effector cell function as a
result of EPS treatment would be detrimental and increase disease pathology.
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Contribution of TGF-β signaling in vivo. TGF-β and PD-L1 mediate
the inhibitory effects of EPS-induced M2 macrophages in vitro, but do these
molecules contribute to protection in vivo? Mice deficient in TGF-β signaling die
before birth and due to the wide-range of effects mediated by TGF-β, selective
inhibition can greatly exacerbate disease, making studies of the in vivo relevance
of the cytokine technically difficult. To determine if TGF-β also mediates T cell
inhibition in vivo, we utilized the anti-CD3 model, where i.p administration of
anti-CD3 causes a robust increase in serum TNFα and IL-2 within 2 hours of
treatment. We first tested if anti-TGF-β alleviates the protective effects of EPS,
using mouse IgG1 as the isotype control. Although neutralization of TGF-β
removes EPS-induced reduction in T cell cytokine production, the isotype control
alone also increases cytokine production. Therefore, it is difficult to determine
the effect of anti-TGF-β on EPS inhibitory effects. In contrast, mice administered
mouse IgG1 isotype control prior to infection with C. rodentium had reduced
disease, making it difficult to discern the effect of TGF-β neutralization following
EPS treatment in this model. This may be due to interactions between the mouse
IgG1 and Fc receptors that generate some sort of protective immune response.
Unfortunately, neutralizing antibodies to TGF-β raised in a different species are
not available.
We next tried inhibiting TGF-β through the TGF-β receptor kinase
inhibitor SB-423512, or the vehicle control DMSO. Unfortunately, this inhibitor
is highly insoluble in anything but DMSO, and like the isotype control, the DMSO
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control also abolished the protective effects of EPS in the anti-CD3 model.
Similarly in the C. rodentium model, mice administered the TGF-β inhibitor had
exacerbated disease, and control mice administered EPS and DMSO were no
longer protected from disease. These experiments demonstrate that inhibiting
TGF-β in vivo is technically difficult and requires further optimization. We have
not tested the relevance of PD-L1 signaling in vivo, but this would require a CD8+
T cell-specific model since TGF-β also partially restores EPS-induced M2
macrophage inhibition of CD8+ T cells.
Regulatory T cell induction by B. subtilis EPS. One of the wellstudied effects of TGF-β is the induction of Treg cells. We do see an increase in
Treg cells within the peritoneal cavity of EPS treated mice and in co-cultures of
EPS-induced M2 macrophages, but how do CD4+ T cells contribute to protection
from C. rodentium-induced disease? Often times iTreg cells upregulate IL-10 to
suppress immune responses. In preliminary experiments, we do find
upregulation of IL-10 in co-cultures of EPS-induced M2 macrophages and
proliferating T cells, where we also see an increased percentage of Treg cells. We
have not yet found upregulation of IL-10 in vivo, or determined if EPS-induced
Treg cells contribute to protection from C. rodentium-induced inflammation.
Early in the search for the protective cell-type, we tested if CD4-/- mice are
protected by EPS from disease. CD4+ T cells drive much of the pathology of C.
rodentium-induced inflammation, but CD4-/- mice still develop disease, including
diarrhea and damage dependent on MyD88 signaling, but goblet cell-depletion
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and extensive hyperplasia do not occur. We found that

CD4-/-

mice are not

protected by EPS from disease, suggesting that CD4+ T cells are required for EPSmediated protection (Dr. Sara Jones-Burrage, unpublished observations). EPSinduced M2 macrophages are present around 2-4 days post-treatment. Day 4
post-EPS treatment, peritoneal cells still display an M2 macrophage phenotype
and inhibit T cell proliferation compared to peritoneal cells from mice treated
with ∆EPS. C. rodentium first colonizes the cecal patch, then the colon and
begins to induce inflammation 4-7 dpi, however, peak disease doesn’t occur until
10 dpi. EPS-induced M2 macrophages possibly inhibit early T cell recruitment to
the colon, but Treg cells may limit later stages of disease around days 7-10 since
the pathogen is still present at levels comparable to ∆EPS-treated mice. This
could be what occurs in CD4-/- mice that develop M2 macrophages 3 dpt, but still
develop diarrhea by day 10 post-infection. Reconstitution of CD4-/- mice with
CD4+ T cells restores the protective benefits of EPS treatment during infection
(unpublished observations), but since these experiments use total CD4+ T cells
and make the equivalent of a wild-type mouse, we do not know if iTreg cells
mediate this benefit. In order to directly test the contribution of iTreg cells to
EPS-mediated protection from inflammation, we will need to specifically deplete
iTreg with anti-CD25 or use mice in which Treg cells can be inducibly-depleted
with diphtheria toxin.
Potential of Probiotics to Treat Human Diseases.
Regulatory T cell induction by other commensals. Several
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commensal bacteria other than B. subtilis prevent inflammatory diseases by
modulating the immune response (Table I). The beneficial effects of commensals
are described mostly for models of inflammatory bowel disease (IBD), where,
with a few exceptions (Pagnini et al. 2010; Ivanov et al. 2009; Fanning et al.
2012), protection appears to be mediated, in large part, by TLR2 signaling, iTreg
cells, and IL-10. For example, B. fragilis, Bifidobacteria infantis, and Clostridia
species induce Treg cells that ameliorate disease in chemically-induced colitis
models (Shen et al. 2012; Atarashi et al. 2011; O’Mahony et al. 2008; Round &
Mazmanian 2010) and VSL#3 and Bifidobacterium breve induce IL-10producing Tr1 cells (Di Giacinto et al. 2005; Jeon et al. 2012). B. subtilis EPS
induces M2 macrophages that inhibit T cell responses through PD-L1 and TGF-β
and have the capacity to induce Treg cells. We conclude that B. subtilis EPS
induces an anti-inflammatory response distinct from that of all previously
described probiotics.
With the exception of B. subtilis EPS, B. fragilis PSA and sphingolipids,
and Faecalibacterium prausnitzii MAM protein (Mazmanian et al. 2008; Jones
et al. 2014; Sokol et al. 2008; Quévrain et al. 2015; An et al. 2014), most of the
bacterial molecule(s) responsible for protection have not yet been identified or
purified.
Therapeutic potential of probiotics outside the intestine. While
most known probiotics target gastrointestinal disease, many probiotics will likely
be useful for treating or preventing other inflammatory diseases, including
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diabetes, allergy and experimental autoimmune encephalomyelitis (EAE) (Stefka
et al. 2014; Cao et al. 2014; J et al. 2010; Hu et al. 2015). In fact, SFB-induced
Th17 cells prevent the spontaneous development of type-1 diabetes in NOD mice
(Kriegel et al. 2011). Clostridia species alter innate lymphoid cells and prevent
development of food allergy (Stefka et al. 2014), and B. fragilis PSA prevents
development of EAE (J et al. 2010). As our understanding of the mechanisms by
which specific commensal bacteria modulate the immune system increases, we
will likely identify more diseases for which these probiotics will be beneficial.
Therapeutic Potential of B. subtilis EPS.
Therapeutic administration of B. subtilis and EPS. Because EPS
and B. subtilis can elicit an anti-inflammatory response when administered
through several different routes, we think that EPS and/or B. subtilis are good
candidates as therapeutic agents for treating inflammatory diseases. B. subtilis
can be administered as spores that easily transit unharmed through the harsh
conditions of the stomach and upper GIT to a nutrient-rich location in the colon
where the spores can germinate express EPS. Bacterial molecules such as EPS
are attractive therapeutics given that many immunosuppressed individuals
cannot tolerate the whole bacterium. EPS induces M2 macrophages when
administered by intraperitoneal or intravenous injection, but this would be a
cumbersome way to treat humans outside of the clinic. Ideally, EPS would be
administered orally. Administration of EPS by oral gavage did not protect mice
from disease caused by C. rodentium (Dr. Sara Jones, unpublished observations).
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We expect that stomach acid breaks down and inactivates EPS. From early
studies in our lab, we also know that B. subtilis needs to localize to a specific
niche within the GIT to induce a protective response, as an immobile, flagella
mutant strain does not prevent disease. Encapsulating EPS would provide a
vehicle for safe passage through the stomach, but might not ensure that it would
reach the ideal location within the GIT. Investigations of other types of
administration and the elicited immune responses will be vital to translating this
work to humans.
Relevance of B. subtilis in humans. Although purified EPS is our
ideal therapeutic, until we determine the composition and have a more
comprehensive purification process without contamination, EPS is unlikely to
pass any sort of regulatory process for use in humans. Probiotics in a number of
countries already contain B. subtilis and it is regularly consumed in Natto and
miso soup, proving the safety of spore consumption; but is it efficacious? A
member of our lab, Alexander Argianas, found that B. subtilis spores purified
from Natto prevented C. rodentium-induced disease in mice (unpublished
observations). This study suggests that the B. subtilis strains used in Natto
produces EPS. We have shown that EPS induces an M2 macrophages phenotype
in human macrophages similar to what we see in mouse, with increased
expression of CD80 and PD-L1. The M1/M2 macrophage paradigm has not been
well characterized in humans. Part of this is due to differences in marker
expression, but regardless of phenotype, the functions are somewhat conserved
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between mouse and human (Martinez et al. 2008). We have not yet determined
if these cells produce TGF-β or if they are functional, but these studies suggest
that EPS may be beneficial in humans.
Autoimmune disorders. EPS promotes a balance following the
inflammatory Th1 and Th17 insult that occurs during C. rodentium infection.
EPS also decreases T cell responses following i.p. challenge with anti-CD3. We
hypothesize that EPS can suppress other T cell-mediated diseases, specifically
autoimmune disorders. Th1 and Th17 cells that target the CNS drive EAE
pathology; and, both M2 macrophages and TGF-β-bearing CD4+ T cells alleviate
disease symptoms, suggesting EPS may be a potential treatment for disease.
Many other autoimmune diseases, including type 1 diabetes, rheumatoid
arthritis, and systemic lupus erythematosus, are driven by T cells or can be
treated by blocking T cell responses (Raphael et al. 2015), and are attractive
candidates to test if EPS is useful in other disease states.
Graft-versus-host disease. Following allogeneic bone marrow
transplants, recipients are at a high risk for acute and chronic graft-versus-host
disease (GVHD). During GVHD, T cells from the donor attack host tissues, often
in an immunosuppressed patient (Hoffmann et al. 2002). Macrophages are
resistant to irradiation and we hypothesize that EPS treatment of the recipient
patient prior to and following receiving the transplant may reduce pathology
associated with GVHD. Suppression of T cell activation by EPS would be an
attractive therapy for preventing the T cell attack of host tissues.
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All of these diseases discussed thus far are driven by Type 1 immune
responses, and we hypothesize that EPS balances this environment to create a
homeostatic environment. M2 macrophages are canonically thought to
contribute to Type 2 immunity, but EPS-induced M2 macrophages inhibit Th2, as
well as Th1 cytokine responses. We hypothesize that EPS can contribute to the
homeostatic balance of preventing hyper-th1 as well as hyper-Th2 responses.
Allergic disease. Children not exposed to certain bacteria early in life
do not develop a proper Th1/Th2 balance resulting in allergy and asthma (La
Rosa et al. 2003). Allergic disease is caused by the immune system
inappropriately reacting to innocuous substances. The process of allergic
sensitization is initiated by APCs (such as dendritic cells) that capture and
internalize allergen. APCs present antigen, especially to T cells which secrete
cytokines, IL-4, IL-5 and IL-13 that help drive the inflammatory response (Galli &
Tsai 2012). IL-4 is critical for class switch to IgE, the immunoglobulin that
mediates allergic symptoms. Allergen-specific IgE is produced by B cells after
encounter with helper Th2 cells. Once allergen-specific antibodies are generated,
they bind to mast cells and upon subsequent exposure, the allergen cross-links
IgE, causing mast cell degranulation and rapid release of chemical mediator such
as histamine, that recruit of Th2 cells, basophils and eosinophils that exacerbate
the immune response.
Dr. Julie Swartzendruber asked if EPS prevents allergic sensitization, a
hyper-Th2 response, in a mouse model of IgE-mediated allergic sensitization to
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ovalbumin (OVA). In mice pre-treated with EPS, we find a decrease in OVAspecific IgE induced by OVA/alum sensitization, suggesting that EPS prevents
allergic sensitization. A potential mechanism for this suppression is that EPSinduced M2 macrophages inhibit the initial interaction between APCs and T cells,
limiting production of IL-4 and production of IgE. Additionally, TGF-β produced
by M2 macrophages could induce class switch to IgA, instead of IgE.
Alternatively, EPS-induced alterations in DCs mentioned earlier could alter the
generation of a detrimental Th2 response. This study demonstrates that EPS can
prevent allergic sensitization but it is unclear if EPS can prevent allergy
symptoms after sensitization has already occurred.
It is possible that EPS may exacerbate symptoms through the induction of
M2 macrophages. For example, TGF-β increases chemotaxis of eosinophils and
other granulocytes, suggesting that even though TGF-β inhibits Th2 cells, it may
enhance disease by recruitment of other detrimental cells. Future studies need
to be done to test this hypothesis.
Cell targets of EPS. In our current studies, we identified modulation of
macrophages by EPS and have hypothesized DCs may also respond EPS. Both of
these cells are, or can be, myeloid lineage cells (certain DC subsets have a
lymphoid lineage), and are known to phagocytose antigens. Since many of the
signaling pathways overlap between macrophages and DCs, it’s reasonable that
EPS acts exclusively on these cells types. Much of this expectation is based on
binding of EPS to macrophages and low levels of EPS binding to DCs. We do not
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see alterations in T cells following co-culture with

CD4+

T cells and have not

observed any changes directly on B cells. We have not extensively ruled out
effects of EPS on other cell types, which would be necessary for future studies in
humans.
M2 macrophages in health and disease. M2 Macrophages promote
wound healing and tissue repair. Further, they provide immunity to helminth
infections. Arginase-1 and TGF-β mediate protective effects in both tissue
homeostasis and immunity to helminths, suggesting that EPS treatment may
enhance anti-helminth immunity or promote tissue repair.
M2 macrophages also help maintain metabolic homeostasis by secreting
anti-inflammatory cytokines and utilizing oxidative metabolism. During obesity,
M1 macrophages promote chronic inflammation in adipose tissue, which leads to
insulin resistance (Castoldi et al. 2016). A shift to an M1 macrophage phenotype
is characterized by aerobic glycolysis. We have not assessed the metabolic profile
of EPS-induced M2 macrophages. One interesting hypothesis is that
macrophages metabolize EPS, driving M2 macrophage development. The
benefits of B. subtilis and EPS and their anti-inflammatory properties could
extend to promoting a lean (non-obese) metabolism. Future experiments will
discern these possibilities.
Treatment vs. prevention. In many of the diseases discussed, we have
used EPS as a preventative measure. We do know that B. subtilis administered
up to 3 dpi with C. rodentium still prevents disease (Figure 4.4). B. subtilis-
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induced M2 macrophages are present at 4 dpt in the peritoneal cavity and 6 dpt
in the MLN, suggesting the anti-inflammatory response induced by B. subtilis
takes about 4 days to develop. When mice were infected with C. rodentium 3
days prior to B. subtilis treatment, the anti-inflammatory environment developed
after inflammation had already begun (Figure 4.4). In this study, therefore, B.
subtilis treats, rather than prevents, C. rodentium-induced inflammation, but it is
unclear if this occurs in other diseases with EPS.
In humans, it’s not practical for EPS to be administered as a pretreatment
for an unknown or unexpected disease. In certain cases of autoimmunity, such as
MS, the disease is diagnosed early, before much damage has occurred, but for the
majority of diseases, we would use EPS to treat inflammation. Future studies
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Figure 4.4. Therapeutic window of B. subtilis EPS-induced antiinflammatory response.
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testing the capacity of EPS to dampen down T cell responses once they have
already been initiated are necessary to determine the true efficacy of EPS in
humans.
EPS: is there a downside? EPS prevents inflammation in several
different inflammatory conditions and is an exciting therapeutic option for many
disorders. But can otherwise beneficial effects of EPS be detrimental in certain
situations? The anti-inflammatory response induced by EPS is transient. By 5
days post-EPS treatment, peritoneal macrophages resemble those of an untreated
mouse. Further, splenic T cell responses are no different between EPS-treated
mice than untreated mice. We do not expect this transient anti-inflammatory
response to induce detrimental effects. In cases of cancer, however, increased
immunosuppression could lead to tumor growth. Tumor-associated
macrophages (TAMs) bear many similarities to M2 macrophages, including TGFβ expression. TAMs produce anti-inflammatory cytokines and promote
angiogenesis to bring nutrients to the tumor microenvironment, fostering tumor
growth. PD-L1 expression within tumors also promotes tumor growth. Blockade
of the PD-1 pathway has been a breakthrough treatment for many different types
of cancers. Although EPS treatment would be harmful for an established tumor,
we do not know if repeated EPS treatment and maintenance of M2 macrophages
would promote tumor development.
Repeated doses of EPS might also generate EPS-specific antibodies. These
antibodies might induce an inflammatory response or block the induction of M2
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macrophages. Low dose inoculation of certain antigens has also been linked to
induction of allergy. In certain situations, commensal specific antibodies
promote retention of the bacterium within the GIT. Identification of the induced
antibody isotypes, or the particular adaptive immune response elicited might lead
to identification of other disease states in which this response could be beneficial.
Additionally, in the case of B. subtilis, increased prevalence might block
colonization of C. rodentium or other pathogenic bacteria.
In other cases of inflammation such as viral infection, inflammation is
necessary to clear the pathogen. Inhibition of a viral specific response might
render the host unable to clear the pathogen, allowing the virus to manifest in
other organs and have deleterious effects. As with C. rodentium infection, much
of the disease symptoms induced by some viral infections, such as the common
cold, are an exacerbated response to assure clearance of the pathogen. A low
dose of EPS may treat some of these symptoms and still allow the immune
system to clear the infection.
Concluding Remarks.
Bacillus subtilis as a commensal. Clearly, B. subtilis has evolved a
complex interaction with the immune system; yet, B. subtilis is often overlooked
and not considered a true commensal. During these early stages of identifying
mechanisms of immune-modulation by the microbiota, much attention has been
placed on highly prevalent bacterial species. Although B. subtilis is present a low
levels in the GIT, it is detected in a many of the individuals surveyed (Benno et al.
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1984; Benno et al. 1986; Qin et al. 2010). One possibility is that EPS is composed
of similar polysaccharides to another highly prevalent commensal, but such a
commensal has not been identified since no other commensals have been shown
to induce M2 macrophages.
These studies emphasize the importance of organisms present at low levels
and their important role in promoting a balance between the microbiota and the
host. The gut microbiota requires balance with the immune system and many
unavoidable factors, whether environmental, antibiotics or infections, cause
fluctuations in the microbiota and the balance between type 1 and type 2 immune
responses. The hygiene hypothesis suggests that reduced exposure to
microorganisms early in life leads to abnormal development of the immune
system, providing an explanation for the rise in allergic disease, inflammatory
disorders and autoimmunity. The importance of commensal bacteria in shaping
health is now widely recognized, and the potential therapeutic benefits of these
bacteria are being explored in several diseases. Regardless of the prevalence of
certain organisms during homeostasis, individual organisms with the capacity to
induce tolerance possess strong potential to be used as a probiotic to restore
homeostasis when dysbiosis occurs (Figure 4.5).
Probiotics are a multi-billion dollar industry world-wide. Yogurts, pills,
energy drinks, the products and benefits of a healthy microbiota are all over the
news, advertising and day-to-day life. But are these products actually eliciting a
response? Our study highlighting that the mechanism by which B. subtilis limits
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inflammation caused by an enteric pathogen indicates probiotics do actually
prevent disease.
Many probiotics on the market are an undefined cocktail of bacteria; it is
unclear what if any of the components are eliciting a positive effect. More
mechanistic studies are needed to identify which products actually contribute to
human health.
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Figure 4.5. Probiotics maintain balance between type 1 and type 2
immunity. Balance between Type 1 and Type 2 immunity is maintained by
Treg cells, M2 macrophages, and tolerogenic DCs (A). When dysbiosis occurs,
a skewing towards type 1 immunity results in increased autoimmune diseases
and metabolic disorders (B), whereas an detrimental type 2 immune response
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Trillions of bacteria inhabit the gastrointestinal tract; countless bacteria
found in the environment exert beneficial effects as probiotics. The precise
mechanism by which these bacteria modulate the immune system to benefit the
host has been identified for around a dozen of these bacteria. Only four
molecules (EPS, PSA, sphingolipids, and MAM) from three bacteria (B. subtilis,
B. fragilis, and F. prausnitzii) have been identified to mediate these symbiotic
effects. This study highlights a unique mechanism by which a Gram (+)
commensal exopolysaccharide induces an anti-inflammatory environment, as
modeled in Figure 4.6. EPS from B. subtilis, induces anti-inflammatory M2
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Figure 4.6. Model for EPS modulation of immune responses. B.
subtilis and purified EPS induce M2 Macrophages which inhibit CD4+ and
CD8+ T cells through production of TGF-β and PD-L1 and potentially through
induction of regulatory T cells.
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macrophages in a TLR4-dependent manner. These M2 macrophages produce
multiple immune inhibitory molecules, including TGF-β, PD-L1 and arginase-1,
all of which inhibit T cell responses and prevent inflammatory diseases.
Undoubtedly, additional molecules from a large number of commensal bacteria
will be found to regulate immune responses. Understanding the mechanisms by
which EPS and other molecules from commensal organisms regulate the immune
system will lead to new rationally-designed and safe therapeutics for
inflammatory diseases.
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